|  |  |
| --- | --- |
| European Parliament  2019-2024 | EP logo RGB_Mute |

<Commission>{BECA}Special Committee on Beating Cancer</Commission>

<RefProc>2020/2267</RefProc><RefTypeProc>(INI)</RefTypeProc>

<Date>{20/09/2021}20.9.2021</Date>

<TypeAM>AMENDMENTS</TypeAM>

<RangeAM>854 - 1183</RangeAM>

<TitreType>Draft report</TitreType>

<Rapporteur>Véronique Trillet‑Lenoir</Rapporteur>

<DocRefPE>(PE693.752v01-00)</DocRefPE>

<Titre>on Strengthening Europe in the fight against cancer - towards a comprehensive and coordinated strategy</Titre>

<DocRef>(2020/2267(INI))</DocRef>

AM\_Com\_NonLegReport

<RepeatBlock-Amend><Amend>Amendment <NumAm>854</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 53 a (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***53a. Stresses the need for all patients to have a right of access to specific treatments for the sequelae of cancer or cancer treatment, allowing them to regain maximum autonomy and quality of life, such as cognitive rehabilitation in brain tumours, voice rehabilitation in patients with laryngectomies, physical rehabilitation in the case of immobilisation or muscle damage, prostheses in cases of upper or lower limb amputations due to osteosarcoma, treatment of lymphedema in patients who have undergone lymphadenectomy, breast reconstruction treatment, and aesthetic treatments in cases of skin lesions;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>855</NumAm>

<RepeatBlock-By><Members>Sunčana Glavak</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 53 b (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***53b. Insists that both public and private institutions that meet the quality assurance criteria should be included in national cancer control plans as part of Europe's Beating Cancer Plan with the goal of providing the highest level of cancer treatment quality to all patients across the EU;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>856</NumAm>

<RepeatBlock-By><Members>Nicolás González Casares, Alessandra Moretti, Maria Arena, Romana Jerković, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 53 c (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***53c. Considers it necessary to facilitate access to services for people with disabilities by eliminating structural and transport barriers, as well as the equipment itself, designed for non-disabled people;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>857</NumAm>

<RepeatBlock-By><Members>Peter Liese, Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 53 d (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***53d. Stresses the importance of standardized surgical oncology treatments to improve long term quality of life of cancer survivors;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>858</NumAm>

<RepeatBlock-By><Members>Nicolás González Casares, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 53 e (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***53e. Stresses the importance of standardized surgical oncology treatments to improve long term quality of life of cancer survivors;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>859</NumAm>

<RepeatBlock-By><Members>Tomislav Sokol, Sunčana Glavak, Cindy Franssen</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 54</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute; | 54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the ***Member States and the Commission to support the establishment of such reference centres for rare cancers and cancers with complex treatments; calls on the*** Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute; ***recommends the establishment of core objectives for the new network of centres as an early task; stresses that these objectives should include the reduction of inequalities, strengthening of translational, clinical and outcomes research, and integration of clinical care and research; notes that, when developing this EU network, the Commission should consider the need to invest in state-of-the-art equipment and well-trained physicians and other healthcare specialists in various specialties, including nuclear medicine;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>860</NumAm>

<RepeatBlock-By><Members>Tudor Ciuhodaru</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 54</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute; | 54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute; ***considers that, when developing this EU network, the Commission should consider the need to invest in state-of-the-art equipment and recommends that a diversity of well-trained cancer specialties and medical disciplines (such as respiratory, nephrology, cardiology, gastroenterology, nuclear medicine, etc.) be involved from the start in the work of the envisioned EU Network of National Comprehensive Cancer Centres to reinforce multi-disciplinary collaboration, therefore improving outcomes for patients;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>861</NumAm>

<RepeatBlock-By><Members>Nicolás González Casares, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 54</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute; | 54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute; ***considers that, within the plan, reference centres for paediatric cancers should be linked together and coordinated in a paediatric reference centres area; recommends that a diversity of cancer specialties and medical disciplines (such as respiratory, nephrology, cardiology, gastroenterology, etc.) be involved from the start in the work of the envisioned EU Network of National Comprehensive Cancer Centres to reinforce multi-disciplinary collaboration, therefore improving outcomes for patients; calls on the Commission and the Member States to support the sustainability of pre-existing cross-border collaborations;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>862</NumAm>

<RepeatBlock-By><Members>Hilde Vautmans, Irena Joveva, Alin Mituța</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 54</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute; | 54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute; ***considers that, within this Plan, reference centres for paediatric cancers should be linked and coordinated in a paediatric reference centres area; recommends the establishment of core objectives for the new Network of centres as an early task; stresses that these objectives should include the reduction of inequalities, strengthening of translational, clinical and outcomes research, and integration of clinical care and research;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>863</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 54</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute; | 54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute; ***recommends that a diversity of cancer specialties and medical disciplines (such as respiratory, nephrology, cardiology, gastroenterology, etc.) be involved from the start in the work of the envisioned EU Network of National Comprehensive Cancer Centres to reinforce multi-disciplinary collaboration, therefore improving outcomes for patients;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>864</NumAm>

<RepeatBlock-By><Members>Alexis Georgoulis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 54</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute; | 54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute; ***recommends the establishment of core objectives for the new Network of centres as an early task; stresses that these objectives should include the reduction of inequalities, strengthening of translational, clinical and outcomes research, and integration of clinical care and research;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>865</NumAm>

<RepeatBlock-By><Members>Giorgos Georgiou, Kateřina Konečná, Alexis Georgoulis, João Pimenta Lopes</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 54</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute; | 54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute; ***calls on the European Commission and the Members States to support the sustainability of pre-existing cross-border collaborations, such as in the paediatric cancer sector, and the European Reference Networks; recommends the implementation and enforcement of multi-disciplinary collaboration the soonest possible to improve the quality of care for patients; considers that cancer specialties and medical disciplines should be involved from the start in the work of the envisioned EU Network of National Comprehensive Cancer Centres;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>866</NumAm>

<RepeatBlock-By><Members>Maria Spyraki</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 54</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute; | 54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU***, and to support the already existing European Reference Networks (ERNs) as well as the development of guidelines and quality assurance schemes for cancer types (e.g. blood cancers) that will not be covered by the Knowledge Center for Cancer***; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>867</NumAm>

<RepeatBlock-By><Members>Vlad Gheorghe</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 54</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute; | 54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute; ***calls also on the Commission to support Member States by earmarking some of the budget in the cohesion and regional funds to support the establishment of these centres to ensure full coverage of the population;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>868</NumAm>

<RepeatBlock-By><Members>Loucas Fourlas</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 54</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute; | 54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute; ***calls on the Commission and the Members States to support the sustainability of pre-existing cross-border collaborations, such as in the paediatric cancer sector, and the European Reference Networks;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>869</NumAm>

<RepeatBlock-By><Members>Peter Liese</Members>

<AuNomDe>{EPP}on behalf of the EPP Group</AuNomDe>

<Members>Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Marian-Jean Marinescu, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz, Christian Sagartz</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 54</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute; | 54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the ***Member States and the Commission to support the establishment of such reference centres for rare cancers and cancers with complex treatments; calls on the*** Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>870</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 54</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute; | 54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute; ***calls for this network to also be used to harmonise approaches to screening for common comorbidities of cancer;*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>871</NumAm>

<RepeatBlock-By><Members>Ivars Ijabs, Alin Mituța, Irena Joveva, Hilde Vautmans, Nicolae Ştefănuță</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 54</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute; | 54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State***, particularly in the widening countries of the Horizon Europe Programme,*** and to support the coordination of the network of these centres via a European Cancer Institute; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>872</NumAm>

<RepeatBlock-By><Members>Bartosz Arłukowicz</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 54</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute; | 54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU***, as well as the development of common standards of care***; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute; |

Or. <Original>{PL}pl</Original>

</Amend>

<Amend>Amendment <NumAm>873</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 54</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute; | 54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, ***anticipatory and responsive*** research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres via a European Cancer Institute; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>874</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 54</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres ***via a European Cancer Institute***; | 54. Welcomes the planned establishment, as announced in Europe’s Beating Cancer Plan, of an EU network linking recognised National Comprehensive Cancer Centres (reference centres) in every Member State to facilitate the uptake of quality-assured diagnosis and treatments, including training, research and promotion of clinical trials across the EU; calls on the Commission to identify such existing centres within the EU, to promote the establishment of at least one comprehensive cancer centre in each Member State and to support the coordination of the network of these centres; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>875</NumAm>

<RepeatBlock-By><Members>Giorgos Georgiou, Kateřina Konečná, Alexis Georgoulis, João Pimenta Lopes</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 55</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 55. Calls for the identification, reinforcement or creation in each Member State of a National Cancer ***Control Programme (NCCP), consisting of a unique structure, possibly a National Cancer*** Institute***,*** in charge of the implementation and follow-up of the respective ***NCCPs, with adequate*** objectives ***and*** resources; recommends that the ***NCCPs*** are set up in coherence with the European Guide for Quality National Cancer Control Programmes initiated by the European Partnership for Action Against Cancer (EPAAC); welcomes the setting up of a network of these organisations coordinated by the European Cancer ***Institute***; | 55. Calls for the identification, reinforcement or creation in each Member State of a National Cancer Institute in charge of the implementation and ***follow-up*** of the respective ***National Cancer Strategy (NCS); stresses that, for this purpose, clear*** objectives ***should be set accompanied by adequate*** resources ***and management***; recommends that the ***NCSs*** are set up in coherence with the European Guide for Quality National Cancer Control Programmes initiated by the European Partnership for Action Against Cancer (EPAAC); welcomes the setting up of a network of these organisations coordinated by the ***Association of*** European Cancer ***Institutes***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>876</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 55</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 55. Calls for the identification, reinforcement or creation in each Member State of a National Cancer Control Programme (NCCP), consisting of ***a unique structure, possibly a National Cancer Institute, in charge of*** the implementation and follow-up of the respective NCCPs, with adequate objectives and resources; recommends that the NCCPs are set up in coherence with the European Guide for Quality National Cancer Control Programmes initiated by the European Partnership for Action Against Cancer (EPAAC); welcomes the ***setting up of a*** network of these ***organisations coordinated by the European Cancer Institute***; | 55. Calls for the identification, reinforcement or creation in each Member State of a National Cancer Control Programme (NCCP), consisting of ***designated implementation bodies responsible for*** the implementation and follow-up of the respective NCCPs, with adequate objectives and resources; recommends that the NCCPs are set up in coherence with the European Guide for Quality National Cancer Control Programmes initiated by the European Partnership for Action Against Cancer (EPAAC); welcomes the ***establishment of a European*** network of these ***national bodies***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>877</NumAm>

<RepeatBlock-By><Members>Nicolae Ştefănuță, Alin Mituța, Ivars Ijabs, Vlad Gheorghe</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 55</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 55. Calls for the identification, reinforcement or creation in each Member State of a National Cancer Control Programme (NCCP), consisting of a unique structure, possibly a National Cancer Institute, in charge of the implementation and follow-up of the respective NCCPs, with adequate objectives and resources; recommends that the NCCPs are set up in coherence with the European Guide for Quality National Cancer Control Programmes initiated by the European Partnership for Action Against Cancer (EPAAC); welcomes the setting up of a network of these organisations coordinated by the European Cancer Institute; | 55. Calls for the identification, reinforcement or creation in each Member State of a National Cancer Control Programme (NCCP), consisting of a unique structure, possibly a National Cancer Institute, in charge of the implementation and follow-up of the respective NCCPs, with adequate objectives and resources; recommends that the NCCPs are set up in coherence with the European Guide for Quality National Cancer Control Programmes initiated by the European Partnership for Action Against Cancer (EPAAC) ***and calls for the inclusion of a dedicated paediatric cancer and rare cancer component in all NCCPs to ensure that appropriate resources and implementation programmes are allocated to the specific needs of these patients***; welcomes the setting up of a network of these organisations coordinated by the European Cancer Institute; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>878</NumAm>

<RepeatBlock-By><Members>Loucas Fourlas</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 55</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 55. Calls for the identification, reinforcement or creation in each Member State of a National Cancer Control Programme (NCCP), consisting of a unique structure, possibly a National Cancer Institute, in charge of the implementation and follow-up of the respective NCCPs, with adequate objectives and resources; recommends that the NCCPs are set up in coherence with the European Guide for Quality National Cancer Control Programmes initiated by the European Partnership for Action Against Cancer (EPAAC); welcomes the setting up of a network of these organisations coordinated by the European Cancer Institute; | 55. Calls for the identification, reinforcement or creation in each Member State of a National Cancer Control Programme (NCCP), consisting of a unique structure, possibly a National Cancer Institute, in charge of the implementation and follow-up of the respective NCCPs, with adequate objectives and resources; recommends that the NCCPs are set up in coherence with the European Guide for Quality National Cancer Control Programmes initiated by the European Partnership for Action Against Cancer (EPAAC); welcomes the setting up of a network of these organisations coordinated by the European Cancer Institute; ***calls for the inclusion of a dedicated paediatric cancer component in all NCCPs to ensure that appropriate resources and implementation programmes are allocated to the specific needs of these patients;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>879</NumAm>

<RepeatBlock-By><Members>Vlad Gheorghe</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 55</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 55. Calls for the identification, reinforcement or creation in each Member State of a National Cancer Control Programme (NCCP), consisting of a unique structure, possibly a National Cancer Institute, in charge of the implementation and follow-up of the respective NCCPs, with adequate objectives and resources; recommends that the NCCPs are set up in coherence with the European Guide for Quality National Cancer Control Programmes initiated by the European Partnership for Action Against Cancer (EPAAC); welcomes the setting up of a network of these organisations coordinated by the European Cancer Institute; | 55. Calls for the identification, reinforcement or creation in each Member State of a National Cancer Control Programme (NCCP), consisting of a unique structure, possibly a National Cancer Institute, in charge of the implementation and follow-up of the respective NCCPs, with adequate objectives and resources; recommends that the NCCPs are set up in coherence with the European Guide for Quality National Cancer Control Programmes initiated by the European Partnership for Action Against Cancer (EPAAC); welcomes the setting up of a network of these organisations coordinated by the European Cancer Institute; ***stresses that a NCCP should include provisions on adequate staff capacities so as to guarantee sufficient number of oncology medical workers in each Member State, commensurate with the overall population number;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>880</NumAm>

<RepeatBlock-By><Members>Bronis Ropė</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 55</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 55. Calls for the identification, reinforcement or creation in each Member State of a National Cancer Control Programme (NCCP), consisting of a unique structure, possibly a National Cancer Institute, in charge of the implementation and follow-up of the respective NCCPs, with adequate objectives and resources; recommends that the NCCPs are set up in coherence with the European Guide for Quality National Cancer Control Programmes initiated by the European Partnership for Action Against Cancer (EPAAC); welcomes the setting up of a network of these organisations coordinated by the European Cancer Institute; | 55. Calls for the identification, reinforcement or creation in each Member State of a National Cancer Control Programme (NCCP), consisting of a unique structure, possibly a National Cancer Institute, in charge of the implementation and follow-up of the respective NCCPs, with adequate objectives and resources; ***calls for the NCCPs’ contents to resemble as closely as possible Europe's Beating Cancer Plan in order to facilitate the latter’s successful implementation;*** recommends that the NCCPs are set up in coherence with the European Guide for Quality National Cancer Control Programmes initiated by the European Partnership for Action Against Cancer (EPAAC); welcomes the setting up of a network of these organisations coordinated by the European Cancer Institute; |

Or. <Original>{LT}lt</Original>

</Amend>

<Amend>Amendment <NumAm>881</NumAm>

<RepeatBlock-By><Members>Dolors Montserrat, Aldo Patriciello, Juan Ignacio Zoido Álvarez, Herbert Dorfmann, Rosa Estaràs Ferragut, Francisco José Millán Mon, José Manuel García-Margallo y Marfil, Gabriel Mato, Esteban González Pons, Lídia Pereira, Pilar del Castillo Vera, Cindy Franssen, Antonio López-Istúriz White, Adrián Vázquez Lázara, Pablo Arias Echeverría, Javier Zarzalejos, Ewa Kopacz, Isabel Benjumea Benjumea</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 55</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 55. Calls for the identification, reinforcement or creation in each Member State of a National Cancer Control Programme (NCCP), consisting of a unique structure, possibly a National Cancer Institute, in charge of the implementation and follow-up of the respective NCCPs, with adequate objectives and resources; recommends that the NCCPs are set up in coherence with the European Guide for Quality National Cancer Control Programmes initiated by the European Partnership for Action Against Cancer (EPAAC); welcomes the setting up of a network of these organisations coordinated by the European Cancer Institute; | 55. Calls for the identification, reinforcement or creation in each Member State of a National Cancer Control Programme (NCCP)***, in coherence with WHO guidance on NCCPs***, consisting of a unique structure, possibly a National Cancer Institute, in charge of the implementation and follow-up of the respective NCCPs, with adequate objectives and resources; recommends that the NCCPs are set up in coherence with the European Guide for Quality National Cancer Control Programmes initiated by the European Partnership for Action Against Cancer (EPAAC); welcomes the setting up of a network of these organisations coordinated by the European Cancer Institute; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>882</NumAm>

<RepeatBlock-By><Members>Bronis Ropė</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 55 a (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***55a. Strongly encourages the drive to improve cancer control standards in EU countries by entrusting oversight over NCCPs to the unique structures of the National Cancer Institutes; stresses that, since the services provided by these institutions as centres of excellence are more efficient due to the integration of scientific and clinical activities and the rapid implementation of scientific innovations, a network of national cancer centres of excellence must be created and developed within and between EU Member States, from which at least 90% of cancer patients would obtain services; stresses that the full functioning of these unique scientific and medical institutions in the field of oncology depends on the development of an appropriate legal framework and on ensuring the financial stability of these institutions;*** |

Or. <Original>{LT}lt</Original>

</Amend>

<Amend>Amendment <NumAm>883</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin, Stefania Zambelli</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 55 b (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***55b. Highlights the importance of personalised medicine in identifying the best treatment option for each patient throughout their illness; points out that this approach delivers better results, reduces the risk of side effects in patients suffering from cancer, and also cuts costs while improving the effectiveness of healthcare systems;*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>884</NumAm>

<RepeatBlock-By><Members>Michèle Rivasi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 55 c (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***55c. Calls on Member States to integrate the specificities of rare cancers in adults as well as paediatric cancers in distinct sections in all the NCCPs; calls on the Commission to coordinate the creation of national networks for rare adult cancers and develop mechanisms to better integrate European Reference Networks (ERNs) in their respective national healthcare systems;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>885</NumAm>

<RepeatBlock-By><Members>Giorgos Georgiou, Alexis Georgoulis, João Pimenta Lopes</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 55 d (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***55d. Calls for the inclusion of a dedicated paediatric cancer component in all National Cancer Strategies (NCSs) to ensure that appropriate resources and implementation programmes are allocated to the specific needs of these patients;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>886</NumAm>

<RepeatBlock-By><Members>Hilde Vautmans, Irena Joveva</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 55 e (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***55e. Calls on the Commission and EU Member States to provide early access to new forms of therapy and surgery through the NCCP, including treatments accompanied by molecular diagnostics, robot surgery and radiation therapy;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>887</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 55 f (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***55f. Calls for the most holistic approach possible towards patients which considers their overall physical and mental health, including their diet and the potential consequences of polymedication; suggests, to this end, that the oncology team and practitioner attending to a patient remain in constant contact before, during and after treatment;*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>888</NumAm>

<RepeatBlock-By><Members>João Pimenta Lopes, Giorgos Georgiou, Alexis Georgoulis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Subheading III.B</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| III.B. Equal access to cancer care***: towards a European Medicines Market*** | III.B. Equal access to cancer care |

Or. <Original>{PT}pt</Original>

</Amend>

<Amend>Amendment <NumAm>889</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Subheading III.b</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| III.b Equal access to cancer care**:**  ***towards a European Medicines Market*** | III.b Equal access to cancer care |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>890</NumAm>

<RepeatBlock-By><Members>Michèle Rivasi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Subheading III.b</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| III.b Equal access to cancer care: towards ***a European*** Medicines ***Market*** | III.b Equal access to cancer care: towards ***equal access to*** medicines ***in Europe*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>891</NumAm>

<RepeatBlock-By><Members>Peter Liese</Members>

<AuNomDe>{EPP}on behalf of the EPP Group</AuNomDe>

<Members>Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Marian-Jean Marinescu, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Subheading III.b</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| III.b Equal access to cancer care: towards a European Medicines Market | III.b Equal access to cancer care ***and treatment in all Member states***: towards a European Medicines Market |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>892</NumAm>

<RepeatBlock-By><Members>Michèle Rivasi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 56</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 56. Calls on the Commission to strengthen the European ***medicines market*** in order to guarantee equal access to treatment, reduce medicine shortages, overcome the problem of high prices for innovative treatments, and improve cancer treatments for adults and children; | 56. Calls on the Commission to strengthen the European ***regulatory environment*** in order to guarantee equal access to ***adequate*** treatment ***options, including medicines, surgery and radiotherapy***, reduce medicine shortages, overcome the problem of high prices for innovative treatments, and improve ***efficacy and safety of*** cancer treatments for adults and children; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>893</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná, Alexis Georgoulis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 56</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 56. Calls on the Commission ***to strengthen*** the European medicines market ***in order to guarantee equal access to treatment, reduce medicine shortages, overcome the problem of high prices for innovative treatments, and improve cancer treatments for adults and children***; | 56. Calls on the Commission ***and antitrust authorities to assess and defend*** the European medicines market ***keeping the attention on the acquisition of SMEs by large pharmaceutical companies that undermine fair competition***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>894</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 56</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 56. Calls on the Commission to ***strengthen*** the European medicines market ***in order*** to guarantee equal access to treatment, reduce medicine shortages, overcome the problem of high prices for innovative treatments, and improve cancer treatments for adults and children; | 56. Calls on the Commission to ***develop a plan of collaboration between Member States in order to improve the functioning of*** the European medicines market ***so as*** to guarantee equal access ***and availability*** to treatment, reduce medicine shortages, overcome the problem of high prices for innovative treatments, and improve cancer treatments for adults and children; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>895</NumAm>

<RepeatBlock-By><Members>Giorgos Georgiou, Alexis Georgoulis, João Pimenta Lopes</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 56</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 56. Calls on the Commission to ***strengthen*** the European medicines market in order to guarantee equal access to treatment, reduce medicine shortages, overcome the problem of high prices for innovative treatments, ***and*** improve cancer treatments for adults and children; | 56. Calls on the Commission to ***evaluate and form*** the European medicines market in order to guarantee equal access to treatment, reduce medicine shortages, overcome the problem of high prices for innovative treatments, improve cancer treatments for adults and children***, and thus ensuring health as a human right and a public good for all***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>896</NumAm>

<RepeatBlock-By><Members>Peter Liese</Members>

<AuNomDe>{EPP}on behalf of the EPP Group</AuNomDe>

<Members>Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 56</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 56. Calls on the Commission to strengthen the European medicines market in order to ***guarantee*** equal access to treatment, reduce medicine shortages, overcome the problem of high prices for innovative treatments, and improve cancer treatments for adults and children; | 56. Calls on the Commission to strengthen the European medicines market in order to ***improve*** equal access to treatment, reduce medicine shortages, overcome the problem of high prices for innovative treatments, and improve cancer treatments for adults and children; ***encourages a multi-stakeholder dialogue on access to medicines and innovation based on models such as ACCELERATE in the paediatric cancer sector and involving all relevant actors including academia, industry and patient representatives;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>897</NumAm>

<RepeatBlock-By><Members>Tomislav Sokol, Sunčana Glavak, Cindy Franssen</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 56</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 56. Calls on the Commission to strengthen the European medicines market in order to guarantee equal access to treatment, reduce medicine shortages, overcome the problem of high prices for innovative treatments, and improve cancer treatments for adults and children; | 56. Calls on the Commission to strengthen the European medicines market in order to guarantee equal access to treatment, reduce medicine shortages, overcome the problem of high prices for innovative treatments, and improve cancer treatments for adults and children; ***encourages a multi-stakeholder dialogue on access to medicines and innovation based on models such as ACCELERATE in the paediatric cancer sector and involving all relevant actors including academia, industry and patient representatives; considers, in this respect, that market access for nuclear medicine applications should be harmonised across all Member States;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>898</NumAm>

<RepeatBlock-By><Members>Loucas Fourlas</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 56</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 56. Calls on the Commission to strengthen the European medicines market in order to guarantee equal access to treatment, reduce medicine shortages, overcome the problem of high prices for innovative treatments, and improve cancer treatments for adults and children; | 56. Calls on the Commission to strengthen the European medicines market in order to guarantee equal access to treatment, reduce medicine shortages, overcome the problem of high prices for innovative treatments, and improve cancer treatments for adults and children; ***encourages a multi-stakeholder dialogue on access to medicines and innovation based on models such as ACCELERATE in the paediatric cancer sector and involving all relevant actors including academia, industry and patient representatives;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>899</NumAm>

<RepeatBlock-By><Members>Tudor Ciuhodaru</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 56</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 56. Calls on the Commission to strengthen the European medicines market in order to guarantee equal access to treatment, reduce medicine shortages, overcome the problem of high prices for innovative treatments, and improve cancer treatments for adults and children; | 56. Calls on the Commission to strengthen the European medicines market in order to guarantee equal access to treatment, reduce medicine shortages, overcome the problem of high prices for innovative treatments, and improve cancer treatments for adults and children; ***considers, in this respect, that market access for nuclear medicine applications should be harmonised across all Member States;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>900</NumAm>

<RepeatBlock-By><Members>Bartosz Arłukowicz</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 56</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 56. Calls on the Commission to strengthen the European medicines market in order to guarantee equal access to treatment, reduce medicine shortages, overcome the problem of high prices for innovative treatments, and improve cancer treatments for adults and children; | 56. Calls on the Commission to strengthen the European medicines market in order to guarantee equal access to ***innovative*** treatment, ***including personalised medicine,*** reduce medicine shortages, overcome the problem of high prices for innovative treatments, and improve cancer treatments for adults and children; |

Or. <Original>{PL}pl</Original>

</Amend>

<Amend>Amendment <NumAm>901</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 56</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 56. Calls on the Commission to strengthen the European medicines market in order to guarantee equal access to treatment, reduce medicine shortages, overcome the problem of high prices for innovative treatments, and improve cancer treatments for adults and children; | 56. Calls on the Commission to strengthen the European medicines market in order to guarantee equal access to treatment, reduce medicine shortages, overcome the problem of high prices for innovative treatments, ***encourage the use of generic and biosimilar medicines*** and improve cancer treatments for adults and children; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>902</NumAm>

<RepeatBlock-By><Members>Ondřej Knotek, Irena Joveva</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 56</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 56. Calls on the Commission to strengthen the European medicines market in order to guarantee equal access to treatment, reduce medicine shortages, overcome the problem of high prices for innovative treatments, and improve cancer treatments for adults and children; | 56. Calls on the Commission to strengthen the European medicines market in order to guarantee equal access to treatment, reduce medicine shortages, overcome the problem of high prices for innovative ***technologies and*** treatments, and improve cancer treatments for adults and children; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>903</NumAm>

<RepeatBlock-By><Members>João Pimenta Lopes, Giorgos Georgiou, Alexis Georgoulis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 56 a (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***56a. Calls on the Member States to step up national research and production capacity for medicines and other health products, including by establishing national medicines laboratories, with a view to providing equal access to treatment, reducing medicines shortages and dependence on the pharmaceutical industry, securing cost-free access to innovative treatments and improving cancer treatments for adults and children; calls on the Member States, further, to provide cost-free access to treatments and medicines used by cancer patients by means of their public health services and to consider medicine policies that provide cost-free access to medicine for users over the age of 65, the chronically ill and families in economic need;*** |

Or. <Original>{PT}pt</Original>

</Amend>

<Amend>Amendment <NumAm>904</NumAm>

<RepeatBlock-By><Members>Michèle Rivasi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 56 b (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***56b. Calls for strengthening the EU medicine marketing authorisation framework and evidentiary requirements on medicine safety and efficacy; highlights the importance of randomised controlled clinical trials that compare an investigational pharmaceutical product against standard treatment for evidence on its added value; calls for generating evidence on the efficacy of cancer medicines based on clinically relevant endpoints; calls for clinical trials to be adequately representative of the patient population;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>905</NumAm>

<RepeatBlock-By><Members>Giorgos Georgiou, Kateřina Konečná, Alexis Georgoulis, João Pimenta Lopes</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 56 c (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***56c. Calls on the Commission to discourage practices which extend market exclusivity, prolong intellectual property protection and lead to profit maximization, through strategic use of intellectual property rights, such as incremental patenting of existing products (“ever-greening” strategies), and to promote generic competition for off-patent rare disease drugs;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>906</NumAm>

<RepeatBlock-By><Members>Michèle Rivasi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 57</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 57. Calls on the Commission to ***introduce in its Pharmaceutical Strategy a revision of*** Directive 2001/83/EC of 6 November 2001 establishing a Community code relating to medicinal products for human use27 ; | 57. Calls on the Commission to ***revise*** Directive 2001/83/EC of 6 November 2001 establishing a Community code relating to medicinal products for human use27 ***and Regulation (EC) No 726/2004 to strengthen the marketing authorisation framework, improve medicine availability and increase generic and biosimilar competition***; |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 27 OJ L 311, 28.11.2001, p. 67. | 27 OJ L 311, 28.11.2001, p. 67. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>907</NumAm>

<RepeatBlock-By><Members>Tudor Ciuhodaru</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 57</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 57. Calls on the Commission to introduce in its Pharmaceutical Strategy a revision of Directive 2001/83/EC of 6 November 2001 establishing a Community code relating to medicinal products for human use27 ; | 57. Calls on the Commission to introduce in its Pharmaceutical Strategy a revision of Directive 2001/83/EC of 6 November 2001 establishing a Community code relating to medicinal products for human use27; ***considers that, while recognising nuclear medicine as one of the most efficient ways to tackle the disease, the revision of the Directive 2001/83/EC should recognise the particularities of nuclear medicine by addressing the challenges currently limiting the further deployment of innovation in the sector;*** |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 27 OJ L 311, 28.11.2001, p. 67. | 27 OJ L 311, 28.11.2001, p. 67. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>908</NumAm>

<RepeatBlock-By><Members>João Pimenta Lopes, Giorgos Georgiou, Alexis Georgoulis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 58</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 58. Notes that cancer patients are frequently affected by medicine shortages; calls on the Commission ***to present a specific strategy for managing*** shortages of all medicines and medical products ***in Europe*** and of cancer medicines in particular; ***supports the*** development of a common basket of the cancer drugs of which there may be shortages to ensure that patients have continuous access to appropriate treatment; | 58. Notes that cancer patients are frequently affected by medicine shortages ***or high medicine costs***; calls on the Commission ***and the Member States to work together to counter*** shortages of all medicines and medical products ***in every country*** and of cancer medicines in particular***, which will require every state to build their research, development and production capacity for medicines and other medical products, thus safeguarding their national sovereignty in this area***; ***considers that any*** development of a common basket of the cancer drugs***, within the framework of cooperation among Member States,*** of which there may be shortages to ensure that patients have continuous access to appropriate treatment ***must not undermine the autonomy or sovereignty of every Member State in their consolidation of their own reserve in line with their needs and interests or their development of capacity in the production of medicines and other medical products***; |

Or. <Original>{PT}pt</Original>

</Amend>

<Amend>Amendment <NumAm>909</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 58</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 58. Notes that cancer patients are frequently affected by medicine shortages; calls on the Commission to present a specific strategy ***for managing*** shortages of all medicines and medical products in Europe and of cancer medicines in particular; supports the development of a common basket of the cancer drugs of which there may be shortages to ensure that patients have continuous access to appropriate treatment; | 58. Notes that cancer patients are frequently affected by medicine shortages; calls on the Commission to present a specific strategy ***to improve collaboration between Member States in order to manage and prevent*** shortages of all ***essential*** medicines and medical products in Europe and of cancer medicines in particular; supports the development of a common basket of the cancer drugs of which there may be shortages to ensure that patients have continuous access to appropriate treatment; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>910</NumAm>

<RepeatBlock-By><Members>Michèle Rivasi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 58</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 58. Notes that cancer patients are frequently affected by medicine shortages; calls on the Commission to present a specific strategy for managing shortages of all medicines and medical products in Europe and of cancer medicines in particular; supports the development of ***a common basket of the*** cancer drugs of which there may be shortages to ensure that patients have continuous access to appropriate treatment; | 58. Notes that cancer patients are frequently affected by medicine shortages; calls on the Commission to present a specific strategy for ***preventing and*** managing shortages of all medicines and medical products in Europe and of cancer medicines in particular; supports the development of ***critical*** cancer drugs of which there may be shortages to ensure that patients have continuous access to appropriate treatment; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>911</NumAm>

<RepeatBlock-By><Members>Hilde Vautmans, Irena Joveva</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 58</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 58. Notes that cancer patients are frequently affected by medicine shortages; calls on the Commission to present a specific strategy for managing shortages of all medicines and medical products in Europe and of cancer medicines in particular; supports the development of a common basket of the cancer drugs of which there may be shortages to ensure that patients have continuous access to appropriate treatment; | 58. Notes that cancer patients are frequently affected by medicine shortages; calls on the Commission to present a specific strategy for managing shortages of all medicines and medical products in Europe and of cancer medicines in particular; ***underlines specifically the fundamental issues posed by the shortage of paediatric medicines; underscores that Articles 24 and 35 of the EU Charter of Fundamental rights and Article 168 of TEU prescribe that children have the right to a high level of human health protection and to care, as is necessary for their wellbeing, as well as to high quality and safe medicines;*** supports the development of a common basket of the cancer drugs of which there may be shortages to ensure that patients have continuous access to appropriate treatment; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>912</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 58</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 58. Notes that cancer patients are frequently affected by medicine shortages; calls on the Commission to present a specific strategy for managing shortages of all medicines and medical products in Europe and of cancer medicines in particular; supports the development of a common basket of the cancer drugs of which there may be shortages to ensure that patients have continuous access to appropriate treatment; | 58. Notes that cancer patients are frequently affected by medicine shortages ***and that severe disruptions in the supply of cancer treatments are highly detrimental for cancer patients, carers and families***; calls on the Commission ***to develop a clear and harmonised definition as well as detailed and transparent requirements and*** to present a specific strategy for managing shortages of all medicines and medical products in Europe and of cancer medicines in particular; supports the development of a common basket of the cancer drugs of which there may be shortages to ensure that patients have continuous access to appropriate treatment; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>913</NumAm>

<RepeatBlock-By><Members>Nicolás González Casares, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 58</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 58. Notes that cancer patients are frequently affected by medicine shortages; calls on the Commission to present a specific strategy for managing shortages of all medicines and medical products in Europe and of cancer medicines in particular; supports the development of a common basket of the cancer drugs of which there may be shortages to ensure that patients have continuous access to appropriate treatment; | 58. Notes that cancer patients are frequently affected by medicine shortages; calls on the Commission to present a specific strategy for managing shortages of all medicines and medical products in Europe and of cancer medicines in particular***, including shortages of inexpensive essential cancer medicines***; supports the development of a common basket of the cancer drugs of which there may be shortages to ensure that patients have continuous access to appropriate treatment; ***highlights also the enormous problems posed by medicines shortages in paediatrics from an ethical and fundamental rights perspective;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>914</NumAm>

<RepeatBlock-By><Members>Alessandra Moretti</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 58</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 58. Notes that cancer patients are frequently affected by medicine shortages; calls on the Commission to present a specific strategy for managing shortages of all medicines and medical products in Europe and of cancer medicines in particular; supports the development of a common basket of the cancer drugs of which there may be shortages to ensure that patients have continuous access to appropriate treatment; | 58. Notes that cancer patients are frequently affected by medicine shortages; calls on the Commission to present a specific strategy for managing shortages of all medicines and medical products in Europe and of cancer medicines in particular***, including shortages of inexpensive essential cancer medicines***; supports the development of a common basket of the cancer drugs of which there may be shortages to ensure that patients have continuous access to appropriate treatment; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>915</NumAm>

<RepeatBlock-By><Members>Tomislav Sokol, Sunčana Glavak, Deirdre Clune, Cindy Franssen</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 58</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 58. Notes that cancer patients are frequently affected by medicine shortages; calls on the Commission to present a specific strategy for managing shortages of all medicines and medical products in Europe and of cancer medicines in particular; supports the development of a common basket of the cancer drugs of which there may be shortages to ensure that patients have continuous access to appropriate treatment; | 58. Notes that cancer patients are frequently affected by medicine shortages; calls on the Commission ***to develop a consistent definition of shortages and standardised reporting requirements as well as*** to present a specific strategy for managing shortages of all medicines and medical products in Europe and of cancer medicines in particular; supports the development of a common basket of the cancer drugs of which there may be shortages to ensure that patients have continuous access to appropriate treatment***, based on transparently and appropriately defined patient needs***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>916</NumAm>

<RepeatBlock-By><Members>Nicolae Ştefănuță, Alin Mituța, Ivars Ijabs, Vlad Gheorghe</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 58</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 58. Notes that cancer patients are frequently affected by medicine shortages; calls on the Commission to present a specific strategy for managing shortages of all medicines and medical products in Europe and of cancer medicines in particular; supports the development of a common basket of the cancer drugs of which there may be shortages to ensure that patients have continuous access to appropriate treatment; | 58. Notes that cancer patients are frequently affected by medicine shortages; calls on the Commission to present a specific strategy for managing shortages of all medicines and medical products in Europe and of cancer medicines in particular; ***calls on the Commission to start an inquiry into the effects of parallel trade on medicine shortages;*** supports the development of a common basket of the cancer drugs of which there may be shortages to ensure that patients have continuous access to appropriate treatment; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>917</NumAm>

<RepeatBlock-By><Members>Marian-Jean Marinescu</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 58 a (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***58a. Calls on the Commission to include in the EU Statistics on Income and Living Conditions (EU-SILC) data on self-reported unmet needs regarding access to cancer medicines, as so far access to medicines, including cancer medicines, is not measured in the EU-SILC, and to start the development of a common basket of the cancer drugs that risk shortages from the data collected in the EU-SILC;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>918</NumAm>

<RepeatBlock-By><Members>Bronis Ropė</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 58 b (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***58b. Points out that, in order to ensure equal access to treatment, reduce shortages in innovative medicines and reduce disparities in the price of medicines, it is essential that uniform quality protocols for the diagnosis and treatment of oncological diseases, which should be regularly updated with the involvement of professional organisations, be established and applied as a matter of priority in the Member States;*** |

Or. <Original>{LT}lt</Original>

</Amend>

<Amend>Amendment <NumAm>919</NumAm>

<RepeatBlock-By><Members>Bronis Ropė</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 58 c (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***58c. Deplores the existing differences in the reimbursement systems for cancer medicines in the Member States and proposes that vital and binding lists of essential cancer medicines be established in a harmonised way, at EU level, so that cancer patients in the Member States will have the right to reimbursement by the national health insurance funds in a harmonised manner in all the Member States;*** |

Or. <Original>{LT}lt</Original>

</Amend>

<Amend>Amendment <NumAm>920</NumAm>

<RepeatBlock-By><Members>Bronis Ropė</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 58 d (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***58d. Stresses that the availability of innovative medicines cannot be limited by bureaucratic reimbursement mechanisms; calls not only for the joint evaluation of medical technologies and medicines, but also for all medicines registered by the European Medicines Agency (EMA) and technologies recognised in the EU to be automatically registered in all EU countries without additional bureaucratic screening mechanisms; considers that the availability of medicines and technologies can only be limited by a country's economic resources and that this should be addressed by making cancer treatment a priority area for European and national health systems;*** |

Or. <Original>{LT}lt</Original>

</Amend>

<Amend>Amendment <NumAm>921</NumAm>

<RepeatBlock-By><Members>Michèle Rivasi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 59</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 59. Calls for the reinforcement ***and*** diversification of the supply chain***, in particular that of cancer drugs,*** within the EU, close monitoring of medicine tensions and shortages***,*** and the creation of a strategic stockpile of ***such*** medicines; | 59. Calls for the reinforcement***,*** diversification ***and increased transparency*** of the ***medicines*** supply chain within the EU, close monitoring of medicine ***supply chains,*** tensions and shortages***; calls for the EU pharmaceutical legislation to introduce a legal obligation for pharmaceutical companies to maintain adequate safety stocks*** and the creation of a strategic stockpile of ***critical*** medicines***, active ingredients or raw materials, particularly where the number of suppliers is limited***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>922</NumAm>

<RepeatBlock-By><Members>Alessandra Moretti</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 59</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 59. Calls for the reinforcement and diversification of the supply ***chain***, in particular that of cancer drugs, within the EU, close monitoring of ***medicine*** tensions and shortages, and the creation of a ***strategic*** stockpile of such medicines; | 59. Calls for the reinforcement and diversification of the supply, in particular that of cancer drugs, within the EU, close monitoring of ***supply*** tensions and shortages, and the creation of a ***European*** stockpile of such medicines; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>923</NumAm>

<RepeatBlock-By><Members>Tomislav Sokol, Sunčana Glavak</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 59</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 59. Calls for the reinforcement and diversification of the supply chain, in particular that of cancer drugs, within the EU, close monitoring of medicine tensions and shortages, and the creation of a strategic stockpile of such medicines; | 59. Calls for the reinforcement and diversification of the supply chain, in particular that of cancer drugs, within the EU, close monitoring of medicine tensions and shortages ***at EU level***, and the creation of a strategic stockpile of such medicines; ***urges the Commission, in the context of the EU Public Procurement Directive 2014/24/EU, to develop guidelines to support public procurement practices in the pharmaceutical field for cancer drugs, in particular with regard to the implementation of the criteria of the most economically advantageous tender (MEAT), aimed at ensuring long-term sustainability, competition and security of supply and stimulating investment in manufacturing; calls for remedies against single-winner, price-only tenders that can cause severe price erosion, reducing the number of suppliers on the market and often resulting in short lead times and penalties being applied to companies, which in turn increases the risk of shortages of medical products; calls, in this respect, for the necessary measures to develop a robust supply chain for nuclear medicine which goes beyond irradiation and includes the supply of target material and processing capabilities;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>924</NumAm>

<RepeatBlock-By><Members>Peter Liese</Members>

<AuNomDe>{EPP}on behalf of the EPP Group</AuNomDe>

<Members>Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Marian-Jean Marinescu, Maria Spyraki, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 59</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 59. Calls for the reinforcement and diversification of the supply chain, in particular that of cancer drugs, within the EU, close monitoring of medicine tensions and shortages, and the creation of a strategic stockpile of such medicines; | 59. Calls for the reinforcement and diversification of the supply chain, in particular that of cancer drugs, within the EU, close monitoring of medicine tensions and shortages ***at EU level***, and the creation of a strategic stockpile of such medicines; ***urges the Commission, in the context of the EU Public Procurement Directive 2014/24/EU, to develop guidelines to support public procurement practices in the pharmaceutical field for cancer drugs, in particular with regard to the implementation of the criteria of the most economically advantageous tender (MEAT), aimed at ensuring long-term sustainability, competition and security of supply and stimulating investment in manufacturing;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>925</NumAm>

<RepeatBlock-By><Members>Dolors Montserrat, Aldo Patriciello, Juan Ignacio Zoido Álvarez, Herbert Dorfmann, Rosa Estaràs Ferragut, Francisco José Millán Mon, Nathalie Colin-Oesterlé, José Manuel García-Margallo y Marfil, Gabriel Mato, Esteban González Pons, Lídia Pereira, Pilar del Castillo Vera, Antonio López-Istúriz White, Adrián Vázquez Lázara, Pablo Arias Echeverría, Javier Zarzalejos, Ewa Kopacz, Isabel Benjumea Benjumea</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 59</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 59. Calls for the reinforcement and diversification of the supply chain, in particular that of cancer drugs, within the EU, close monitoring of medicine tensions and shortages, and the creation of a strategic stockpile of such medicines; | 59. Calls for the reinforcement and diversification of the supply chain, in particular that of cancer drugs, within the EU, close monitoring of medicine tensions and shortages ***at EU level***, and the creation of a strategic stockpile of such medicines; ***urges the Commission, in the context of the EU Public Procurement Directive 2014/24/EU, to develop guidelines to support public procurement practices in the pharmaceutical field for cancer drugs, not relying exclusively or prominently on the criterion of price, in order to foster the sustainability of the supply chain and the resilience of the national health systems, and to avoid a delocalization aimed at reducing the costs of manufacturing;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>926</NumAm>

<RepeatBlock-By><Members>Nicolás González Casares, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 59</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 59. Calls for the reinforcement and diversification of the supply chain, in particular that of cancer drugs, within the EU, close monitoring of medicine tensions and shortages, and the creation of a strategic stockpile of such medicines; | 59. Calls for the reinforcement and diversification of the supply chain, in particular that of cancer drugs, within the EU, close monitoring of medicine tensions and shortages, and the creation of a strategic stockpile of such medicines; ***stresses the importance of the role of sustainable procurement practices in preventing medicine shortages; calls on the Commission to support Member States in the prevention of shortages by developing EU guidelines on procurement of medicines, aimed at ensuring long-term sustainability, competition, security of supply and stimulating investments in manufacturing;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>927</NumAm>

<RepeatBlock-By><Members>Tudor Ciuhodaru</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 59</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 59. Calls for the reinforcement and diversification of the supply chain, in particular that of cancer drugs, within the EU, close monitoring of medicine tensions and shortages, and the creation of a strategic stockpile of such medicines; | 59. Calls for the reinforcement and diversification of the supply chain, in particular that of cancer drugs, within the EU, close monitoring of medicine tensions and shortages, and the creation of a strategic stockpile of such medicines; ***calls, in this respect, for the necessary measures to develop a robust supply chain for nuclear medicine which goes beyond irradiation and includes the supply of target material and processing capabilities;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>928</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 59</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 59. Calls for the reinforcement and diversification of the supply chain, in particular that of cancer drugs, within the EU, close monitoring of medicine tensions and shortages, and the creation of a strategic stockpile of such medicines; | 59. Calls for the reinforcement and diversification of the supply chain, in particular that of cancer drugs, within the EU, close monitoring of medicine tensions and shortages, ***the strengthening of stocks' transparency at a national level, the establishment of an alert system notifying the growing risks of shortages,*** and the creation of a strategic stockpile of such medicines; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>929</NumAm>

<RepeatBlock-By><Members>João Pimenta Lopes, Giorgos Georgiou, Alexis Georgoulis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 59</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 59. Calls for the reinforcement and diversification of the supply chain, in particular that of cancer drugs***, within the EU***, close monitoring of medicine tensions and shortages, and the creation of a strategic stockpile of such medicines; | 59. Calls for the reinforcement and diversification of the ***Member States’*** supply chain, in particular that of cancer drugs, close monitoring of medicine tensions and shortages, and the creation of a strategic stockpile of such medicines; |

Or. <Original>{PT}pt</Original>

</Amend>

<Amend>Amendment <NumAm>930</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 59 a (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***59a. Stresses the importance of the role of sustainable procurement practices in preventing medicine shortages; recalls that, as recognised in the EU industrial strategy, public procurement can lead to market consolidation and increase the risk of shortages; calls on the Commission to support Member States in the prevention of shortages by developing EU rules on procurement of medicines, under the current public procurement directive, aimed at ensuring long-term sustainability, competition, security of supply and stimulating investments in manufacturing; considers that these targeted guidelines should cover clarifications and recommendations to Member States on how to implement multi-winner framework agreements, apply Most Economically Advantageous Tender(MEAT) criteria, recognise investments in security of supply for Europe, as well as ensure timely procurement processes to promote the plurality of manufacturers and competition of multi-source medicines as soon as they are available;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>931</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 59 b (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***59b. Recalls that just-in-time drug production increases the risk of shortages; calls on Member States to implement shortage management plans, including binding pharmaceutical industries to constitute a security reserve in order to better prevent cancer drugs stock shortages;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>932</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 60</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| ***60. Points out that generic and biosimilar medicines enable efficient and safe cancer care, increased competition and savings for healthcare systems, thus helping to improve access to medicines for patients; stresses that their market entry should not be hampered or delayed;*** | ***deleted*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>933</NumAm>

<RepeatBlock-By><Members>Alessandra Moretti</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 60</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 60. Points out that generic and biosimilar medicines enable efficient and safe cancer care, increased competition and savings for healthcare systems, thus helping to improve access to medicines ***for*** patients; stresses that their market entry should not be hampered or delayed; | 60. Points out that generic and biosimilar medicines enable efficient and safe cancer care, increased competition and savings for healthcare systems, thus helping to improve access to medicines ***and other healthcare products and services for patients; calls for the introduction of a strategic objective in the Europe's Beating Cancer Plan as well as in the national cancer strategies to actively promote the use of off-patent medicines, where appropriate and beneficial for the*** patients; stresses that their market entry should not be hampered or delayed ***and calls for the entry to market at the day 1 after IP expires to provide life-saving oncological generic and biosimilar medicines to patients***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>934</NumAm>

<RepeatBlock-By><Members>Nicolás González Casares, Alessandra Moretti, Maria Arena, Romana Jerković, Sara Cerdas, Marc Angel, Estrella Durá Ferrandis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 60</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 60. Points out that generic and biosimilar medicines enable efficient and safe cancer care, increased competition and savings for healthcare systems, thus helping to improve access to medicines for patients; stresses that their market entry should not be hampered or delayed; | 60. Points out that generic and biosimilar medicines enable efficient and safe cancer care, increased competition and savings for healthcare systems, thus helping to improve access to medicines ***and other healthcare products and services for patients; calls for the introduction of a strategic objective in the Europe's Beating Cancer Plan as well as in the national cancer strategies to actively promote the use of off-patent medicines, where appropriate and beneficial*** for patients; stresses that their market entry should not be hampered or delayed ***and their development process should be promoted and funded***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>935</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná, Alexis Georgoulis, Giorgos Georgiou</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 60</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 60. Points out that generic and biosimilar medicines enable efficient and safe cancer care, increased competition and savings for healthcare systems, thus helping to improve access to medicines for patients; stresses that their market entry should not be hampered or delayed; | 60. Points out that generic and biosimilar medicines enable efficient and safe cancer care, increased competition and savings for healthcare systems, thus helping to improve access to medicines for patients; stresses that their market entry should not be hampered or delayed ***because of unfair business strategies***; ***urges for removing barriers to uptake and foster biosimilar medicines competition by designing policies that create a healthy long-term competition and promote biosimilar medicines use in the EU and National Cancer Strategies to ignite competition;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>936</NumAm>

<RepeatBlock-By><Members>Michèle Rivasi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 60</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 60. Points out that generic and biosimilar medicines enable efficient and safe cancer care, increased competition and savings for healthcare systems, thus helping to improve access to medicines for patients; stresses that their market entry should not be hampered or delayed; | 60. Points out that generic and biosimilar medicines enable efficient and safe cancer care, increased competition and savings for healthcare systems, thus helping to improve access to medicines for patients; stresses that their market entry should not be hampered or delayed; ***calls on the Commission to increase resources to address anti-competitive and abusive market practices, including extension of market exclusivity and intellectual property protection, excessive pricing and pay-for-delay deals leading to competition distortion and profit maximisation;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>937</NumAm>

<RepeatBlock-By><Members>Nicolae Ştefănuță, Alin Mituța, Ivars Ijabs, Vlad Gheorghe</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 60</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 60. Points out that generic and biosimilar medicines enable efficient and safe cancer care, increased competition and savings for healthcare systems, thus helping to improve access to medicines for patients; stresses that their market entry should not be hampered or delayed; | 60. Points out that generic and biosimilar medicines enable efficient and safe cancer care, increased competition and savings for healthcare systems, thus helping to improve access to medicines for patients; stresses that their market entry should not be hampered or delayed; ***calls on the Commission to address the misuse of the IPR (industrial property rights) system to delay market entry of generic and biosimilar medicines;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>938</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 60</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 60. Points out that generic and biosimilar medicines enable efficient and safe cancer care, increased competition and savings for healthcare systems, thus helping to improve access to medicines for patients; stresses that their market entry should not be hampered or delayed; | 60. Points out that generic and biosimilar medicines enable efficient and safe cancer care, increased competition and savings for healthcare systems, thus helping to improve access to medicines for patients; stresses that their market entry should not be hampered or delayed ***provided that intellectual property rights are respected;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>939</NumAm>

<RepeatBlock-By><Members>Ondřej Knotek, Irena Joveva</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 60</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 60. Points out that generic and biosimilar medicines enable efficient and safe cancer care, increased competition and savings for healthcare systems, thus helping to improve access to medicines for patients; stresses that their market entry should not be hampered or delayed; | 60. Points out that generic and biosimilar medicines enable efficient and safe cancer care, increased competition***, innovation*** and savings for healthcare systems, thus helping to improve access to medicines for patients; stresses that their market entry should not be hampered or delayed; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>940</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 61</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| ***61. Considers that Member States should converge on the evaluation of medical technologies; welcomes, therefore, the provisional agreement on the Health Technology Assessment (HTA) Regulation reached by the European Parliament and the Council on 22 June 202128 to support harmonised access to innovative cancer diagnosis and treatments;*** | ***deleted*** |
| ***\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_*** |  |
| ***28 Commission proposal of 31 January 2018 for a regulation on health technology assessment and amending Directive 2011/24/EU (COM(2018)0051).*** |  |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>941</NumAm>

<RepeatBlock-By><Members>João Pimenta Lopes, Giorgos Georgiou</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 61</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 61. Considers that Member States should converge on the evaluation of medical technologies***; welcomes, therefore, the provisional agreement on the Health Technology Assessment (HTA) Regulation reached by the European Parliament and the Council on 22 June 2021***28 to support ***harmonised*** access to innovative cancer diagnosis and treatments; | 61. Considers that Member States should converge on the evaluation of medical technologies to support access to innovative cancer diagnosis and treatments; |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |  |
| ***28 Commission proposal of 31 January 2018 for a regulation on health technology assessment and amending Directive 2011/24/EU (COM(2018)0051).*** |  |

Or. <Original>{PT}pt</Original>

</Amend>

<Amend>Amendment <NumAm>942</NumAm>

<RepeatBlock-By><Members>Alessandra Moretti</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 61</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 61. Considers that Member States should converge on the evaluation of medical technologies; welcomes, therefore, the provisional agreement on the Health Technology Assessment (HTA) Regulation reached by the European Parliament and the Council on 22 June 202128 to support harmonised access to innovative cancer diagnosis and treatments; | 61. Considers that Member States should converge on the evaluation of medical technologies; welcomes, therefore, the provisional agreement on the Health Technology Assessment (HTA) Regulation reached by the European Parliament and the Council on 22 June 202128 to support harmonised access to innovative cancer diagnosis and treatments; ***supports cancer medicines being used as a pilot to jointly assess medicines under the Health Technology Assessment (HTA) regulation; calls on the Commission and Member States to take further measures aimed at encouraging the uptake and use of Joint Clinical Assessments that are to be carried out under the regulation; highlights the existence of tools being used by the World Health Organization (WHO) to incorporate cancer medicines on the WHO Model List of Essential Medicines;*** |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 28 Commission proposal of 31 January 2018 for a regulation on health technology assessment and amending Directive 2011/24/EU (COM(2018)0051). | 28 Commission proposal of 31 January 2018 for a regulation on health technology assessment and amending Directive 2011/24/EU (COM(2018)0051). |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>943</NumAm>

<RepeatBlock-By><Members>Nicolás González Casares, Maria Arena, Romana Jerković, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 61</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 61. Considers that Member States should converge on the evaluation of medical technologies; welcomes, therefore, the provisional agreement on the Health Technology Assessment (HTA) Regulation reached by the European Parliament and the Council on 22 June 202128 to support harmonised access to innovative cancer diagnosis and treatments; | 61. Considers that Member States should converge on the evaluation of medical technologies; welcomes, therefore, the provisional agreement on the Health Technology Assessment (HTA) Regulation reached by the European Parliament and the Council on 22 June 202128 to support harmonised access to innovative cancer diagnosis and treatments; ***supports cancer medicines being used as a pilot to jointly assess medicines under the Health Technology Assessment (HTA) regulation; calls on the Commission and Member States to take further measures aimed at encouraging the uptake and use of Joint Clinical Assessments that are to be carried out under the regulation; highlights the existence of tools being used by the World Health Organization (WHO) to incorporate cancer medicines on the WHO Model List of Essential Medicines;*** |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 28 Commission proposal of 31 January 2018 for a regulation on health technology assessment and amending Directive 2011/24/EU (COM(2018)0051). | 28 Commission proposal of 31 January 2018 for a regulation on health technology assessment and amending Directive 2011/24/EU (COM(2018)0051). |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>944</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 61</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 61. Considers that Member States should converge on the evaluation of medical technologies; welcomes, therefore, the provisional agreement on the Health Technology Assessment (HTA) Regulation reached by the European Parliament and the Council on 22 June 202128 to support harmonised access to innovative cancer diagnosis and treatments; | 61. Considers that Member States should converge on the evaluation of medical technologies; welcomes, therefore, the provisional agreement on the Health Technology Assessment (HTA) Regulation reached by the European Parliament and the Council on 22 June 202128 to support harmonised access to innovative cancer diagnosis and treatments; ***encourages more equitable access to medicines for patients across Europe by increasing the quality and efficiency of decision-making process; calls on Member States to intensify the close European cooperation on joint clinical assessments to use HTA resources more effectively after the pandemic and create a viable framework;*** |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 28 Commission proposal of 31 January 2018 for a regulation on health technology assessment and amending Directive 2011/24/EU (COM(2018)0051). | 28 Commission proposal of 31 January 2018 for a regulation on health technology assessment and amending Directive 2011/24/EU (COM(2018)0051). |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>945</NumAm>

<RepeatBlock-By><Members>Michèle Rivasi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 61</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 61. Considers that Member States should converge on the evaluation of medical technologies; welcomes, therefore, the provisional agreement on the Health Technology Assessment (HTA) Regulation reached by the European Parliament and the Council on 22 June 202128 to support harmonised access to innovative cancer diagnosis and treatments; | 61. Considers that Member States should converge on the evaluation of medical technologies; welcomes, therefore, the provisional agreement on the Health Technology Assessment (HTA) Regulation reached by the European Parliament and the Council on 22 June 202128 to support harmonised ***assessment of and*** access to innovative cancer diagnosis and treatments; ***calls for enhanced collaboration between HTA authorities and developers on the design of clinical trials;*** |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 28 Commission proposal of 31 January 2018 for a regulation on health technology assessment and amending Directive 2011/24/EU (COM(2018)0051). | 28 Commission proposal of 31 January 2018 for a regulation on health technology assessment and amending Directive 2011/24/EU (COM(2018)0051). |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>946</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná, Alexis Georgoulis, Giorgos Georgiou</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 61</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 61. Considers that Member States should converge on the evaluation of medical technologies; welcomes, therefore, the provisional agreement on the Health Technology Assessment (HTA) Regulation reached by the European Parliament and the Council on 22 June 202128 to support harmonised access to innovative cancer diagnosis and treatments; | 61. Considers that Member States should converge on the evaluation of medical technologies; welcomes, therefore, the provisional agreement on the Health Technology Assessment (HTA) Regulation reached by the European Parliament and the Council on 22 June 202128 to support harmonised access to innovative cancer diagnosis and treatments; ***calls for the mandatory involvement of HTA experts in the design of clinical trials used for marketing authorization application;*** |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 28 Commission proposal of 31 January 2018 for a regulation on health technology assessment and amending Directive 2011/24/EU (COM(2018)0051). | 28 Commission proposal of 31 January 2018 for a regulation on health technology assessment and amending Directive 2011/24/EU (COM(2018)0051). |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>947</NumAm>

<RepeatBlock-By><Members>Søren Gade</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 61</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 61. Considers that Member States should converge on ***the*** evaluation of medical technologies; welcomes, therefore, the provisional agreement on the Health Technology Assessment (HTA) Regulation reached by the European Parliament and the Council on 22 June 202128 to support harmonised access to innovative cancer diagnosis and treatments; | 61. Considers that Member States should converge on ***evidence-based scientific*** evaluation of medical technologies; welcomes, therefore, the provisional agreement on the Health Technology Assessment (HTA) Regulation reached by the European Parliament and the Council on 22 June 202128 to support harmonised access to innovative cancer diagnosis and treatments; |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 28 Commission proposal of 31 January 2018 for a regulation on health technology assessment and amending Directive 2011/24/EU (COM(2018)0051). | 28 Commission proposal of 31 January 2018 for a regulation on health technology assessment and amending Directive 2011/24/EU (COM(2018)0051). |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>948</NumAm>

<RepeatBlock-By><Members>Ondřej Knotek, Irena Joveva</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 61</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 61. Considers that Member States should converge on the evaluation of medical technologies; welcomes, therefore, the provisional agreement on the Health Technology Assessment (HTA) Regulation reached by the European Parliament and the Council on 22 June 202128 to support harmonised access to innovative cancer diagnosis and treatments; | 61. Considers that Member States should converge on the evaluation of medical technologies; welcomes, therefore, the provisional agreement on the Health Technology Assessment (HTA) Regulation reached by the European Parliament and the Council on 22 June 202128 to support harmonised ***and faster*** access to innovative cancer diagnosis and treatments; |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 28 Commission proposal of 31 January 2018 for a regulation on health technology assessment and amending Directive 2011/24/EU (COM(2018)0051). | 28 Commission proposal of 31 January 2018 for a regulation on health technology assessment and amending Directive 2011/24/EU (COM(2018)0051). |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>949</NumAm>

<RepeatBlock-By><Members>Tomislav Sokol, Sunčana Glavak, Deirdre Clune, Cindy Franssen</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 61</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 61. Considers that Member States should converge on the evaluation of medical technologies; welcomes, therefore, the provisional agreement on the Health Technology Assessment (HTA) Regulation reached by the European Parliament and the Council on 22 June 202128 to support harmonised access to innovative cancer diagnosis and treatments; | 61. Considers that Member States should converge on the evaluation of medical technologies; welcomes, therefore, the provisional agreement on the Health Technology Assessment (HTA) Regulation reached by the European Parliament and the Council on 22 June 202128 to support harmonised ***and faster*** access to innovative cancer diagnosis and treatments; |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 28 Commission proposal of 31 January 2018 for a regulation on health technology assessment and amending Directive 2011/24/EU (COM(2018)0051). | 28 Commission proposal of 31 January 2018 for a regulation on health technology assessment and amending Directive 2011/24/EU (COM(2018)0051). |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>950</NumAm>

<RepeatBlock-By><Members>Bronis Ropė</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 61 a (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***61a. Points out that the comprehensive assessment of health technologies requires significant financial resources and is therefore often difficult to implement in the smaller Member States, which leads to inequalities in health care between Member States; calls for the promotion of cooperation between Member States in the joint assessment of medical technologies, with a view to eventually eliminating existing disparities in capacity in this field;*** |

Or. <Original>{LT}lt</Original>

</Amend>

<Amend>Amendment <NumAm>951</NumAm>

<RepeatBlock-By><Members>Nicolae Ştefănuță, Alin Mituța, Ivars Ijabs, Vlad Gheorghe</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 61 a (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***61a. Considers that lessons learnt from the COVID-19 pandemic, like the use of rolling review for promising medicine during public health emergencies should also be used for promising oncological medicine in order to accelerate the timely approval of innovative cancer therapies, reducing delays and speeding up access to potential lifesaving treatments for patient;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>952</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 62</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| ***62. Insists on the need to ensure equal access to affordable drugs, in particular cancer drugs, within the EU; calls for collective negotiation on the price of medicines with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the Valetta Declaration; considers that pharmaceutical companies should respect conditionalities on charging an affordable price for medicines developed in the framework of publicly funded research;*** | ***deleted*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>953</NumAm>

<RepeatBlock-By><Members>Maria Arena</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 62</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 62. Insists on the need to ensure equal access to affordable drugs, in particular cancer drugs, within the EU; calls for collective negotiation on the price of medicines with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the Valetta Declaration; ***considers that*** pharmaceutical ***companies should respect*** conditionalities ***on charging an affordable price for*** medicines ***developed in the framework of*** publicly funded research; | 62. ***Recalls that all patients have the right to optimal treatment, regardless of their financial means, gender, age or nationality; notes with concern that there is a great disparity in the availability of and access to different cancer therapies, with unaffordability being one of the main reasons;*** insists ***therefore*** on the need to ensure equal access to affordable drugs, in particular cancer drugs, within the EU; calls for collective negotiation on the price of medicines with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the Valetta Declaration; ***calls on the Commission to make fair pricing and affordability of new treatments a core element of the Europe’s Beating Cancer Plan and the*** Pharmaceutical ***Strategy for Europe, notably by attaching*** conditionalities ***to both national and European public funding (e.g., Horizon Europe, Innovative*** Medicines ***Initiative - IMI) and ensure that public investment in R&D is accounted for and that medicines resulting from*** publicly funded research ***are available for a fair and affordable price***; ***calls for more transparency throughout the pharmaceutical system, especially regarding pricing components, reimbursement criteria and the actual (net) prices of medicines in different European countries to ensure fairer prices and bring public accountability in the pharmaceutical sector;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>954</NumAm>

<RepeatBlock-By><Members>Nicolás González Casares, Alessandra Moretti, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 62</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 62. Insists on the need to ensure equal access to ***affordable*** drugs, in particular cancer drugs, within the EU; calls for collective negotiation on the price of medicines with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the Valetta Declaration; considers that ***pharmaceutical companies*** should ***respect*** conditionalities ***on charging an affordable price for*** medicines developed in the framework of publicly funded research; | 62. Insists on the need to ensure ***affordable prices and*** equal access to drugs, in particular cancer drugs, within the EU***, to avoid patients having their treatments delayed or incomplete***; calls for collective negotiation on the price of medicines with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the Valetta Declaration; considers that ***relevant public authorities*** should ***introduce*** conditionalities ***related to affordability, availability and access to*** medicines developed in the framework of publicly funded research; ***underlines that this should also be the case for medicines benefiting from specific regulatory or market protection such as medicines developed to treat rare or paediatric cancers;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>955</NumAm>

<RepeatBlock-By><Members>Andrey Slabakov, Angel Dzhambazki, Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 62</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 62. ***Insists on*** the need to ensure equal access to affordable drugs, in particular cancer drugs, within the EU; ***calls for*** collective negotiation on the price of medicines with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the Valetta Declaration; ***considers that pharmaceutical companies should respect conditionalities on charging an affordable price for*** medicines ***developed in the framework of publicly funded research***; | 62. ***Acknowledges*** the need to ensure equal access to affordable drugs, in particular cancer drugs, within the EU; ***points out the possibility for Member States to engage in voluntary*** collective negotiation on the price of medicines with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the Valetta Declaration; ***highlights the vastly different conditions, national healthcare and reimbursement systems, patient profiles, infrastructure capacities and financial burdens of Member States as some of the main factors dictating the pricing of*** medicines; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>956</NumAm>

<RepeatBlock-By><Members>Peter Liese</Members>

<AuNomDe>{EPP}on behalf of the EPP Group</AuNomDe>

<Members>Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Marian-Jean Marinescu, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 62</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 62. Insists on the need to ensure equal access to affordable drugs, in particular cancer drugs, within the EU; calls ***for collective*** negotiation ***on the price of medicines*** with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the Valetta Declaration; considers that pharmaceutical companies should respect conditionalities on charging an affordable price for medicines developed in the framework of publicly funded research; | 62. Insists on the need to ensure equal access to affordable drugs, in particular cancer drugs, within the EU; calls ***on Member States to consider joint price*** negotiation with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the Valetta Declaration; considers that pharmaceutical companies should respect conditionalities on charging an affordable price for medicines developed in the framework of publicly funded research; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>957</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 62</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 62. Insists on the need to ensure equal access to affordable drugs, in particular cancer drugs, within the EU; calls for collective negotiation on the price of medicines with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the Valetta Declaration; considers that pharmaceutical companies should respect conditionalities on charging an affordable price for medicines developed in the framework of publicly funded research; | 62. Insists on the need to ensure equal access to affordable drugs, in particular cancer drugs, within the EU; calls for ***voluntary*** collective negotiation on the price of medicines with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the Valetta Declaration; considers that pharmaceutical companies should respect conditionalities on charging an affordable price for medicines developed in the framework of publicly funded research; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>958</NumAm>

<RepeatBlock-By><Members>Tudor Ciuhodaru</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 62</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 62. Insists on the need to ensure equal access to affordable drugs, in particular cancer drugs, within the EU; calls for collective negotiation on the price of medicines with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the ***Valetta*** Declaration; considers that pharmaceutical companies should respect conditionalities on charging an affordable price for medicines developed in the framework of publicly funded research; | 62. Insists on the need to ensure equal access to affordable drugs, in particular cancer drugs, within the EU; calls for collective negotiation on the price of medicines with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the ***Valletta*** Declaration***, including the setting of price ceilings***; considers that pharmaceutical companies should respect conditionalities on charging an affordable price for medicines developed in the framework of publicly funded research; |

Or. <Original>{RO}ro</Original>

</Amend>

<Amend>Amendment <NumAm>959</NumAm>

<RepeatBlock-By><Members>Michèle Rivasi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 62</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 62. Insists on the need to ensure equal access to affordable drugs, in particular cancer drugs, within the EU; calls for collective negotiation on the price of medicines with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the Valetta Declaration; considers that pharmaceutical companies should respect conditionalities on charging an affordable price for medicines developed in the framework of publicly funded research; | 62. Insists on the need to ensure equal access to affordable drugs ***with proven patient benefit***, in particular cancer drugs, within the EU; calls for collective negotiation on the price of medicines with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the Valetta Declaration; considers that pharmaceutical companies should respect conditionalities on charging an affordable price for medicines developed in the framework of publicly funded research; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>960</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 62</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 62. Insists on the need to ensure equal access to affordable drugs, in particular cancer drugs, within the EU; calls for collective negotiation on the price of medicines with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the Valetta Declaration; considers that pharmaceutical companies should respect conditionalities on charging an affordable price for medicines developed in the framework of publicly funded research; | 62. Insists on the need to ensure equal access to affordable drugs, in particular cancer drugs, within the EU; calls for collective negotiation on the price of medicines with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the Valetta Declaration; considers that pharmaceutical companies should respect conditionalities on charging an affordable price for medicines developed in the framework of publicly funded ***anticipatory and responsive*** research; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>961</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 62</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 62. Insists on the need to ensure equal access to affordable drugs, in particular cancer drugs, within the EU; calls for collective negotiation on the price of medicines with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the ***Valetta*** Declaration; considers that pharmaceutical companies should respect conditionalities on charging an affordable price for medicines developed in the framework of publicly funded research; | 62. Insists on the need to ensure equal access to ***safe, effective and*** affordable drugs, in particular cancer drugs, within the EU; calls for collective negotiation on the price of medicines with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the ***Valletta*** Declaration; considers that pharmaceutical companies should respect conditionalities on charging an affordable price for medicines developed in the framework of publicly funded research; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>962</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná, Alexis Georgoulis, Giorgos Georgiou</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 62</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 62. Insists on the need to ensure equal access to affordable drugs, in particular cancer drugs, within the EU; calls for collective negotiation on the price of medicines with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the Valetta Declaration; considers that pharmaceutical companies should respect conditionalities on charging an affordable price for medicines developed ***in the framework of publicly funded research***; | 62. Insists on the need to ensure equal access to affordable drugs, in particular cancer drugs, within the EU; calls for collective negotiation on the price of medicines with pharmaceutical industries, as per the Beneluxa Initiative on Pharmaceutical Policy and the Valetta Declaration; considers that pharmaceutical companies should respect conditionalities on charging an affordable price for medicines developed***, in particular with the support of public funding;*** ; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>963</NumAm>

<RepeatBlock-By><Members>Hilde Vautmans, Irena Joveva</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 62 a (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***62a. Calls on the Commission and Member states to use HTA in reimbursement decisions and to promote innovative reimbursement schemes among Member States;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>964</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 63</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| ***63. Strongly advocates the extension of joint procurement procedures for cancer medicines to improve affordability and access to cancer treatments at EU level;*** | ***deleted*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>965</NumAm>

<RepeatBlock-By><Members>Peter Liese</Members>

<AuNomDe>{EPP}on behalf of the EPP Group</AuNomDe>

<Members>Tomislav Sokol, Liudas Mažylis, Marian-Jean Marinescu, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz, Christian Sagartz</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 63</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 63. Strongly advocates the extension of joint procurement procedures ***for*** cancer medicines to improve affordability and access to cancer treatments at EU level; | 63. Strongly advocates the extension of joint procurement procedures***, especially for (ultra)rare types, paediatric and novel*** cancer medicines ***and treatments*** to improve affordability and access to cancer treatments at EU level; ***highlights that joint public procurement should not hinder patient access, medical innovation or competition;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>966</NumAm>

<RepeatBlock-By><Members>Nicolás González Casares, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 63</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 63. Strongly advocates the extension of joint procurement procedures for cancer medicines to improve affordability and access to cancer treatments at EU level; | 63. Strongly advocates the extension of joint procurement procedures for ***diagnostics procedures as well as companion diagnostic tests and*** cancer medicines to improve affordability and access to cancer treatments at EU level; ***considers that special attention to paediatric and rare cancers should be given in this regard;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>967</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 63</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 63. Strongly advocates the extension of joint procurement procedures for cancer medicines ***to*** improve affordability and access to cancer treatments at EU level; | 63. Strongly advocates the extension of joint procurement procedures for cancer medicines***, especially in times of health crises, to counter shortages and*** improve affordability and access to cancer treatments at EU level; ***notes that the procedures should improve response times and be transparent;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>968</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 63</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 63. ***Strongly advocates*** the extension of joint procurement procedures for cancer medicines to improve affordability and access to cancer treatments at EU level; | 63. ***Calls for assessing the possibility for*** the extension of joint procurement procedures for cancer medicines to improve affordability and access to cancer treatments at EU level; ***calls on the Commission to make an assessment of the ICU joint procurement initiative and take the lesson learned to improve this tool; considers that this should not impact pre-existing contractual agreements with suppliers of medical countermeasures and should be carried out in accordance with Directive 2014/24/EU on public procurement1a*** ***in a transparent manner, while respecting the following conditions: the procurement process, criteria, timelines, specifications, and formalities must be transparent and workable; a preliminary consultation phase involving potential participating manufacturers must take place; clear volume commitments irrespective of the selected supply modality must be ensured;*** |
|  | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
|  | ***1a*** ***Directive 2014/24/EU of the European Parliament and of the Council of 26 February 2014 on public procurement (OJ L 94, 28.3.2014, p. 65)*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>969</NumAm>

<RepeatBlock-By><Members>Aldo Patriciello</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 63</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 63. ***Strongly advocates*** the extension of joint procurement procedures for cancer medicines to improve affordability and access to cancer treatments at EU level; | 63. ***Calls for assessing the possibility for*** the extension of joint procurement procedures for cancer medicines to improve affordability and access to cancer treatments at EU level; ***calls on the Commission to make an assessment of the ICU joint procurement initiative and take the lesson learned to improve this tool; considers that this should not impact pre-existing contractual agreements with suppliers of medical countermeasures and should be carried out in accordance with Directive 2014/24/EU on public procurement1a*** ***in a transparent manner, while respecting the following conditions: the procurement process, criteria, timelines, specifications, and formalities must be transparent and workable; a preliminary consultation phase involving potential participating manufacturers must take place; clear volume commitments irrespective of the selected supply modality must be ensured;*** |
|  | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
|  | ***1a*** ***Directive 2014/24/EU of the European Parliament and of the Council of 26 February 2014 on public procurement (OJ L 94, 28.3.2014, p. 65)*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>970</NumAm>

<RepeatBlock-By><Members>Andrey Slabakov, Angel Dzhambazki, Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 63</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 63. ***Strongly advocates*** the extension of joint procurement procedures for cancer medicines to improve affordability and access to cancer treatments at EU level; | 63. ***Acknowledges the possibility for*** the extension of joint procurement procedures ***on the basis of a joint assessment of the value of the product,*** for cancer medicines to improve affordability and access to cancer treatments at EU level; ***insists that a thorough impact assessment taking stock of the current and ongoing experience of EU joint procurements would be needed prior to expand this tool to additional areas; stresses that EU joint procurement should be used only in exceptional circumstances and for extraordinary public cross-border health threats where access to medicines cannot be ensured as efficiently by other means;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>971</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 63</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 63. ***Strongly advocates the extension of*** joint procurement procedures for cancer medicines ***to*** improve affordability and access to cancer treatments at EU level; | 63. ***Points out that*** joint procurement procedures for cancer medicines ***could*** improve affordability and access to cancer treatments at EU level; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>972</NumAm>

<RepeatBlock-By><Members>Hilde Vautmans, Irena Joveva</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 63</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 63. Strongly advocates the extension of joint procurement procedures for cancer medicines to improve affordability and access to cancer treatments at EU level; | 63. Strongly advocates the extension of joint procurement procedures for cancer medicines to improve affordability and access to cancer treatments at EU level; ***considers, in this respect, that special attention should be given to paediatric cancers and rare cancers;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>973</NumAm>

<RepeatBlock-By><Members>Alin Mituța, Nicolae Ştefănuță, Hilde Vautmans, Vlad Gheorghe</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 63</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 63. Strongly advocates the extension of joint procurement procedures for cancer medicines to improve affordability and access to cancer treatments at EU level; | 63. Strongly advocates the extension of joint procurement procedures for cancer medicines ***and cancer preventing vaccines like HPV and hepatitis B vaccines*** to improve affordability and access to cancer treatments at EU level; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>974</NumAm>

<RepeatBlock-By><Members>Bronis Ropė</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 63</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 63. Strongly advocates the extension of joint procurement procedures for cancer medicines to improve affordability and access to cancer treatments at EU level; | 63. Strongly advocates the ***centralisation and*** extension of joint ***European*** procurement procedures for cancer medicines to improve affordability and access to cancer treatments at EU level; |

Or. <Original>{LT}lt</Original>

</Amend>

<Amend>Amendment <NumAm>975</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 63</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 63. Strongly advocates the extension of joint procurement procedures for cancer ***medicines*** to improve affordability and access to cancer treatments ***at EU level***; | 63. Strongly advocates the extension of joint procurement procedures for cancer ***health technologies*** to improve affordability and access to cancer treatments ***in all Member States***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>976</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná, Alexis Georgoulis, Giorgos Georgiou</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 63 a (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***63a. Considers that it is crucial to reduce inequalities within EU healthcare systems, as well as discrepancies between the approval and access to medicines; recommends, therefore, that the mandatory uptake of joint clinical assessments under the HTA regulation be considered, to provide equal access to optimal cancer care to all patients;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>977</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 64</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| ***64. Calls for a review of data exclusivity in the authorisation process of medicines29, i.e. the period of time within which the marketing authorisation holder of a medicine enjoys exclusive access to the results of preclinical tests and clinical trials, so that compulsory licensing can allow for the market entry of cancer treatments in the event of a health crisis (such as the COVID-19 crisis) or to overcome the rising cost of specific treatments;*** | ***deleted*** |
| ***\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_*** |  |
| ***29 In particular Article 14 of Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, OJ L 136, 30.4.2004, p. 1.*** |  |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>978</NumAm>

<RepeatBlock-By><Members>Peter Liese</Members>

<AuNomDe>{EPP}on behalf of the EPP Group</AuNomDe>

<Members>Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 64</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 64. Calls ***for a review of data exclusivity*** in the ***authorisation process of medicines29*** ***, i.e. the*** period of time ***within which the marketing authorisation holder of a medicine enjoys exclusive*** access to ***the results of preclinical tests and clinical trials, so that compulsory licensing can allow for the market entry of*** cancer ***treatments in the event of a health crisis (such as the COVID-19 crisis) or to overcome the rising cost of specific treatments***; | 64. Calls ***on the Commission to support a regulatory framework which strengthens incentives for rare cancer treatment*** in the ***EU to effectively address existing shortcomings; underlines that the patent systems all over the world are drafted in a way that for a specific*** period of time***, i.e. only for the duration of the patent, the inventor is allowed to commercially exploit its patent, whereas thereafter the invention can be freely exploited by anyone; calls on the Commission to develop new targeted incentives to ensure equitable*** access to cancer ***medicines also in areas where the development of products would otherwise not be sustainable***; |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |  |
| ***29 In particular Article 14 of Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, OJ L 136, 30.4.2004, p. 1.*** |  |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>979</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 64</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 64. ***Calls for a review of data exclusivity*** in the ***authorisation process*** of medicines29 ***, i.e. the period of time within which the marketing authorisation holder of a medicine enjoys*** exclusive access to ***the results of preclinical tests and clinical trials, so that compulsory licensing can allow for the market entry of cancer*** treatments in the ***event of a health crisis (such as the COVID-19 crisis) or to overcome the rising cost of specific treatments***; | 64. ***Acknowledges the progress and improvements made*** in the ***EU regulations addressing the disclosure of sensitive and confidential information in the framework of the authorisation*** of medicines29***; notes that*** exclusive access to ***certain information provides the necessary legal certainty to operators to develop innovative*** treatments ***and medicines*** in the ***fight against cancer***; |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 29 In particular Article 14 of Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, OJ L 136, 30.4.2004, p. 1. | 29 In particular Article 14 of Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, OJ L 136, 30.4.2004, p. 1. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>980</NumAm>

<RepeatBlock-By><Members>Michèle Rivasi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 64</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 64. Calls for a review of data exclusivity in the authorisation process of medicines29 , i.e. the period of time within which the marketing authorisation holder of a medicine enjoys exclusive access to the results of preclinical tests and clinical trials, so that compulsory licensing can allow for the market entry of cancer treatments in the event of a health crisis (such as the COVID-19 crisis) or to overcome the rising cost of specific treatments; | 64. Calls for a review of data exclusivity in the authorisation process of medicines29 , i.e. the period of time within which the marketing authorisation holder of a medicine enjoys exclusive access to the results of preclinical tests and clinical trials, so that compulsory licensing can allow for the market entry of cancer treatments ***through a waiver of data and market exclusivity*** in the event of a health crisis (such as the COVID-19 crisis) or to overcome the rising cost of specific treatments; |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 29 In particular Article 14 of Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, OJ L 136, 30.4.2004, p. 1. | 29 In particular Article 14 of Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, OJ L 136, 30.4.2004, p. 1. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>981</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 64</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 64. Calls for a review of data exclusivity in the authorisation process of medicines29 , i.e. the period of time within which the marketing authorisation holder of a medicine enjoys exclusive access to the results of preclinical tests and clinical trials, so that compulsory licensing can allow for the market entry of cancer treatments in the event of a health crisis (such as the COVID-19 ***crisis***) or to overcome the rising cost of specific treatments; | 64. Calls for a review of data exclusivity in the authorisation process of medicines29 , i.e. the period of time within which the marketing authorisation holder of a medicine enjoys exclusive access to the results of preclinical tests and clinical trials, so that compulsory licensing can allow for the market entry of cancer treatments in the event of a ***major*** health crisis (such as the ***ongoing*** COVID-19 ***pandemic***) or to overcome the rising cost of specific treatments; |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 29 In particular Article 14 of Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, OJ L 136, 30.4.2004, p. 1. | 29 In particular Article 14 of Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, OJ L 136, 30.4.2004, p. 1. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>982</NumAm>

<RepeatBlock-By><Members>Nicolás González Casares, Alessandra Moretti, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 64 a (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***64a. Welcomes the Commission initiative to revise the EU legislation on medicines for orphan, paediatric and rare diseases that will benefit patients suffering from cancers with low incidence and few treatment options, especially in the area of paediatric oncology;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>983</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 65</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| ***65. Calls on the Commission to submit a proposal for the revision of Directive 89/105/EEC on the transparency of measures regulating the prices of medicinal products30 in order to ensure effective controls and full transparency of the procedures used to determine the price and reimbursement of the cost of medicines, in particular cancer medicines, in Member States; calls for pharmaceutical companies to provide information on financing with public resources, as well as on the tax benefits and subsidies they have received; requests that the calculation of drug costs should take into account the use of public funds; calls on the European Medicines Agency (EMA) to increase the number of audits in order to assess pharmaceutical companies’ compliance with the requirements on transparency;*** | ***deleted*** |
| ***\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_*** |  |
| ***30 Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems, OJ L 40, 11.2.1989, p. 8.*** |  |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>984</NumAm>

<RepeatBlock-By><Members>Peter Liese</Members>

<AuNomDe>{EPP}on behalf of the EPP Group</AuNomDe>

<Members>Tomislav Sokol, Liudas Mažylis, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 65</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 65. Calls on the Commission ***to submit a proposal for the revision of Directive 89/105/EEC*** on the ***transparency of measures regulating the prices of medicinal products30*** ***in order to ensure effective controls and full transparency of the procedures used to determine the price and reimbursement of the cost of*** medicines, in particular cancer medicines***, in Member States***; ***calls for pharmaceutical companies to provide information on financing with public resources, as well as on the tax benefits and subsidies they have received; requests that the calculation of drug costs should take into account the use of public funds; calls on the European Medicines Agency (EMA) to increase the number of audits in order to assess pharmaceutical companies’ compliance with the requirements on transparency;*** | 65. Calls on the Commission ***and Member States to support pricing models based on real production costs, innovation and value to patients; calls also*** on the ***Commission to investigate novel pricing and payment models and their possible impact on patient access to innovative*** medicines, in particular cancer medicines; |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |  |
| ***30 Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems, OJ L 40, 11.2.1989, p. 8.*** |  |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>985</NumAm>

<RepeatBlock-By><Members>Andrey Slabakov, Angel Dzhambazki, Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 65</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 65. Calls on the Commission to ***submit a proposal for the revision of*** Directive 89/105/EEC on the transparency of measures regulating the prices of medicinal products30 ***in order to ensure effective controls and full transparency of the procedures used to determine the price and reimbursement of the cost of medicines, in particular cancer medicines, in Member States***; calls for pharmaceutical companies to provide information on financing with public resources, as well as on the tax benefits and subsidies they have received; requests that the calculation of drug costs should take into account the use of public funds; calls on the European Medicines Agency (EMA) to increase the number of audits in order to assess pharmaceutical companies’ compliance with the requirements on transparency; | 65. Calls on the Commission to ***launch an in-depth assessment on the need to review*** Directive 89/105/EEC on the transparency of measures regulating the prices of medicinal products30; calls for pharmaceutical companies to provide information on financing with public resources, as well as on the tax benefits and subsidies they have received; requests that the calculation of drug costs should take into account the use of public funds; calls on the European Medicines Agency (EMA) to increase the number of audits in order to assess pharmaceutical companies’ compliance with the requirements on transparency; |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 30 Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems, OJ L 40, 11.2.1989, p. 8. | 30 Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems, OJ L 40, 11.2.1989, p. 8. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>986</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 65</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 65. Calls on the Commission to submit a proposal for the revision of Directive 89/105/EEC on the transparency of measures regulating the prices of medicinal products30 in order to ensure effective controls and full transparency of the procedures used to determine the price and reimbursement of the cost of medicines, in particular cancer medicines, in Member States; calls for pharmaceutical companies to provide information on financing with public resources, as well as on the tax benefits and subsidies they have received; requests that the calculation of drug costs should take into account the use of public funds; ***calls on the European Medicines Agency (EMA) to increase the number of audits in order to assess pharmaceutical companies’ compliance with the requirements on transparency;*** | 65. Calls on the Commission to submit a proposal for the revision of Directive 89/105/EEC on the transparency of measures regulating the prices of medicinal products30 in order to ensure***, under the framework of Member States internal regulations,*** effective controls and full transparency of the procedures used to determine the price and reimbursement of the cost of medicines, in particular cancer medicines, in Member States; calls for pharmaceutical companies to provide information on financing with public resources, as well as on the tax benefits and subsidies they have received; requests that the calculation of drug costs should take into account the use of public funds; |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 30 Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems, OJ L 40, 11.2.1989, p. 8. | 30 Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems, OJ L 40, 11.2.1989, p. 8. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>987</NumAm>

<RepeatBlock-By><Members>Michèle Rivasi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 65</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 65. Calls on the Commission to submit a proposal for the revision of Directive 89/105/EEC on the transparency of measures regulating the prices of medicinal products30 in order to ensure effective controls and full transparency of the procedures used to determine the price and reimbursement of the cost of medicines, in particular cancer medicines, in Member States; calls for pharmaceutical companies to provide information on financing with public resources, as well as on the tax benefits and subsidies they have received; requests that the calculation of drug costs should take into account the use of public funds; calls on the European Medicines Agency (EMA) to increase the number of audits in order to assess pharmaceutical companies’ compliance with the requirements on transparency; | 65. Calls on the Commission to submit a proposal for the revision of Directive 89/105/EEC on the transparency of measures regulating the prices of medicinal products30 in order to ensure effective controls and full transparency of the procedures used to determine the price and reimbursement of the cost of medicines, in particular cancer medicines, in Member States; calls for pharmaceutical companies to provide information on ***research and development costs, including the*** financing with public resources, as well as on the tax benefits and subsidies they have received; requests that the calculation of drug costs should take into account the use of public funds; calls on the European Medicines Agency (EMA) to increase the number of audits in order to assess pharmaceutical companies’ compliance with the requirements on transparency; ***calls on the Commission to promote and facilitate information-sharing among Member States on the net prices of medicines and to contribute to the implementation of the World Health Assembly (WHA) Resolution on Improving the transparency of markets for medicines, vaccines and other health products, which calls for taking appropriate measures to publicly share information on net prices;*** |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 30 Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems, OJ L 40, 11.2.1989, p. 8. | 30 Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems, OJ L 40, 11.2.1989, p. 8. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>988</NumAm>

<RepeatBlock-By><Members>Nicolás González Casares, Maria Arena, Romana Jerković, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 65</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 65. Calls on the Commission to submit a proposal for the revision of Directive 89/105/EEC on the transparency of measures regulating the prices of medicinal products30 in order to ensure effective controls and full transparency of the procedures used to determine the price and reimbursement of the cost of medicines, in particular cancer medicines, in Member States; calls ***for*** pharmaceutical companies to provide information on financing with public resources, as well as on the tax benefits and subsidies they have received; requests that the calculation of drug costs should take into account the use of public funds; calls on the European Medicines Agency (EMA) to increase the number of audits in order to assess pharmaceutical companies’ compliance with the requirements on transparency; | 65. Calls on the Commission to submit a proposal for the revision of Directive 89/105/EEC on the transparency of measures regulating the prices of medicinal products30 in order to ensure effective controls and full transparency of the procedures used to determine the price and reimbursement of the cost of medicines, in particular cancer medicines, in Member States; calls ***on competent authorities to request*** pharmaceutical companies to provide information on financing with public resources***, prior to marketing authorization***, as well as on the tax benefits and subsidies they have received; requests that the calculation of drug costs should take into account the use of public funds; calls on the European Medicines Agency (EMA) to increase the number of audits in order to assess pharmaceutical companies’ compliance with the requirements on transparency; |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 30 Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems, OJ L 40, 11.2.1989, p. 8. | 30 Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems, OJ L 40, 11.2.1989, p. 8. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>989</NumAm>

<RepeatBlock-By><Members>Tudor Ciuhodaru</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 65</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 65. Calls on the Commission to submit a proposal for the revision of Directive 89/105/EEC on the transparency of measures regulating the prices of medicinal products30 in order to ensure effective controls and full transparency of the procedures used to determine the price and reimbursement of the cost of medicines, in particular cancer medicines, in Member States; calls for pharmaceutical companies to provide information on financing with public resources, as well as on the tax benefits and subsidies they have received; requests that the calculation of drug costs should take into account the use of public funds; calls on the European Medicines Agency (EMA) to increase the number of audits in order to assess pharmaceutical companies’ compliance with the requirements on transparency; | 65. Calls on the Commission to submit a proposal for the revision of Directive 89/105/EEC on the transparency of measures regulating the prices of medicinal products30 in order to ensure effective controls and full transparency of the procedures used to determine the price and reimbursement of the cost of medicines, in particular cancer medicines, in Member States; calls for pharmaceutical companies to provide information on financing with public resources, as well as on the tax benefits and subsidies they have received***, in order to prevent unjustified prices appearing***; requests that the calculation of drug costs should take into account the use of public funds; calls on the European Medicines Agency (EMA) to increase the number of audits in order to assess pharmaceutical companies’ compliance with the requirements on transparency; |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 30 Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems, OJ L 40, 11.2.1989, p. 8. | 30 Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems, OJ L 40, 11.2.1989, p. 8. |

Or. <Original>{RO}ro</Original>

</Amend>

<Amend>Amendment <NumAm>990</NumAm>

<RepeatBlock-By><Members>Marian-Jean Marinescu</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 65 a (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***65a. Calls on the Commission to develop a fair pricing model for medicinal products, in particular for cancer medicines, that would reflect the real cost of research and production, include a justified limit for expenditures on marketing, take into consideration sustainable profitability for the industry and introduce a bonus system that rewards the added therapeutic value;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>991</NumAm>

<RepeatBlock-By><Members>Hilde Vautmans, Irena Joveva</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 65 b (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***65b. Calls on the Commission to promote the revision of the Paediatric regulation aimed at resolving the gap in paediatric cancer products, which represent less than 20% of adult cancer approved products;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>992</NumAm>

<RepeatBlock-By><Members>Hilde Vautmans, Irena Joveva</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 65 c (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***65c. Calls on the EMA, Commission and Member States to assess the efficacy and outcomes of cancer treatments, allowing for more personalised treatment and outcome based reimbursement;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>993</NumAm>

<RepeatBlock-By><Members>Alessandra Moretti</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 66</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 66. Notes that huge advances in biology have revealed that cancer is an umbrella term for more than 200 diseases, and that precision or personalised medicine can be made available through the drug targeting of various mutations; considers that precision or personalised medicine, consisting of a treatment choice based on individual tumour biomarkers, is a promising way to improve cancer treatment; encourages Member States, therefore, to promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to personalised treatment for patients; | 66. Notes that huge advances in biology have revealed that cancer is an umbrella term for more than 200 diseases, and that precision or personalised medicine can be made available through the drug targeting of various mutations; considers that precision or personalised medicine, consisting of a treatment choice based on individual tumour biomarkers, is a promising way to improve cancer treatment; encourages Member States, therefore, to promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to personalised treatment for patients; ***highlights the fact that the research community, including scientific societies, are conducting extensive research in the area of precision medicine; calls for the inclusion of existing and ongoing research, especially in the area of oncology, to be taken into account while implementing the actions of Europe’s Beating Cancer Plan focussing on personalised medicine, including the European Cancer Imaging Initiative, the Partnership on Personalised Medicine, the Roadmap towards Personalised Prevention and the new digital platforms;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>994</NumAm>

<RepeatBlock-By><Members>Nicolás González Casares, Maria Arena, Romana Jerković, Sara Cerdas, Marc Angel, Estrella Durá Ferrandis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 66</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 66. Notes that huge advances in biology have revealed that cancer is an umbrella term for more than 200 diseases, and that precision or personalised medicine can be made available through the drug targeting of various ***mutations***; considers that precision or personalised medicine, consisting of a treatment choice based on individual tumour ***biomarkers***, is a promising way to improve cancer treatment; encourages Member States, therefore, to promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to personalised treatment for patients; | 66. Notes that huge advances in biology have revealed that cancer is an umbrella term for more than 200 diseases, and that precision or personalised medicine can be made available through the drug targeting of various ***tumour cell genotypes/phenotypes***; considers that precision or personalised medicine, consisting of a treatment choice based on individual tumour ***genotypes/phenotypes***, is a promising way to improve cancer treatment; encourages Member States, therefore, to promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to personalised treatment for patients; ***notes that the fragmentation and classification of cancers, based on specific genotypes, should not lead to the definition of "artificial rare diseases" to increase financial compensation;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>995</NumAm>

<RepeatBlock-By><Members>Michèle Rivasi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 66</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 66. Notes that huge advances in biology have revealed that cancer is an umbrella term for more than 200 diseases, and that precision or personalised medicine can be made available through the drug targeting of various mutations; considers that precision or personalised medicine, consisting of a treatment choice based on individual tumour biomarkers, is a promising way to improve cancer treatment; encourages Member States, therefore, to promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to personalised treatment for patients; | 66. Notes that huge advances in biology have revealed that cancer is an umbrella term for more than 200 diseases, and that precision or personalised medicine can be made available through the drug targeting of various mutations; considers that precision or personalised medicine, consisting of a treatment choice based on individual tumour biomarkers, is a promising way to improve cancer treatment; encourages Member States, therefore, to promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to personalised treatment for patients; ***stresses the need for a careful consideration of personalised medicines for prevalent diseases, including some cancer indications, which should not fall within the remit of the orphan medicinal products regulation in order to prevent an unsustainable incentive system;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>996</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 66</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 66. Notes that huge advances in biology have revealed that cancer is an umbrella term for more than 200 diseases, and that precision or personalised medicine can be made available through the drug targeting of various ***mutations***; considers that precision or personalised medicine, consisting of a treatment choice based on individual tumour biomarkers, is a promising way to improve cancer treatment; encourages Member States, therefore, to promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to personalised treatment ***for*** patients; | 66. Notes that huge advances in biology have revealed that cancer is an umbrella term for more than 200 diseases, and that precision or personalised medicine can be made available through the drug targeting of various ***genetic alterations***; considers that precision or personalised medicine, consisting of a treatment choice based on individual tumour biomarkers, is a promising way to improve cancer treatment; encourages Member States, therefore, to promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to personalised treatment ***of*** patients; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>997</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 66</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 66. Notes that huge advances in biology have revealed that cancer is an umbrella term for more than 200 diseases, and that precision or personalised medicine can be made available through the drug targeting of various mutations; considers that precision or personalised medicine, consisting of a treatment choice based on individual tumour biomarkers, is a promising way to improve cancer treatment; encourages Member States, therefore, to promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to personalised treatment for patients; | 66. Notes that huge advances in biology have revealed that cancer is an umbrella term for more than 200 diseases, and that precision or personalised medicine can be made available through the drug targeting of various mutations; considers that precision or personalised medicine, consisting of a treatment choice based on individual tumour biomarkers, is a promising way to improve cancer treatment; encourages Member States, therefore, to promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to personalised treatment for patients***, in full respect of their data privacy, including ensuring that patients are informed of, and give permission for, the use of their health data***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>998</NumAm>

<RepeatBlock-By><Members>Giorgos Georgiou, Alexis Georgoulis, João Pimenta Lopes</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 66</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 66. Notes that huge advances in biology have revealed that cancer is an umbrella term for more than 200 diseases, and that precision or personalised medicine can be made available through the drug targeting of various mutations; considers that precision or personalised medicine, consisting of a treatment choice based on individual tumour biomarkers, is a promising way to improve cancer treatment; encourages Member States, therefore, to promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to personalised treatment for patients; | 66. Notes that huge advances in biology have revealed that cancer is an umbrella term for more than 200 diseases, and that precision or personalised medicine can be made available through the drug targeting of various mutations; considers that precision or personalised medicine, consisting of a treatment choice based on individual tumour biomarkers, is a promising way to improve cancer treatment; encourages Member States, therefore, to promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to personalised treatment for patients ***in respect of data privacy and ensuring that patients are informed and consent to the use of their health data for research and market purposes***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>999</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 66</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 66. Notes that huge advances in biology have revealed that cancer is an umbrella term for more than 200 diseases, and that precision or personalised medicine can be made available through the drug targeting of various mutations; considers that precision or personalised medicine, consisting of a treatment choice based on individual tumour biomarkers, is a promising way to improve cancer treatment; encourages Member States, therefore, to promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to personalised treatment for patients; | 66. Notes that huge advances in biology have revealed that cancer is an umbrella term for more than 200 diseases, and that precision or personalised medicine can be made available through the drug targeting of various mutations; considers that precision or personalised medicine, consisting of a treatment choice based on individual tumour biomarkers, is a promising way to improve cancer treatment; encourages Member States, therefore, to ***develop personalised medicine across the EU through cooperation between Member States and data interoperability, to*** promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to personalised treatment for patients; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1000</NumAm>

<RepeatBlock-By><Members>Tomislav Sokol, Sunčana Glavak, Deirdre Clune, Cindy Franssen</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 66</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 66. Notes that huge advances in biology have revealed that cancer is an umbrella term for more than 200 diseases, and that precision or personalised medicine can be made available through the drug targeting of various mutations; considers that precision or personalised medicine, consisting of a treatment choice based on individual tumour biomarkers, is a promising way to improve cancer treatment; encourages Member States, therefore, to promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to personalised treatment for patients; | 66. Notes that huge advances in biology have revealed that cancer is an umbrella term for more than 200 diseases, and that precision or personalised medicine can be made available through the drug targeting of various mutations; considers that precision or personalised medicine, consisting of a treatment choice based on individual tumour biomarkers, is a promising way to improve cancer treatment; encourages Member States, therefore, to ***increase the awareness of personalised medicine among healthcare professionals and patients, to*** promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to personalised treatment for patients; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1001</NumAm>

<RepeatBlock-By><Members>Andrey Slabakov, Angel Dzhambazki, Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 66</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 66. Notes that huge advances in biology have revealed that cancer is an umbrella term for more than 200 diseases, and that precision or personalised medicine can be made available through the drug targeting of various mutations; considers that precision or personalised medicine, consisting of a treatment choice based on individual tumour biomarkers, is a promising way to improve cancer treatment; encourages Member States, therefore, to promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to personalised treatment for patients; | 66. Notes that huge advances in biology have revealed that cancer is an umbrella term for more than 200 diseases, and that precision or personalised medicine can be made available through the drug targeting of various mutations; considers that precision or personalised medicine, consisting of a treatment choice based on individual tumour biomarkers, is a promising way to improve cancer treatment; encourages Member States, therefore, to promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to ***advanced diagnostics and*** personalised treatment for patients; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1002</NumAm>

<RepeatBlock-By><Members>Nicolás González Casares, Alessandra Moretti, Maria Arena, Romana Jerković, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 66 a (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***66a. Highlights the fact that the research community, including scientific societies, are conducting extensive research in the area of precision medicine; calls for the inclusion of existing and ongoing research, especially in the area of oncology, to be taken into account while implementing the actions of Europe’s Beating Cancer Plan focussing on personalised medicine, including the European Cancer Imaging Initiative, the Partnership on Personalised Medicine, the Roadmap towards Personalised Prevention and the new digital platforms;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1003</NumAm>

<RepeatBlock-By><Members>Hilde Vautmans, Irena Joveva</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 67</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 67. Calls for the full and rapid application of Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use31 ; considers that the application of the regulation would facilitate the launch of large clinical trials carried out in a harmonised, efficient and coordinated manner at European level in order to facilitate research into cancer drugs and improve cancer patients’ and their families’ quality of life; | 67. Calls for the full and rapid application of Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use31 ; considers that the application of the regulation would facilitate the launch of large clinical trials carried out in a harmonised, efficient and coordinated manner at European level in order to facilitate research into cancer drugs and improve cancer patients’ and their families’ quality of life; ***urges for a fresh review of opportunities to reduce the bureaucracy associated to clinical trials, as well as long-term learning from the COVID-19 pandemic on future forms of international trial cooperation and information-sharing;*** |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 31 OJ L 158, 27.5.2014, p. 1. | 31 OJ L 158, 27.5.2014, p. 1. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1004</NumAm>

<RepeatBlock-By><Members>Tomislav Sokol, Sunčana Glavak, Deirdre Clune, Cindy Franssen</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 67</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 67. Calls for the full and rapid application of Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use31 ; considers that the application of the regulation would facilitate the launch of large clinical trials carried out in a harmonised, efficient and coordinated manner at European level in order to facilitate research into cancer drugs and improve cancer patients’ and their families’ quality of life; | 67. Calls for the full and rapid application of Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use31 ; considers that the application of the regulation would facilitate the launch of large clinical trials carried out in a harmonised, efficient and coordinated manner at European level in order to facilitate research into cancer drugs and improve cancer patients’ and their families’ quality of life; ***urges for a fresh review of opportunities to reduce the bureaucracy associated to clinical trials, as well as long term learning from the COVID-19 pandemic on future forms of international trial cooperation and information-sharing;*** |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 31 OJ L 158, 27.5.2014, p. 1. | 31 OJ L 158, 27.5.2014, p. 1. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1005</NumAm>

<RepeatBlock-By><Members>Alexis Georgoulis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 67</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 67. Calls for the full and rapid application of Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use31 ; considers that the application of the regulation would facilitate the launch of large clinical trials carried out in a harmonised, efficient and coordinated manner at European level in order to facilitate research into cancer drugs and improve cancer patients’ and their families’ quality of life; | 67. Calls for the full and rapid application of Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use31 ; considers that the application of the regulation would facilitate the launch of large clinical trials carried out in a harmonised, efficient and coordinated manner at European level in order to facilitate research into cancer drugs and improve cancer patients’ and their ***families’ quality*** of life; ***urges for a fresh review of opportunities to reduce the bureaucracy associated to clinical trials, as well as long-term learning from the COVID-19 pandemic on future forms of international trial cooperation and information-sharing;*** |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 31 OJ L 158, 27.5.2014, p. 1. | 31 OJ L 158, 27.5.2014, p. 1. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1006</NumAm>

<RepeatBlock-By><Members>Alessandra Moretti</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 67</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 67. Calls for the full and rapid application of Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use31 ; considers that the application of the regulation would facilitate the launch of large clinical trials carried out in a harmonised, efficient and coordinated manner at European level in order to facilitate research into cancer drugs and improve cancer patients’ and their families’ quality of life; | 67. Calls for the full and rapid application of Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use31; considers that the application of the regulation would facilitate the launch of large clinical trials carried out in a harmonised, efficient and coordinated manner at European level in order to facilitate research into cancer drugs and improve cancer patients’ and their families’ quality of life; ***considers, furthermore, that the regulation should be applied in a consistent manner in all EU Member States with the aim of rationalising the bureaucratic burden associated with clinical research;*** |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 31 OJ L 158, 27.5.2014, p. 1. | 31 OJ L 158, 27.5.2014, p. 1. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1007</NumAm>

<RepeatBlock-By><Members>Nicolás González Casares, Maria Arena, Romana Jerković, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 67</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 67. Calls for the full and rapid application of Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use31 ; considers that the application of the regulation would facilitate the launch of large clinical trials carried out in a harmonised, efficient and coordinated manner at European level in order to facilitate research into cancer drugs and improve cancer patients’ and their families’ quality of life; | 67. Calls for the full and rapid application of Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use31 ; considers that the application of the regulation would facilitate the launch of large clinical trials carried out in a harmonised, efficient and coordinated manner at European level in order to facilitate research into cancer drugs and improve cancer patients’ and their families’ quality of life; ***considers, furthermore, that the regulation should be implemented in a consistent manner in all EU Member States;*** |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 31 OJ L 158, 27.5.2014, p. 1. | 31 OJ L 158, 27.5.2014, p. 1. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1008</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 67</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 67. Calls for the full and rapid application of Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use31 ; considers that the application of the regulation would facilitate the launch of large clinical trials carried out in a harmonised, efficient and coordinated manner at European level in order to facilitate research into cancer drugs and improve cancer patients’ and their families’ quality of life; | 67. Calls for the full and rapid application of Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use31 ; considers that the application of the regulation would facilitate the launch of large clinical trials carried out in a harmonised, efficient and coordinated manner at European level in order to facilitate ***anticipatory and responsive*** research into cancer drugs and improve cancer patients’ and their families’ quality of life; |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 31 OJ L 158, 27.5.2014, p. 1. | 31 OJ L 158, 27.5.2014, p. 1. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1009</NumAm>

<RepeatBlock-By><Members>Giorgos Georgiou, Alexis Georgoulis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 67</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 67. Calls for the full and rapid application of Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use31 ; considers that the application of the regulation would facilitate the launch of large clinical trials carried out in a harmonised, efficient and coordinated manner at European level in order to facilitate research into cancer drugs and improve cancer patients’ and their families’ quality of life; | 67. Calls for the full and rapid application of Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use31 ; considers that the application of the regulation would facilitate the launch of large clinical trials ***across Europe*** carried out in a harmonised, efficient and coordinated manner at European level in order to facilitate research into cancer drugs and improve cancer patients’ and their families’ quality of life; |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 31 OJ L 158, 27.5.2014, p. 1. | 31 OJ L 158, 27.5.2014, p. 1. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1010</NumAm>

<RepeatBlock-By><Members>Nicolae Ştefănuță, Alin Mituța, Ivars Ijabs, Vlad Gheorghe</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 67</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 67. Calls for the full and rapid application of Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use31 ; considers that the application of the regulation would facilitate the launch of large clinical trials carried out in a harmonised, efficient and coordinated manner at European level in order to facilitate research into cancer drugs and improve cancer patients’ and their families’ quality of life; | 67. Calls for the full and rapid application of Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use31 ; considers that the application of the regulation would facilitate the launch of large clinical trials carried out ***across Europe*** in a harmonised, efficient and coordinated manner at European level in order to facilitate research into cancer drugs and improve cancer patients’ and their families’ quality of life; |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 31 OJ L 158, 27.5.2014, p. 1. | 31 OJ L 158, 27.5.2014, p. 1. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1011</NumAm>

<RepeatBlock-By><Members>Lídia Pereira</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 67 a (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***67a. Recognises the prodigious impact that the Regulation on orphan medicinal products (EC/141/2000)1a*** ***has had on developing innovative medicines, including for rare cancers; acknowledges that many cancers are rare diseases; invites, therefore, the Commission to maintain the philosophy of this Regulation, namely incentives and current disease thresholds to allow for continuous investment in rare cancers;*** |
|  | ***\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_*** |
|  | ***1a*** ***https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32000R0141&from=EN*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1012</NumAm>

<RepeatBlock-By><Members>Alin Mituța, Nicolae Ştefănuță, Hilde Vautmans, Vlad Gheorghe</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 67 a (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***67a. Points out that the PRIME scheme launched by the European Medicines Agency can be a great instrument to enhance support for the development of innovative medicines in oncology so that they can reach the patient sooner;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1013</NumAm>

<RepeatBlock-By><Members>Tomislav Sokol, Sunčana Glavak, Cindy Franssen</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 68</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 68. Calls for a more sustainable environment for conducting research into the repurposing of medicines for cancer treatment and for the creation of an additional project that uses high-performance computing to rapidly test existing molecules and new drug combinations, starting with treatment for cancers with a poor prognosis and rare cancers; | 68. Calls for a more sustainable environment***, including financial support*** for conducting research into the repurposing of medicines for cancer treatment***, especially performed by third parties with no commercial intent*** and for the creation of an additional project that uses high-performance computing to rapidly test existing molecules and new drug combinations, starting with ***high unmet needs,*** treatment for cancers with a poor prognosis and rare cancers; ***suggests an EU cancer policy goal to double the survival rate for cancers with poor prognosis to connect across EU related initiatives;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1014</NumAm>

<RepeatBlock-By><Members>Peter Liese</Members>

<AuNomDe>{EPP}on behalf of the EPP Group</AuNomDe>

<Members>Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Marian-Jean Marinescu, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 68</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 68. Calls for a more sustainable environment for conducting research into the repurposing of medicines for cancer treatment and for the creation of an additional project that uses high-performance computing to rapidly test existing molecules and new drug combinations, starting with treatment for cancers with a poor prognosis and rare cancers; | 68. Calls for a more sustainable environment ***including financial support*** for conducting research into the repurposing of medicines for cancer treatment***, especially performed by third parties with no commercial intent*** and for the creation of an additional project that uses high-performance computing to rapidly test existing molecules and new drug combinations, starting with ***high unmet needs,*** treatment for cancers with a poor prognosis and rare cancers; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1015</NumAm>

<RepeatBlock-By><Members>Michèle Rivasi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 68</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 68. Calls for a more sustainable environment for conducting research into the repurposing of medicines for cancer treatment and for the creation of an additional project that uses high-performance computing to rapidly test existing molecules and new drug combinations, starting with treatment for cancers with a poor prognosis and rare cancers; | 68. Calls for a more sustainable environment for conducting research into the repurposing of medicines for cancer treatment and for the creation of an additional project that uses high-performance computing to rapidly test existing molecules and new drug combinations, starting with treatment for cancers with a poor prognosis and rare cancers; ***calls for a legal framework for the clinical development of repurposed medicines for indications with high unmet needs performed by non-commercial entities, including for the EMA to be given the authority to require labelling changes following assessment of the clinical data from the non-profit research;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1016</NumAm>

<RepeatBlock-By><Members>Alexis Georgoulis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 68</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 68. Calls for a more sustainable environment for conducting research into the repurposing of medicines for cancer treatment and for the creation of an additional project that uses high-performance computing to rapidly test existing molecules and new drug combinations, starting with treatment for cancers with a poor prognosis and rare cancers; | 68. Calls for a more sustainable environment for conducting research into the repurposing of medicines for cancer treatment and for the creation of an additional project that uses high-performance computing to rapidly test existing molecules and new drug combinations, starting with treatment for cancers with a poor prognosis and rare cancers; ***suggests an EU cancer policy goal of doubling survival for poor prognosis tumours to connect across EU related initiatives;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1017</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 68</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 68. Calls for a more sustainable environment for conducting research ***into*** the repurposing of medicines for cancer treatment and for the creation of an additional project that uses high-performance computing to rapidly test existing molecules and new drug combinations, starting with treatment for cancers with a poor prognosis and rare cancers; | 68. Calls for a more sustainable ***and extensible*** environment for conducting ***new studies and analysing existing*** research ***on*** the repurposing of medicines for cancer treatment***, reappraising the functionality of established therapies,*** and for the creation of an additional project that uses high-performance computing to rapidly test existing molecules and new drug combinations, starting with treatment for cancers with a poor prognosis and rare cancers; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1018</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 68</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 68. Calls for a more sustainable environment for conducting research into the repurposing of medicines for cancer treatment and for the creation of an additional project that uses high-performance computing to rapidly test existing molecules and new drug combinations, starting with treatment for cancers with a poor prognosis and rare cancers; | 68. Calls for a more sustainable environment for conducting ***anticipatory and responsive*** research into the repurposing of medicines for cancer treatment and for the creation of an additional project that uses high-performance computing to rapidly test existing molecules and new drug combinations, starting with treatment for cancers with a poor prognosis and rare cancers; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1019</NumAm>

<RepeatBlock-By><Members>Peter Liese</Members>

<AuNomDe>{EPP}on behalf of the EPP Group</AuNomDe>

<Members>Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Marian-Jean Marinescu, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 68 a (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***68a. Stresses the need to promote the innovation of life-saving cancer treatments; calls, therefore, on the Commission to create a pharmaceutical legislation framework and reimbursement system for oncological medicines and therapies, which incentivizes real breakthrough innovations, rather than the so-called ‘me too' pharmaceuticals, which are just another substance for the same indication without major benefits, or the highly expensive pharmaceuticals that offer only minor improvements for patients; considers that resources should instead be concentrated on innovative, life-changing technologies, such as immunotherapy, genomic research (mRNA and CRISPR), DNA sequencing, cell therapy, precision and personalized medicines and microbiome treatments;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1020</NumAm>

<RepeatBlock-By><Members>Nicolás González Casares, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Marc Angel, Estrella Durá Ferrandis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 68 b (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***68b. Acknowledges that many upcoming technologies will require complex regulations (cell and gene therapies, for example); considers that Europe should fund, incentivize and ensure a regulatory process that actively helps and encourages research and innovation, anticipating the needs of researchers in academia, industry and the clinic, actively informing and guiding them on regulatory processes, preparing the ground for future technologies and evaluating them step by step, fostering the entry of safe and effective new treatments to the market;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1021</NumAm>

<RepeatBlock-By><Members>Bronis Ropė</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 68 c (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***68c. Welcomes the increasing availability of personalised cancer therapies through the development of drug repurposing strategies; calls for the wider use of previously developed personalised medicine drugs through a strategy of molecular targets rather than disease localisation in the selection of treatments, through the development of DRUP-type (drug rediscovery protocol) projects;*** |

Or. <Original>{LT}lt</Original>

</Amend>

<Amend>Amendment <NumAm>1022</NumAm>

<RepeatBlock-By><Members>Nicolás González Casares, Alessandra Moretti, Maria Arena, Romana Jerković, Sara Cerdas, Marc Angel, Estrella Durá Ferrandis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 69</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 69. Supports the development of clinical trials on the use of new cancer drugs in adults and children; | 69. ***Reiterates the importance of generating and reporting strong evidence on the efficacy and safety profiles of medicines, both in clinical trials and in post-market entry follow-up studies;*** supports the development of clinical trials on the use of new cancer drugs in adults and children; ***underlines that authorities must ensure transparency, compliance with study conduct requirements and early communication of relevant data to the EMA and the general public;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1023</NumAm>

<RepeatBlock-By><Members>Tudor Ciuhodaru</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 69</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 69. Supports the development of clinical trials on the use of new cancer drugs in adults and children; | 69. Supports the development of clinical trials on the use of new cancer drugs in adults and children; ***supports the development of clinical trials in surgical oncology as part of loco-regional treatment, and promotes greater investment of EU and national research and innovation funds in surgical oncology research;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1024</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 69</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 69. Supports the development of clinical trials on the use of new cancer drugs in adults and children; | 69. Supports the development of clinical trials on the use of new cancer drugs in adults and children***, as called for, for example, in the European Parliament resolution of 15 December 2016 on the regulation on paediatric medicines P8\_TA(2016)0511***; |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>1025</NumAm>

<RepeatBlock-By><Members>Alessandra Moretti</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 69</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 69. Supports the development of clinical trials ***on the use of new*** cancer ***drugs in adults and*** children; | 69. Supports the development of clinical trials ***for the development of more effective and safer forms of treatment, therapies and care for*** cancer ***patients, including*** children ***and the elderly***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1026</NumAm>

<RepeatBlock-By><Members>Tomislav Sokol, Sunčana Glavak, Cindy Franssen</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 69</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 69. Supports the development of clinical trials ***on the use of new cancer drugs in adults and*** children; | 69. Supports the development of clinical trials ***across the EU, for the invention of improved forms of treatment and care for patients, including*** children ***and older patients***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1027</NumAm>

<RepeatBlock-By><Members>Alexis Georgoulis, Giorgos Georgiou</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 69</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 69. Supports the development of clinical trials ***on the use of new cancer drugs in adults and*** children; | 69. Supports the development of clinical trials ***for the discovery of improved forms of treatment and care for patients, including*** children ***and older patients***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1028</NumAm>

<RepeatBlock-By><Members>Hilde Vautmans, Irena Joveva, Alin Mituța</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 69</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 69. Supports the development of clinical trials ***on the use of new cancer drugs in adults and*** children; | 69. Supports the development of clinical trials ***for the discovery of improved forms of treatment and care for patients, including*** children ***and older patients***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1029</NumAm>

<RepeatBlock-By><Members>Giorgos Georgiou, Alexis Georgoulis, João Pimenta Lopes</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 69</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 69. Supports the development of clinical trials on the use of new cancer drugs in adults and children; | 69. Supports the development of clinical trials ***and research across Europe*** on the use of new cancer drugs in adults and children; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1030</NumAm>

<RepeatBlock-By><Members>Ivars Ijabs, Alin Mituța, Irena Joveva, Hilde Vautmans, Nicolae Ştefănuță</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 69</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 69. Supports the development of clinical trials on the use of new cancer drugs in adults and children; | 69. Supports the development of clinical trials on the use of new ***and affordable*** cancer drugs in adults and children; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1031</NumAm>

<RepeatBlock-By><Members>Loucas Fourlas</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 69</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 69. Supports the development of clinical trials on the use of new cancer drugs in adults and children; | 69. Supports the development of clinical trials on the use ***across Europe*** of new cancer drugs in adults and children; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1032</NumAm>

<RepeatBlock-By><Members>Peter Liese</Members>

<AuNomDe>{EPP}on behalf of the EPP Group</AuNomDe>

<Members>Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 69</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 69. Supports the development of clinical trials on the use of new cancer drugs in adults and children; | 69. Supports the development of clinical trials ***across Europe*** on the use of new cancer drugs in adults and children; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1033</NumAm>

<RepeatBlock-By><Members>Nicolae Ştefănuță, Alin Mituța, Ivars Ijabs, Vlad Gheorghe</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 69</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 69. Supports the development of clinical trials on the use of new cancer drugs in adults and children; | 69. Supports the development of clinical trials ***across Europe*** on the use of new cancer drugs in adults and children; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1034</NumAm>

<RepeatBlock-By><Members>Nicolás González Casares, Maria Arena, Romana Jerković, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 69 a (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***69a. Supports the development of clinical trials in surgical oncology as part of loco-regional treatment, and considers it necessary to promote greater investment of EU and national research and innovation funds in surgical oncology research;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1035</NumAm>

<RepeatBlock-By><Members>Peter Liese, Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Marian-Jean Marinescu, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 69 a (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***69a. Supports the development of clinical trials in surgical oncology as part of loco-regional treatment, and promotes greater investment of EU and national research and innovation funds in surgical oncology research;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1036</NumAm>

<RepeatBlock-By><Members>Giorgos Georgiou, Kateřina Konečná, João Pimenta Lopes, Alexis Georgoulis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 70</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| ***70. Welcomes the Commission’s intention to adopt a legislative proposal to establish a Health Emergency Preparedness and Response Authority (HERA) in order to anticipate, incentivise, co-develop and facilitate rapid, equal and sustainable access to cancer innovations for cancer patients; calls for a large consortium of public authorities, private companies and NGOs, including patient associations, to work together to guarantee the accessibility and affordability of cancer treatment options requiring complex technologies, for instance, cellular therapy (CAR T cells), adoptive immunotherapy through the use of tumour genome extracts (messenger RNA) and nanotechnologies;*** | ***deleted*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1037</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin, Angelo Ciocca</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 70</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 70. ***Welcomes the Commission’s intention to adopt a legislative proposal to establish a Health Emergency Preparedness and Response Authority (HERA)*** in order to anticipate, incentivise, co-develop and facilitate rapid, equal and sustainable access to cancer innovations for cancer patients; calls for a large consortium of public authorities, private companies and NGOs, including patient associations, to work together to guarantee the accessibility and affordability of cancer treatment options requiring complex technologies, for instance, cellular therapy (CAR T cells), adoptive immunotherapy through the use of tumour genome extracts (messenger RNA) and nanotechnologies; | 70. ***Strongly supports cooperation among Member States*** in order to anticipate, incentivise, co-develop and facilitate rapid, equal and sustainable access to cancer innovations for cancer patients calls for a large consortium of public authorities, private companies and NGOs, including patient associations, to work together to guarantee the accessibility and affordability of cancer treatment options requiring complex technologies, for instance, cellular therapy (CAR T cells), adoptive immunotherapy through the use of tumour genome extracts (messenger RNA) and nanotechnologies; |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>1038</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión, Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 70</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 70. ***Welcomes*** the Commission’s intention to adopt a legislative proposal to establish a Health Emergency Preparedness and Response Authority (HERA) in order to anticipate, incentivise, co-develop and facilitate rapid, equal and sustainable access to cancer innovations for cancer patients; calls for a large consortium of public authorities, private companies and ***NGOs***, including patient associations, to work together to guarantee the accessibility and affordability of cancer treatment options requiring complex technologies, for instance, cellular therapy (CAR T cells), adoptive immunotherapy through the use of tumour genome extracts (messenger RNA) and nanotechnologies; | 70. ***Takes note of*** the Commission’s intention to adopt a legislative proposal to establish a Health Emergency Preparedness and Response Authority (HERA) in order to anticipate, incentivise, co-develop and facilitate rapid, equal and sustainable access to cancer innovations for cancer patients; calls for a large consortium of public authorities, private companies and ***stakeholders***, including patient associations, to work together to guarantee the accessibility and affordability of cancer treatment options requiring complex technologies, for instance, cellular therapy (CAR T cells), adoptive immunotherapy through the use of tumour genome extracts (messenger RNA) and nanotechnologies; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1039</NumAm>

<RepeatBlock-By><Members>Adam Jarubas</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 70</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 70. Welcomes the Commission’s intention to adopt a legislative proposal to establish a Health Emergency Preparedness and Response Authority (HERA) in order to anticipate, incentivise, co-develop and facilitate rapid, equal and sustainable access to cancer innovations for cancer patients; calls for a large consortium of public authorities, private companies and NGOs, including patient associations, to work together to guarantee the accessibility and affordability of cancer treatment options requiring complex technologies, for instance, cellular therapy (CAR T cells), adoptive immunotherapy through the use of tumour genome extracts (messenger RNA) and nanotechnologies; | 70. Welcomes the Commission’s intention to adopt a legislative proposal to establish a Health Emergency Preparedness and Response Authority(HERA) in order to anticipate, incentivise, co-develop and facilitate rapid, equal and sustainable access to cancer innovations for cancer patients; calls for a large consortium of public authorities, private companies and NGOs, including patient associations ***and academia***, to work together to guarantee the accessibility and affordability of cancer treatment options requiring complex technologies, for instance, cellular therapy (CAR T cells), adoptive immunotherapy through the use of tumour genome extracts (messenger RNA) and nanotechnologies; ***stresses that, to facilitate wider utilisation of the innovative therapies, the EU and Member States must not only do their best to finance currently available therapies but also support the development of more cost- efficient modalities; welcomes, in this regard, the efforts of the Świętokrzyskie Cancer Centre (HCC) in Poland in developing CAR T therapy, which is 6 times less expensive than current options; believes that lowering the costs of the most innovative and effective therapies will increase their wider availability for the benefit of patients in the EU and beyond; calls for securing equal access to innovative therapies, both in the densely populated urban regions and smaller, rural or remote areas;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1040</NumAm>

<RepeatBlock-By><Members>Peter Liese</Members>

<AuNomDe>{EPP}on behalf of the EPP Group</AuNomDe>

<Members>Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Marian-Jean Marinescu, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 70</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 70. Welcomes the Commission’s intention to adopt a legislative proposal to establish a Health Emergency Preparedness and Response Authority (HERA) in order to anticipate, incentivise, co-develop and facilitate rapid, equal and sustainable access to cancer innovations for cancer patients; calls for a large consortium of public authorities, private companies and NGOs, including patient associations, to work together to guarantee the accessibility and affordability of cancer treatment options requiring complex technologies, for instance, cellular therapy (CAR T cells), adoptive immunotherapy through the use of tumour genome extracts (messenger RNA) and nanotechnologies; | 70. Welcomes the Commission’s intention to adopt a legislative proposal to establish a Health Emergency Preparedness and Response Authority (HERA) in order to anticipate, incentivise, co-develop and facilitate rapid, equal and sustainable access to cancer innovations for cancer patients; calls for a large consortium of public authorities, private companies and NGOs, including patient associations, to work together to guarantee the accessibility and affordability of cancer treatment options requiring complex technologies, for instance, cellular therapy (CAR T cells), adoptive immunotherapy through the use of tumour genome extracts (messenger RNA) and nanotechnologies; ***considers that HERA should closely collaborate with public and private entities to plan, coordinate and build an ecosystem of private and public capabilities which can provide suitable emergency frameworks for EU access to key raw materials in case of global supply shocks;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1041</NumAm>

<RepeatBlock-By><Members>Nicolás González Casares, Maria Arena, Romana Jerković, Sara Cerdas, Marc Angel, Estrella Durá Ferrandis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 70</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 70. Welcomes the Commission’s intention to adopt a legislative proposal to establish a Health Emergency Preparedness and Response Authority (HERA) in order to anticipate, incentivise, co-develop and facilitate rapid, equal and sustainable access to cancer innovations for cancer patients; calls for a large consortium of public authorities, private companies and NGOs, including patient associations, to work together to guarantee the accessibility and affordability of cancer treatment options requiring complex technologies, for instance, cellular therapy (CAR T cells), adoptive immunotherapy through the use of tumour genome extracts (messenger RNA) and nanotechnologies; | 70. Welcomes the Commission’s intention to adopt a legislative proposal to establish a Health Emergency Preparedness and Response Authority (HERA) in order to anticipate, incentivise, co-develop and facilitate rapid, equal and sustainable access to cancer innovations for cancer patients***, including diagnostics procedures as well as companion diagnostic tests***; calls for a large consortium of public authorities, private companies and NGOs, including ***academia,*** patient ***and survivors*** associations, to work together to guarantee the accessibility and affordability of cancer treatment options ***and diagnostics procedures as well as companion diagnostic tests*** requiring complex technologies, for instance, cellular therapy (CAR T cells), adoptive immunotherapy through the use of tumour genome extracts (messenger RNA) and nanotechnologies; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1042</NumAm>

<RepeatBlock-By><Members>Hilde Vautmans, Irena Joveva</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 70</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 70. Welcomes the Commission’s intention to adopt a legislative proposal to establish a Health Emergency Preparedness and Response Authority (HERA) in order to anticipate, incentivise, co-develop and facilitate rapid, equal and sustainable access to cancer innovations for cancer patients; calls for a large consortium of public authorities, private companies and NGOs, including patient associations, to work together to guarantee the accessibility and affordability of cancer treatment options requiring complex technologies, for instance, cellular therapy (CAR T cells), adoptive immunotherapy through the use of tumour genome extracts (messenger RNA) and nanotechnologies; | 70. Welcomes the Commission’s intention to adopt a legislative proposal to establish a Health Emergency Preparedness and Response Authority (HERA) in order to anticipate, incentivise, co-develop and facilitate rapid, equal and sustainable access to cancer innovations for cancer patients; calls for a large consortium of public authorities, private companies and NGOs, including patient associations, to work together to guarantee the accessibility and affordability of cancer treatment options requiring complex technologies, for instance, cellular therapy (CAR T cells), adoptive immunotherapy through the use of tumour genome extracts (messenger RNA) and nanotechnologies; ***urges that health workforce planning and resilience be within the remit of the Health Emergency Preparedness and Response Authority;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1043</NumAm>

<RepeatBlock-By><Members>Loucas Fourlas</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 70</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 70. Welcomes the Commission’s intention to adopt a legislative proposal to establish a Health Emergency Preparedness and Response Authority (HERA) in order to anticipate, incentivise, co-develop and facilitate rapid, equal and sustainable access to cancer innovations for cancer patients; calls for a large consortium of public authorities, private companies and NGOs, including patient associations, to work together to guarantee the accessibility and affordability of cancer treatment options requiring complex technologies, for instance, cellular therapy (CAR T cells), adoptive immunotherapy through the use of tumour genome extracts (messenger RNA) and nanotechnologies; | 70. Welcomes the Commission’s intention to adopt a legislative proposal to establish a Health Emergency Preparedness and Response Authority (HERA) in order to anticipate, incentivise, co-develop and facilitate rapid, equal and sustainable access to cancer innovations for cancer patients; calls for a large consortium of public authorities, private companies and NGOs, ***academia, parent,*** including patient ***and survivor*** associations , to work together to guarantee the accessibility and affordability of cancer treatment options requiring complex technologies, for instance, cellular therapy (CAR T cells), adoptive immunotherapy through the use of tumour genome extracts (messenger RNA) and nanotechnologies; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1044</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná, Alexis Georgoulis, Giorgos Georgiou</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 70 a (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***70a. Notes that there is growing evidence that adequate supportive care measures lead to better outcomes and improve the quality of life of cancer patients; points out, in particular, that failure to monitor and assess the nutritional status of cancer patients leads to weight and muscle loss, may undermine the effectiveness of treatments and significantly increase the risk of serious side effects, as well as mortality rates; calls on Member States to make nutritional care a mandatory and fully integrated component of high-quality care throughout the implementation of Europe's Beating Cancer Action Plan, as taking action to ensure early access of patients to proactive nutritional care has the potential to prevent treatment-limiting side effects, allowing more patients to benefit from advances in cancer treatments, whilst improving the quality of life and survival time;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1045</NumAm>

<RepeatBlock-By><Members>Hilde Vautmans, Irena Joveva</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 70 b (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***70b. Calls on Commission and Member States to look for private-public partnerships in setting quality standards, developing production capabilities and a hospitable regulatory environment concerning innovative therapies such as Cellular Therapy, immunotherapy and robotic surgery;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1046</NumAm>

<RepeatBlock-By><Members>Nicolás González Casares, Alessandra Moretti, Maria Arena, Romana Jerković, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 70 c (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***70c. Highlights the importance of addressing the issue of off-label use of medicines, including inexpensive medicines, medicines used for rare cancers among others; calls on the Commission to analyse the existing situation concerning off-label use of medicines;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1047</NumAm>

<RepeatBlock-By><Members>Alessandra Moretti</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 70 c (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***70c. Highlights the importance of addressing the issue of off-label use of medicines, including inexpensive medicines, medicines used for rare cancers among others; calls on the Commission to analyse the existing situation concerning off-label use of medicines;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1048</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión, Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Subheading III.c</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| III.c . Equal access to cancer care: towards a better response to the impact of health crises on cancer patients | III.c . Equal access to ***comprehensive, multidisciplinary and quality*** cancer care: towards a better response to the impact of health crises on cancer patients |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1049</NumAm>

<RepeatBlock-By><Members>Dolors Montserrat, Aldo Patriciello, Juan Ignacio Zoido Álvarez, Herbert Dorfmann, Rosa Estaràs Ferragut, Francisco José Millán Mon, José Manuel García-Margallo y Marfil, Gabriel Mato, Esteban González Pons, Lídia Pereira, Pilar del Castillo Vera, Cindy Franssen, Antonio López-Istúriz White, Adrián Vázquez Lázara, Pablo Arias Echeverría, Javier Zarzalejos, Ewa Kopacz, Isabel Benjumea Benjumea</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Subheading III.c</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| III.c . Equal access to cancer care: towards a better response to the impact of health crises on cancer patients | III.c . Equal access to ***integrated, multidisciplinary and quality*** cancer care: towards a better response to the impact of health crises on cancer patients |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1050</NumAm>

<RepeatBlock-By><Members>Giorgos Georgiou, Alexis Georgoulis, João Pimenta Lopes</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 71</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 71. Underlines that the COVID-19 crisis has had, and is still having, a significant impact on cancer patients’ survival and quality of life at all stages of the disease, due to delays ***in screening***, referral and surgical procedures, treatment ***postponement***, shortages in the supply of medicines and other medical supplies, specialised workforce shortages and ***reduced*** communication ***with*** health professionals; | 71. Underlines that the COVID-19 crisis has had, and is still having, a significant impact on cancer patients’ survival and quality of life at all stages of the disease, due to delays ***and postponements of prevention schemes, clinical trials, screenings***, referral and surgical procedures, treatment, shortages in the supply of medicines and other medical supplies, specialised workforce shortages and ***poor*** communication ***among*** health professionals ***of different categories***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1051</NumAm>

<RepeatBlock-By><Members>Hilde Vautmans, Irena Joveva</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 71</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 71. Underlines that the COVID-19 crisis has had, and is still having, a significant impact on cancer patients’ survival and quality of life at all stages of the disease, due to delays in screening, referral and surgical procedures, treatment postponement, shortages in the supply of medicines and other medical supplies, specialised workforce shortages and reduced communication with health professionals; | 71. Underlines that the COVID-19 crisis has had, and is still having, a significant impact on cancer patients’ survival and quality of life at all stages of the disease, due to delays in ***prevention activities such as HPV vaccination,*** screening, referral and surgical procedures, treatment postponement, shortages in the supply of medicines and other medical supplies, specialised workforce shortages and reduced communication with health professionals; ***highlights evidence suggesting that clinicians across Europe saw 1.5 million fewer cancer patients in the first year of the pandemic, an estimated 100 million cancer screening tests were not performed in Europe as a result of the pandemic, and consequently, 1 million citizens in the EU may presently be undiagnosed with cancer as a consequence of the COVID-19 pandemic;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1052</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 71</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 71. Underlines that the COVID-19 crisis has had, and is still having, a significant impact on cancer patients’ survival and quality of life at all stages of the disease, due to delays in screening, referral and surgical procedures, treatment postponement, shortages in the supply of medicines and other medical supplies, specialised workforce shortages and reduced communication with health professionals; | 71. Underlines that the COVID-19 crisis has had, and is still having, a significant impact on cancer patients’ survival and quality of life at all stages of the disease, due to delays in ***prevention activities such as HPV vaccination,*** screening, referral and surgical procedures, treatment postponement, shortages in the supply of medicines and other medical supplies, specialised workforce shortages and reduced communication with health professionals; ***highlights evidence suggesting that clinicians across Europe saw 1.5 million fewer cancer patients in the first year of the pandemic, an estimated 100million cancer screening tests were not performed in Europe as a result of the pandemic, and consequently, 1 million citizens in the EU may presently be undiagnosed with cancer as a consequence of the COVID-19 pandemic;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1053</NumAm>

<RepeatBlock-By><Members>Alexis Georgoulis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 71</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 71. Underlines that the COVID-19 crisis has had, and is still having, a significant impact on cancer patients’ survival and quality of life at all stages of the disease, due to delays in screening, referral and surgical procedures, treatment postponement, shortages in the supply of medicines and other medical supplies, specialised workforce shortages and reduced communication with health professionals; | 71. Underlines that the COVID-19 crisis has ***led to an increase in undiagnosed cancers and*** had, and is still having, a significant impact on cancer patients’ survival and quality of life at all stages of the disease, due to delays in ***prevention activities such as HPV vaccination,*** screening, referral and surgical procedures, treatment postponement, shortages in the supply of medicines and other medical supplies, specialised workforce shortages and reduced communication with health professionals; ***highlights evidence suggesting that clinicians across Europe saw 1.5 million fewer cancer patients in the first year of the pandemic, an estimated 100 million cancer screening tests were not performed in Europe as a result of the pandemic, and consequently, 1 million citizens in the EU may presently be undiagnosed with cancer as a consequence of the COVID-19 pandemic;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1054</NumAm>

<RepeatBlock-By><Members>Tudor Ciuhodaru</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 71</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 71. Underlines that the COVID-19 crisis has had, and is still having, a significant impact on cancer patients’ survival and quality of life at all stages of the disease, due to delays in screening, referral and surgical procedures, treatment postponement, shortages in the supply of medicines and other medical supplies, specialised workforce shortages and reduced communication with health professionals; | 71. Underlines that the COVID-19 crisis has ***led to an increase in undiagnosed cancers and*** had, and is still having, a significant impact on cancer patients’ survival and quality of life at all stages of the disease, due to delays in screening, referral and surgical procedures, treatment postponement, shortages in the supply of medicines and other medical supplies, specialised workforce shortages and reduced communication with health professionals; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1055</NumAm>

<RepeatBlock-By><Members>Alessandra Moretti</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 71</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 71. Underlines that the COVID-19 crisis has had, and is still having, a significant impact on cancer patients’ survival and quality of life at all stages of the disease, due to delays in screening, referral and surgical procedures, treatment postponement, shortages in the supply of medicines and other medical supplies, specialised workforce shortages ***and*** reduced communication with health professionals; | 71. Underlines that the COVID-19 crisis has had, and is still having, a significant impact on cancer patients’ survival and quality of life at all stages of the disease, due to delays in screening ***and prevention activities like HPV vaccination***, referral and surgical procedures, treatment postponement, shortages in the supply of medicines and other medical supplies, specialised workforce shortages***,*** reduced communication with health professionals; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1056</NumAm>

<RepeatBlock-By><Members>Tomislav Sokol, Sunčana Glavak, Cindy Franssen</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 71</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 71. Underlines that the COVID-19 crisis has had, and is still having, a significant impact on cancer patients’ survival and quality of life at all stages of the disease, due to delays in screening, referral and surgical procedures, treatment postponement, shortages in the supply of medicines and other medical supplies, specialised workforce shortages and reduced communication with health professionals; | 71. Underlines that the COVID-19 crisis has had, and is still having, a significant impact on cancer patients’ survival and quality of life at all stages of the disease, due to delays in screening, referral and surgical procedures, treatment postponement, shortages in the supply of medicines and other medical supplies, specialised workforce shortages and reduced communication with health professionals; ***highlights evidence suggesting that clinicians across Europe saw 1.5 million fewer cancer patients in the first year of the pandemic, an estimated 100 million cancer screening tests were not performed in Europe as a result of the pandemic, and consequently, 1 million citizens in the EU may presently be undiagnosed with cancer as a consequence of the COVID-19 pandemic;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1057</NumAm>

<RepeatBlock-By><Members>Nicolás González Casares, Maria Arena, Romana Jerković, Sara Cerdas, Marc Angel, Estrella Durá Ferrandis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 71</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 71. Underlines that the COVID-19 crisis has had, and is still having, a significant impact on cancer patients’ survival and quality of life at all stages of the disease, due to delays in screening, referral and surgical procedures, treatment postponement, shortages in the supply of medicines and other medical supplies, specialised workforce shortages ***and*** reduced communication with health professionals; | 71. Underlines that the COVID-19 crisis has had, and is still having, a significant impact on cancer patients’ survival and quality of life at all stages of the disease, due to delays in screening, referral and surgical procedures, treatment postponement, shortages in the supply of medicines and other medical supplies, specialised workforce shortages***,*** reduced communication with health professionals***, patients’ fear of infection and impairments in diagnostics and treatment of diseases considered as risk factors for cancer, such as viral infections***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1058</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 71</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 71. Underlines that the COVID-19 crisis has had, and is still having, a significant impact on cancer patients’ survival and quality of life at all stages of the disease, due to delays in screening, referral and surgical procedures, treatment postponement, shortages in the supply of medicines and other medical supplies, specialised workforce shortages ***and*** reduced communication with health professionals; | 71. Underlines that the COVID-19 crisis has had, and is still having, a significant impact on cancer patients’ survival and quality of life at all stages of the disease, due to delays in screening, referral and surgical procedures, treatment postponement, shortages in the supply of medicines and other medical supplies, specialised workforce shortages***,*** reduced communication with health professionals ***and patients’ fear of infection***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1059</NumAm>

<RepeatBlock-By><Members>Ondřej Knotek, Irena Joveva</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 71</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 71. Underlines that the COVID-19 crisis has had, and is still having, a significant impact on cancer patients’ survival and quality of life at all stages of the disease, due to delays in screening, referral and surgical procedures, treatment postponement, shortages in the supply of medicines and other medical supplies, specialised workforce shortages and reduced communication with health professionals; | 71. Underlines that the COVID-19 crisis has had, and is still having, a significant impact on cancer patients’ survival and quality of life at all stages of the disease, due to delays in screening, referral***, diagnosis*** and surgical procedures, treatment postponement, shortages in the supply of medicines and other medical supplies, specialised workforce shortages and reduced communication with health professionals; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1060</NumAm>

<RepeatBlock-By><Members>Giorgos Georgiou, Kateřina Konečná, Alexis Georgoulis, João Pimenta Lopes</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 71 a (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***71a. Deplores the fact that patients still face many difficulties in accessing quality, public health care services since many oncology departments at public hospitals are suffering from workforce shortages and lack of capacity; calls, therefore, for the creation of high-quality radiotherapy departments and modern oncology centres at public hospitals, based on European guidelines and in line with the most recent scientific evidence;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1061</NumAm>

<RepeatBlock-By><Members>Søren Gade</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 72</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 72. Considers that the COVID-19 pandemic was a real stress test for the EU’s health systems; underlines that the main lesson learned should be the need to build an emergency strategy to allow Member States to react accordingly in times of any future health crises; stresses that specific measures under this emergency strategy should ***be aimed at the protection of*** vulnerable groups***, including cancer patients***; | 72. Considers that the COVID-19 pandemic was a real stress test for the EU’s health systems; underlines that the main lesson learned should be the need to build an emergency strategy to allow Member States to react accordingly in times of any future health crises; stresses that ***vulnerable groups, including cancer patients, are particularly exposed during a health crisis; stresses that*** specific measures under this emergency strategy ***– including e.g. advance purchase agreements (APAs) –*** should ***support the development, production and stockpiling of products to protect these*** vulnerable groups; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1062</NumAm>

<RepeatBlock-By><Members>Bartosz Arłukowicz</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 72</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 72. Considers that the COVID-19 pandemic was a real stress test for the EU’s health systems; underlines that the main lesson learned should be the need to build an emergency strategy to allow Member States to react accordingly in times of any future health crises; stresses that specific measures under this emergency strategy should be aimed at the protection of vulnerable groups, including cancer patients; | 72. Considers that the COVID-19 pandemic was a real stress test for the EU’s health systems; underlines that the main lesson learned should be the need to build an emergency strategy to allow Member States to react accordingly in times of any future health crises; ***stresses the need to coordinate crisis strategies at European level;*** stresses that specific measures under this emergency strategy should be aimed at the protection of vulnerable groups, including cancer patients; ***calls for the creation of structures that can strengthen cooperation on health policy at EU level, including through the creation of a committee or sub-committee on health in the European Parliament;*** |

Or. <Original>{PL}pl</Original>

</Amend>

<Amend>Amendment <NumAm>1063</NumAm>

<RepeatBlock-By><Members>Giorgos Georgiou, Alexis Georgoulis, João Pimenta Lopes</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 72</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 72. Considers that the COVID-19 pandemic was a real stress test for the EU’s health systems; underlines that the main lesson learned should be the need to build an emergency strategy to allow Member States to react ***accordingly in times of*** any future health crises; stresses that specific measures under this emergency strategy should be aimed at the protection of vulnerable groups, including cancer patients; | 72. Considers that the COVID-19 pandemic was a real stress test for the EU’s health systems; underlines that the main lesson learned should be the need to ***invest in public health sector and*** build an emergency strategy to allow Member States to react ***simultaneously against*** any future health crises; stresses that specific measures under this emergency strategy should be aimed at the protection of vulnerable groups, including cancer patients***, and the protection of health as a human right and a public good***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1064</NumAm>

<RepeatBlock-By><Members>Nicolás González Casares, Maria Arena, Romana Jerković, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 72</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 72. Considers that the COVID-19 pandemic was a real stress test for the EU’s health systems; underlines that the main lesson learned should be the need to build an emergency strategy to allow Member States to react accordingly in times of any future health crises; stresses that specific measures under this emergency strategy should be aimed at the protection of vulnerable groups, including cancer patients; | 72. Considers that the COVID-19 pandemic was a real stress test for the EU’s health systems; underlines that the main lesson learned should be the need to build an emergency strategy to allow Member States to react accordingly in times of any future health crises; stresses that specific measures under this emergency strategy should be aimed at the protection of vulnerable groups ***that cannot wait until the end of the crisis***, including cancer patients; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1065</NumAm>

<RepeatBlock-By><Members>Nicolás González Casares, Alessandra Moretti, Maria Arena, Romana Jerković, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 72 a (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***72a. Calls on the Commission and the Member States to diligently collect data via suitable registries to monitor the effects of vaccines in the vulnerable population, including patients with cancer and their immune response;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1066</NumAm>

<RepeatBlock-By><Members>Alessandra Moretti</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 72 a (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***72a. Calls on the Commission and the Member States to diligently collect data via suitable registries to monitor the effects of vaccines in the vulnerable population, including patients with cancer and their immune response;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1067</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 73</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals; | 73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals; ***recognises that the pandemic has exacerbated the crucial role of informal carers, who provide most of the daily care for cancer patients and who face a clear lack of support (may it be in terms of social rights, training, psychological help, information, recognition); calls on the Commission and the Members States to create online training platforms as well as therapeutic care programmes granting qualifications and recognising their competences;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1068</NumAm>

<RepeatBlock-By><Members>Nicolae Ştefănuță, Alin Mituța, Ivars Ijabs, Vlad Gheorghe</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 73</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals; | 73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals; ***recognises the fact that the pandemic has increased the care burden for informal carers, who provide most of the daily care required by cancer patients and who need (practical and policy) support;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1069</NumAm>

<RepeatBlock-By><Members>Giorgos Georgiou, Alexis Georgoulis, João Pimenta Lopes</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 73</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing ***health*** workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals ***in cancer care***; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals; | 73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing workforce shortages ***of the public health sector***; acknowledges the urgency of ensuring a sufficient number of specialised health professionals ***especially in public healthcare systems***; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals; ***underlines that new approaches for human-centred healthcare are required in order to ensure access to diagnostics, therapeutics and quality public health services for all;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1070</NumAm>

<RepeatBlock-By><Members>Bartosz Arłukowicz</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 73</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals; | 73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals; ***stresses the need for work on a skill mix in order to optimise the response to staffing needs in the health sector; supports the exchange of good practices between Member States in this regard;*** |

Or. <Original>{PL}pl</Original>

</Amend>

<Amend>Amendment <NumAm>1071</NumAm>

<RepeatBlock-By><Members>Peter Liese</Members>

<AuNomDe>{EPP}on behalf of the EPP Group</AuNomDe>

<Members>Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 73</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals; | 73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals; ***underlines the need to work on the so called skill-mix in order to optimise the response on the workforce shortages in healthcare; supports the exchange of best practices between Member States in that area;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1072</NumAm>

<RepeatBlock-By><Members>Hilde Vautmans, Irena Joveva</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 73</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals; | 73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals; ***suggests that the Cancer Inequalities Registry may serve a function in measuring and reporting on pre-existing workforce shortages;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1073</NumAm>

<RepeatBlock-By><Members>Alexis Georgoulis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 73</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals; | 73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals; ***suggests that the Cancer Inequalities Registry may serve as a tool in measuring and reporting on workforce shortages;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1074</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión, Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 73</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals; | 73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care***, doctors and nurses***; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals ***in both primary and specialized care***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1075</NumAm>

<RepeatBlock-By><Members>Nicolás González Casares, Maria Arena, Romana Jerković, Sara Cerdas, Marc Angel, Estrella Durá Ferrandis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 73</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals; | 73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals***, both in primary and specialized care***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1076</NumAm>

<RepeatBlock-By><Members>Dolors Montserrat, Aldo Patriciello, Juan Ignacio Zoido Álvarez, Herbert Dorfmann, Rosa Estaràs Ferragut, Francisco José Millán Mon, José Manuel García-Margallo y Marfil, Gabriel Mato, Esteban González Pons, Lídia Pereira, Pilar del Castillo Vera, Cindy Franssen, Antonio López-Istúriz White, Adrián Vázquez Lázara, Pablo Arias Echeverría, Javier Zarzalejos, Ewa Kopacz, Isabel Benjumea Benjumea</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 73</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals; | 73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals ***in both primary and specialised care***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1077</NumAm>

<RepeatBlock-By><Members>Tudor Ciuhodaru</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 73</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals; | 73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals ***and their retraining should they be specialists in other fields***; |

Or. <Original>{RO}ro</Original>

</Amend>

<Amend>Amendment <NumAm>1078</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 73</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals; | 73. Notes with concern that the COVID-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals; ***therefore encourages the Member States to drop numerus clausus policies;*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>1079</NumAm>

<RepeatBlock-By><Members>Bartosz Arłukowicz</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 73 a (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***73a. Stresses the urgent need for the European Union to support measures to maintain the continuity of use of health systems during and after the pandemic in order to eliminate delays in diagnosis and treatment for cancer patients;*** |

Or. <Original>{PL}pl</Original>

</Amend>

<Amend>Amendment <NumAm>1080</NumAm>

<RepeatBlock-By><Members>Tomislav Sokol, Sunčana Glavak, Cindy Franssen</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 74</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 74. Advocates the development of a digital health system to monitor symptoms and ensure cancer treatment and care at home; calls for permanent access to medical consultations and psychosocial services to be guaranteed through the use of telemedicine or in health threat-free environments in hospitals; | 74. Advocates the development of a digital health system to monitor symptoms and ensure cancer treatment and care at home; ***encourages the creation of a secure digital communication channel enabling health professionals to monitor patients’ symptoms remotely;*** calls for permanent access to medical ***and nutrition*** consultations and psychosocial ***services to*** be guaranteed through the use of telemedicine or in health threat-free environments in hospitals; ***calls for cross-sector and cross-country collaboration and knowledge sharing that will be crucial for further enhancing the quality of cancer care in the EU;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1081</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión, Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 74</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 74. Advocates the development of a digital health system to monitor symptoms and ensure cancer treatment and care at home; calls for permanent access to medical consultations and psychosocial services to be guaranteed through the use of telemedicine or in health threat-free environments in hospitals; | 74. Advocates the development of a digital health system to monitor symptoms and ensure cancer treatment and care at home ***but without forgetting the value of face-to-face care and training provided by professional carers***; calls for permanent access to medical consultations***, nursing*** and psychosocial services to be guaranteed through the use of telemedicine ***and telecare*** or in health threat-free environments in hospitals; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1082</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 74</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 74. Advocates the development of a digital health system to monitor symptoms and ensure cancer treatment and care at home; calls for permanent access to medical consultations and psychosocial services to be guaranteed through the use of telemedicine or in health threat-free environments in hospitals; | 74. Advocates the development of a digital health system to monitor symptoms and ensure cancer treatment and care at home; calls for permanent access to medical consultations and psychosocial services to be guaranteed through the use of telemedicine or in health threat-free environments in hospitals; ***calls for the stimulation of the development of therapeutics that can support a transition to home care;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1083</NumAm>

<RepeatBlock-By><Members>Bartosz Arłukowicz</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 74</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 74. Advocates the development of a digital health system to monitor symptoms and ensure cancer treatment and care at home; calls for permanent access to medical consultations and psychosocial services to be guaranteed through the use of telemedicine or in health threat-free environments in hospitals; | 74. Advocates the development of a digital health system to monitor symptoms and ensure cancer treatment and care at home; calls for permanent access to medical consultations and psychosocial services***, as well as contact between patient and doctor and between the attending doctor and the patient's family,*** to be guaranteed through the use of telemedicine or in health threat-free environments in hospitals; |

Or. <Original>{PL}pl</Original>

</Amend>

<Amend>Amendment <NumAm>1084</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 74</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 74. Advocates the development of a digital health system to monitor symptoms and ensure cancer treatment and care at home; calls for permanent access to medical consultations and psychosocial services to be guaranteed through the use of telemedicine or in health threat-free environments in hospitals; | 74. Advocates the development of a digital health system to monitor symptoms and ensure cancer treatment and care at home***, in strict accordance with patient confidentiality and the GDPR***; calls for permanent access to medical consultations and psychosocial services to be guaranteed through the use of telemedicine or in health threat-free environments in hospitals; |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>1085</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 74</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 74. Advocates the development of a digital health system to monitor symptoms and ensure cancer treatment ***and care at home***; calls for permanent access to medical consultations and psychosocial services to be guaranteed through the use of telemedicine ***or in health threat-free environments in*** hospitals; | 74. Advocates the development of a digital health system to monitor symptoms and ensure ***continued*** cancer treatment ***in out-of-hospital care***; calls for permanent access to medical consultations and psychosocial services to be guaranteed through the use of telemedicine ***technologies or safe*** hospitals ***in the event of a public health crisis or major event***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1086</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná, Alexis Georgoulis, João Pimenta Lopes, Giorgos Georgiou</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 74</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 74. Advocates the development of a digital health system to monitor symptoms and ensure cancer treatment and care ***at home***; calls for permanent access to medical consultations and psychosocial services to be guaranteed through the use of telemedicine or in health threat-free environments in hospitals; | 74. Advocates the development of a digital health system to monitor symptoms and ensure cancer treatment and care ***outside hospital***; calls for permanent access to medical consultations and psychosocial services to be guaranteed through the use of telemedicine or in health threat-free environments in hospitals; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1087</NumAm>

<RepeatBlock-By><Members>Hilde Vautmans, Irena Joveva</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 74</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 74. Advocates the development of a digital health system to monitor symptoms and ensure cancer treatment and care at home; calls for permanent access to medical consultations and psychosocial services to be guaranteed through the use of telemedicine or in health threat-free environments in hospitals; | 74. Advocates the development of a digital health system to monitor symptoms and ensure cancer treatment and care at home; calls for permanent access to medical consultations and psychosocial services to be guaranteed through the use ***and integration*** of telemedicine ***within the healthcare systems*** or in health threat-free environments in hospitals; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1088</NumAm>

<RepeatBlock-By><Members>Nicolás González Casares, Maria Arena, Romana Jerković, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 74</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 74. Advocates the development of a digital health system to monitor symptoms and ensure cancer treatment and care at home; calls for permanent access to medical consultations and psychosocial services to be guaranteed through the use of telemedicine or in health threat-free environments in hospitals; | 74. Advocates the development of a digital health system to monitor symptoms and ensure cancer treatment and care at home; calls for permanent access to medical consultations and psychosocial services to be guaranteed through the use of telemedicine or in health threat-free environments in hospitals ***or, when possible and safe, pharmacies***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1089</NumAm>

<RepeatBlock-By><Members>Adam Jarubas, Ewa Kopacz</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 75</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 75. Asks for enhanced communication between health professionals, patients and public authorities regarding the effectiveness and safety of health interventions, in particular cancer screening, diagnosis and treatment, and for increased awareness campaigns in times of crises; | 75. Asks for enhanced communication between health professionals, patients and public authorities regarding the effectiveness and safety of health interventions, in particular cancer screening, diagnosis and treatment, and for increased awareness campaigns in times of crises***, as well as information on how to eliminate or limit harm caused by certain behaviours, including choosing less harmful alternative products if other options fail***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1090</NumAm>

<RepeatBlock-By><Members>Michèle Rivasi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 75</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 75. Asks for enhanced communication between health professionals, patients and public authorities regarding the effectiveness and safety of health interventions, in particular cancer screening, diagnosis and treatment, and for increased awareness campaigns in times of crises; | 75. Asks for enhanced communication between health professionals, patients and public authorities regarding the effectiveness and safety of health interventions, in particular cancer screening, diagnosis and treatment, and for increased awareness campaigns in times of crises***,*** ***which can be performed by national civil societies organisations, if financially supported***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1091</NumAm>

<RepeatBlock-By><Members>Alin Mituța, Nicolae Ştefănuță, Hilde Vautmans, Vlad Gheorghe</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 75</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 75. Asks for enhanced communication between health professionals, patients and public authorities regarding the effectiveness and safety of health interventions, in particular cancer screening, diagnosis and treatment, ***and*** for increased awareness campaigns in times of crises; | 75. Asks for enhanced communication between health professionals, patients and public authorities regarding the effectiveness and safety of health interventions, in particular cancer screening, diagnosis and treatment, for increased awareness campaigns in times of crises***, and for carrying out multidisciplinary tumour boards***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1092</NumAm>

<RepeatBlock-By><Members>Giorgos Georgiou, Kateřina Konečná, Alexis Georgoulis, João Pimenta Lopes</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 75</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 75. Asks for enhanced communication between health professionals, patients ***and*** public authorities regarding the effectiveness and safety of health interventions, in particular cancer screening, diagnosis and treatment, and for increased awareness campaigns in times of crises; | 75. Asks for enhanced communication between health professionals, ***parents, caregivers,*** patients***, survivors,*** public authorities***, and society*** regarding the effectiveness and safety of health interventions, in particular cancer screening, diagnosis and treatment, and for increased awareness campaigns in times of crises; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1093</NumAm>

<RepeatBlock-By><Members>Nicolae Ştefănuță, Alin Mituța, Ivars Ijabs, Vlad Gheorghe</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 75</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 75. Asks for enhanced communication between health professionals, patients and public authorities regarding the effectiveness and safety of health interventions, in particular cancer screening, diagnosis and treatment, and for increased awareness campaigns in times of crises; | 75. Asks for enhanced communication between health professionals, patients***, parents, survivors*** and public authorities regarding the effectiveness and safety of health interventions, in particular cancer screening, diagnosis and treatment, and for increased awareness campaigns in times of crises; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1094</NumAm>

<RepeatBlock-By><Members>Loucas Fourlas</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 75</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 75. Asks for enhanced communication between health professionals, patients and public authorities regarding the effectiveness and safety of health interventions, in particular cancer screening, diagnosis and treatment, and for increased awareness campaigns in times of crises; | 75. Asks for enhanced communication between health professionals, ***parents,*** patients***, survivors*** and public authorities regarding the effectiveness and safety of health interventions, in particular cancer screening, diagnosis and treatment, and for increased awareness campaigns in times of crises; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1095</NumAm>

<RepeatBlock-By><Members>Nicolás González Casares, Alessandra Moretti, Maria Arena, Romana Jerković, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 75</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 75. Asks for enhanced communication between health professionals, patients and public authorities regarding the effectiveness and safety of health interventions, in particular cancer screening, diagnosis and treatment, and for increased awareness campaigns in times of crises; | 75. Asks for enhanced communication between health professionals, patients***, survivors*** and public authorities regarding the effectiveness and safety of health interventions, in particular cancer screening, diagnosis and treatment, and for increased awareness campaigns in times of crises; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1096</NumAm>

<RepeatBlock-By><Members>Andrey Slabakov, Angel Dzhambazki, Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 75</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 75. Asks for enhanced communication between health professionals, patients and public authorities regarding the effectiveness and safety of health interventions, in particular cancer screening, diagnosis and treatment, and for increased awareness campaigns in times of crises; | 75. Asks for enhanced communication between health professionals, patients and public authorities regarding the effectiveness and safety of health interventions, in particular cancer screening, diagnosis and treatment, and for increased awareness campaigns ***for prevention and risk reduction*** in times of crises; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1097</NumAm>

<RepeatBlock-By><Members>Nicolás González Casares, Alessandra Moretti, Maria Arena, Romana Jerković, Sara Cerdas, Marc Angel, Estrella Durá Ferrandis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 76</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 76. Calls on the Commission and the Member States to adopt European prevention and management plans to address ***cancer drug*** shortages in times of health crises; | 76. Calls on the Commission and the Member States to adopt European prevention and management plans to address shortages ***of medicines, devices, products and staff*** in times of health crises; ***underlines the responsibilities of market authorization holders (MAHs) and wholesale distributors with respect to the relevant EU legislation and in particular with regard to Directive 2001/83/EC; calls on the Commission and Member States to ensure that MAHs and wholesale distributors comply with the requirements of Directive 2001/83/EC in order to ensure appropriate and continued supply of medicines;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1098</NumAm>

<RepeatBlock-By><Members>Alessandra Moretti</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 76</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 76. Calls on the Commission and the Member States to adopt European prevention and management plans to address cancer drug shortages in times of health crises; | 76. Calls on the Commission and the Member States to adopt European prevention and management plans to address cancer drug shortages in times of health crises; ***underlines the responsibilities of Market Authorization Holders (MAHs) and wholesale distributors with respect to the relevant EU legislation and in particular with respect to Directive 2001/83/EC; calls on the Commission and Member States to ensure that MAHs and wholesale distributors comply with the requirements of Directive 2001/83/EC in order to ensure appropriate and continued supply of medicines;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1099</NumAm>

<RepeatBlock-By><Members>Tomislav Sokol, Sunčana Glavak, Cindy Franssen</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 76</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 76. Calls on the Commission and the Member States to adopt European prevention and management plans ***to*** address ***cancer drug*** shortages in times of health crises; | 76. Calls on the Commission and the Member States to adopt European prevention and management plans ***as part of a coherent and holistic contingency strategy to prevent and*** address shortages ***of medicines, devices, products and staff*** in times of health crises; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1100</NumAm>

<RepeatBlock-By><Members>Alexis Georgoulis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 76</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 76. Calls on the Commission and the Member States to adopt European prevention and management plans ***to*** address ***cancer drug*** shortages in times of health crises; | 76. Calls on the Commission and the Member States to adopt European prevention and management plans ***as part of a coherent and holistic contingency strategy to prevent and*** address shortages ***of medicines, devices, products and staff*** in times of health crises; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1101</NumAm>

<RepeatBlock-By><Members>Kateřina Konečná, Alexis Georgoulis, Giorgos Georgiou</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 76</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 76. Calls on the Commission and the Member States to adopt European prevention and management ***plans to address*** cancer drug shortages in times of health crises; | 76. Calls on the Commission and the Member States to adopt European prevention and management ***guidelines and enforce transparency over the supply and provision of*** cancer drug shortages in times of health crises; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1102</NumAm>

<RepeatBlock-By><Members>Hilde Vautmans, Irena Joveva</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 76 a (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***76a. Calls on Member States and the Commission to embark on a formal and public process of lesson-learning from the COVID-19 pandemic, encompassing all elements of the pandemic management, including impacts for cancer and other disease conditions;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1103</NumAm>

<RepeatBlock-By><Members>Tomislav Sokol, Sunčana Glavak, Cindy Franssen</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 76 a (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***76a. Calls on Member States and the Commission to embark on a formal and public process of lesson-learning from the COVID-19 pandemic, encompassing all elements of the pandemic management, including impacts for cancer and other disease conditions;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1104</NumAm>

<RepeatBlock-By><Members>Alexis Georgoulis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 76 a (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***76a. Calls on Member States and the Commission to embark on a formal and public process of lesson-learning from the COVID-19 pandemic, encompassing all elements of the pandemic management, including impacts for cancer and other disease conditions;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1105</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Subheading IV</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| IV. ***Strong support to cancer patients,*** survivors and caregivers | IV. Survivors***, their families*** and caregivers |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1106</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 77</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 77. Stresses that cancer patients should not suffer a ‘double punishment’ in their daily lives; calls ***for the adoption of an anti-discrimination directive, as well as*** for the fair and equal implementation of directives on financial services, such as the Consumer Credit Directive32 , without any discrimination against cancer patients and survivors; | 77. Stresses that cancer patients should not suffer a ‘double punishment’ in their daily lives; calls for the fair and equal implementation of directives on financial services, such as the Consumer Credit Directive32 , without any discrimination against cancer patients and survivors; |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 32 Directive 2008/48/EC of the European Parliament and of the Council of 23 April 2008 on credit agreements for consumers, OJ L 133, 22.5.2008, p. 66. | 32 Directive 2008/48/EC of the European Parliament and of the Council of 23 April 2008 on credit agreements for consumers, OJ L 133, 22.5.2008, p. 66. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1107</NumAm>

<RepeatBlock-By><Members>Andrey Slabakov, Angel Dzhambazki, Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 77</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 77. Stresses that cancer patients should not suffer a ‘double punishment’ in their daily lives; calls for the adoption of ***an*** anti-discrimination ***directive***, as well as for the fair and equal implementation of directives on financial services, such as the Consumer Credit Directive32 , without any discrimination against cancer patients and survivors; | 77. Stresses that cancer patients should not suffer a ‘double punishment’ in their daily lives; calls for the adoption of ***a set of recommendations on*** anti-discrimination, as well as for the fair and equal implementation of directives on financial services, such as the Consumer Credit Directive32 , without any discrimination against cancer patients and survivors; |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| 32 Directive 2008/48/EC of the European Parliament and of the Council of 23 April 2008 on credit agreements for consumers, OJ L 133, 22.5.2008, p. 66. | 32 Directive 2008/48/EC of the European Parliament and of the Council of 23 April 2008 on credit agreements for consumers, OJ L 133, 22.5.2008, p. 66. |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1108</NumAm>

<RepeatBlock-By><Members>Alexis Georgoulis, João Pimenta Lopes, Giorgos Georgiou</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 77 a (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***77a. Calls on the Commission and Member States to design information and awareness raising campaigns in order to eliminate cancer-related stigma1a******1b*** ***functioning at the same time as a tool to improve screening, early diagnosis and survival rates;*** |
|  | ***\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_*** |
|  | ***1a*** ***https://www.livestrong.org/sites/default/files/what-we-do/reports/lsglobalresearchreport.pdf*** |
|  | ***1b*** ***https://www.rti.org/rti-press-publication/perceived-experienced-and-internalized-cancer-stigma*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1109</NumAm>

<RepeatBlock-By><Members>Nicolae Ştefănuță, Alin Mituța, Ivars Ijabs, Vlad Gheorghe</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 77 b (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***77b. Calls on the Commission to consider an EU Strategy on Care and Caring, to ensure appropriate, accessible, and high-quality long-term care;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1110</NumAm>

<RepeatBlock-By><Members>Alexis Georgoulis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 77 c (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***77c. Calls on the Commission and the Member States to include in their taxation policies measures such as tax reductions or exemptions in order to support and relieve cancer patients and their caregivers;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1111</NumAm>

<RepeatBlock-By><Members>Alexis Georgoulis, Giorgos Georgiou</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 77 d (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***77d. Calls on the Commission and the Member States to design policies supporting the re-introduction of cancer patients to the labour market, including measures such as tools to motivate employers, as well as tools to educate and train patients in case they need to change their career path;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1112</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión, Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 78</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 78. Emphasises the importance of specific EU recommendations to improve the ***quality of life of*** patients, including via supportive ***care*** (pain relief, psychological services, adapted physical activity, nutritional support, social assistance***, access to reproductive health*** and restoration of aesthetic integrity); asks Member States for recognition of sequelae (physical or mental disabilities), as well as social discrimination; | 78. Emphasises the importance of specific EU recommendations to improve the ***essential issues in the treatment of all cancer*** patients ***and their families***, including via supportive ***integral care, from a bio-psycho-social perspective*** (pain relief, psychological services, adapted physical activity, nutritional support, social assistance and restoration of aesthetic integrity) ***integrated into cancer care from diagnosis and throughout the entire disease*** ; asks Member States for recognition of sequelae (physical or mental disabilities), as well as social discrimination; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1113</NumAm>

<RepeatBlock-By><Members>Dolors Montserrat, Aldo Patriciello, Juan Ignacio Zoido Álvarez, Herbert Dorfmann, Rosa Estaràs Ferragut, Francisco José Millán Mon, José Manuel García-Margallo y Marfil, Gabriel Mato, Esteban González Pons, Lídia Pereira, Pilar del Castillo Vera, Antonio López-Istúriz White, Adrián Vázquez Lázara, Pablo Arias Echeverría, Javier Zarzalejos, Ewa Kopacz, Isabel Benjumea Benjumea</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 78</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 78. Emphasises the importance of specific EU recommendations to improve the quality of life of patients, including via supportive care (pain relief, psychological services, adapted physical activity, nutritional support, social assistance, access to reproductive health and restoration of aesthetic integrity); asks Member States for recognition of sequelae (physical or mental disabilities), as well as social discrimination; | 78. Emphasises the importance of specific EU recommendations to improve the quality of life of patients, including via ***comprehensive*** supportive care ***from a bio-psycho-social perspective*** (pain relief, psychological services, adapted physical activity***, scientific evidence-based complementary therapies***, nutritional support, social assistance, access to reproductive health and restoration of aesthetic integrity) ***and integrated into cancer care from diagnosis and throughout the disease process***; asks Member States for recognition of sequelae (physical or mental disabilities), as well as social discrimination; ***recognizes the importance of palliative care as special care for people with life threatening illness and their families, relieving pain and physical, psychosocial and spiritual suffering, while benefitting health systems; highlights that NCCPs should offer palliative care and a Pain Management Plan for everyone who needs it, for the entire disease trajectory from the beginning and alongside the disease, for adults and also for children; urges the EU to work with Member States to address barriers for palliative care, to provide palliative care through primary health care centres as well as at home, and promote palliative care education for all health professionals;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1114</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 78</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 78. Emphasises the importance of specific EU recommendations to improve the quality of life of patients, including via supportive care (pain relief, psychological services, adapted physical activity, nutritional support, social assistance, access to reproductive health and restoration of aesthetic integrity); asks Member States for recognition of sequelae (physical or mental disabilities), as well as social discrimination; | 78. ***Recognises that cancer is a financially burdensome disease, even beyond cancer treatments;*** emphasises the importance of specific EU recommendations to improve the quality of life of patients, including via supportive care (pain relief, psychological services, adapted physical activity, ***complementary therapies,*** nutritional support, social assistance ***encompassing all day-to-day tasks such as household help or child care***, access to reproductive health and restoration of aesthetic integrity)***; recognizes that these types of supportive care are often only developed by private health insurances***; asks Member States for recognition of sequelae (physical or mental disabilities), as well as social discrimination; ***asks the Commission to propose guidelines for Member States to address the importance of establishing comprehensive coverage systems that guarantee these needs;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1115</NumAm>

<RepeatBlock-By><Members>Peter Liese</Members>

<AuNomDe>{EPP}on behalf of the EPP Group</AuNomDe>

<Members>Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 78</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 78. Emphasises the importance of specific EU recommendations to improve the quality of life of patients, including via supportive care (pain relief, psychological services, adapted physical activity, nutritional support, social assistance, access to reproductive health and restoration of aesthetic integrity); asks Member States for recognition of sequelae (physical or mental disabilities), as well as social discrimination; | 78. Emphasises the importance of specific EU recommendations to improve the quality of life of patients, including via supportive care (pain relief, psychological services, adapted physical activity, nutritional support, social assistance, access to reproductive health and restoration of aesthetic integrity)***, and access to specialised supportive centres***; asks Member States for recognition of sequelae (physical or mental disabilities), as well as social discrimination; ***calls on the Commission to set up a platform for the exchange of best practice in palliative care and support research in palliative care; calls on Member States to include the aspect of pain management for patients in treatment and survivors;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1116</NumAm>

<RepeatBlock-By><Members>Alexis Georgoulis, João Pimenta Lopes, Giorgos Georgiou</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 78</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 78. Emphasises the importance of specific EU recommendations to improve the quality of life of patients, including via supportive care (pain relief, psychological services, adapted physical activity, nutritional support, social assistance, access to reproductive health and restoration of aesthetic integrity); asks Member States for recognition of sequelae (physical or mental disabilities), as well as social discrimination; | 78. Emphasises the importance of specific EU recommendations to improve the quality of life of patients, including via supportive care (pain relief, psychological services, adapted physical activity, nutritional support, social assistance, access to reproductive health and restoration of aesthetic integrity); ***notes that there is a need to focus on the quality of life for a rising number of chronic cancer patients whose illness cannot be cured but which may be stabilised for a number of years;*** asks Member States for recognition of sequelae (physical or mental disabilities), as well as social discrimination; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1117</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 78</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 78. Emphasises the importance of specific EU recommendations to improve the quality of life of patients, including via supportive care (pain relief, psychological services, adapted physical activity, nutritional support, social assistance, access to reproductive health and restoration of aesthetic integrity); asks Member States ***for recognition of*** sequelae (physical or mental disabilities), as well as social discrimination; | 78. Emphasises the importance of specific EU recommendations to improve the quality of life of patients, including via supportive care (pain relief, psychological services, adapted physical activity, nutritional support, social assistance, access to reproductive health and restoration of aesthetic integrity); asks Member States ***to do more in recognising*** sequelae (physical or mental disabilities), as well as ***confronting*** social ***stigma and*** discrimination***, which can limit opportunities for employment and social interaction***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1118</NumAm>

<RepeatBlock-By><Members>Nicolás González Casares, Alessandra Moretti, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 78</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 78. Emphasises the importance of specific EU recommendations to improve the quality of life of patients, including via supportive care (pain relief, psychological services, adapted physical activity, nutritional support, social assistance, access to reproductive health and restoration of aesthetic integrity); asks Member States for recognition of sequelae (physical or mental disabilities), as well as social discrimination; | 78. Emphasises the importance of specific EU recommendations to improve the quality of life of patients ***and survivors***, including via supportive care (pain relief, psychological services, adapted physical activity, nutritional support, social assistance, access to reproductive health and restoration of aesthetic integrity) ***from the diagnosis and during the whole treatment***; asks Member States for recognition of sequelae (physical or mental disabilities), as well as social discrimination; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1119</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 78</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 78. Emphasises the importance of specific EU recommendations to improve the quality of life of patients, including via supportive care (pain relief, psychological services, adapted physical activity, nutritional support, social assistance, access to reproductive health and restoration of aesthetic integrity); asks Member States for recognition of sequelae (physical or mental disabilities), as well as social ***discrimination***; | 78. Emphasises the importance of specific EU recommendations to improve the quality of life of patients, including via supportive care (pain relief, psychological services, adapted physical activity, nutritional support, social assistance, ***support for managing comorbidities,*** access to reproductive health and restoration of aesthetic integrity); asks Member States for recognition of sequelae (physical or mental disabilities), as well as social ***hardship***; |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>1120</NumAm>

<RepeatBlock-By><Members>Giorgos Georgiou, Alexis Georgoulis, João Pimenta Lopes</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 78</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 78. Emphasises the importance of specific EU recommendations to improve the quality of life of patients, including via supportive care (pain relief, psychological services, adapted physical activity, nutritional support, social assistance, access to reproductive health and restoration of aesthetic integrity); asks Member States for recognition of sequelae (physical or mental disabilities), as well as social discrimination; | 78. Emphasises the importance of specific EU recommendations to improve the quality of life of patients, including via supportive care (pain relief, psychological services, adapted physical activity, nutritional support, social assistance, access to reproductive health and restoration of aesthetic integrity); asks Member States for recognition of sequelae (physical or mental disabilities), as well as social discrimination***, including in the workplaces***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1121</NumAm>

<RepeatBlock-By><Members>Michèle Rivasi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 78</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 78. Emphasises the importance of specific EU recommendations to improve the quality of life of patients, including via supportive care (pain relief, psychological services, adapted physical activity, nutritional support, social assistance, access to reproductive health and restoration of aesthetic integrity); asks Member States for recognition of sequelae (physical or mental disabilities), as well as social discrimination; | 78. Emphasises the importance of specific EU recommendations to improve the quality of life of patients, including via supportive care (pain relief, psychological services, adapted physical activity, nutritional support, ***integrative medicine,*** social assistance, access to reproductive health and restoration of aesthetic integrity); asks Member States for recognition of sequelae (physical or mental disabilities), as well as social discrimination; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1122</NumAm>

<RepeatBlock-By><Members>Ondřej Knotek, Irena Joveva</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 78</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 78. Emphasises the importance of specific EU recommendations to improve the quality of life of patients, including via supportive care (pain relief, psychological services, adapted physical activity, nutritional support, social assistance, access to reproductive health and restoration of aesthetic integrity); asks Member States for recognition of sequelae (physical or mental disabilities), as well as social discrimination; | 78. Emphasises the importance of specific EU recommendations to improve the quality of life of patients, including via supportive care (pain relief, psychological services, adapted physical activity***, access to education***, nutritional support, social assistance, access to reproductive health and restoration of aesthetic integrity); asks Member States for recognition of sequelae (physical or mental disabilities), as well as social discrimination; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1123</NumAm>

<RepeatBlock-By><Members>Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 78 a (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***78a. Draws attention to the estimation that between 10% and 20% of the 1.3 million cancer deaths in the EU in 2020 can be attributed to malnutrition, rather than cancer itself (ESPEN practical guideline: Clinical Nutrition in cancer); calls for incorporating clinical nutrition in all aspects of cancer treatment, including cancer screening, cancer treatment, cancer support and cancer research; recognizes that all cancer patients should be screened for malnutrition and, wherever indicated, they must be provided with clinical nutritional support in addition to other therapies by qualified personnel; recommends that nutrition management be an integral ethical part of all research involving cancer patients, including clinical research; also recommends that proper nutritional support be included in the cancer patients' Charter of Rights;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1124</NumAm>

<RepeatBlock-By><Members>Bronis Ropė</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 78 b (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***78b. Strongly urges the Member States to ensure that all cancer patients are fully informed about the possibility of fertility preservation procedures prior to the start of active treatment; calls for the development of guidelines at EU level for health professionals, defining the age at which cancer patients should be informed about the availability of reproductive health procedures; encourages, furthermore, the Member States to make provision for all cancer patients covered by compulsory national health insurance to be reimbursed for such services by national health insurance schemes;*** |

Or. <Original>{LT}lt</Original>

</Amend>

<Amend>Amendment <NumAm>1125</NumAm>

<RepeatBlock-By><Members>Michèle Rivasi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 78 c (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***78c. Underlines that surveys demonstrate that around 37% of cancer patients use complementary treatments in addition to their conventional cancer treatment; calls for inclusion of holistic treatment methods in cancer centres using the combination of conventional and complementary therapies, also known as integrative oncology, including fostering the development of a high quality multidisciplinary workforce to improve patients’ quality of life and well-being, including mental, psychosocial and nutritional support; calls for increased research investment to assess the validity of the integrative approach of cancer care;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1126</NumAm>

<RepeatBlock-By><Members>Nicolás González Casares, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 78 d (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***78d. Notes that up to 10-20% of cancer patients die due to consequences of malnutrition rather than for the tumour itself1a; calls for clinical nutrition to be incorporated in all aspects of cancer treatment; recognizes that all cancer patients should be screened for malnutrition and, whenever indicated, cancer patients should receive clinical nutritional support by qualified personnel; recommends that proper nutritional support be included in the cancer patients’ Charter of Rights;*** |
|  | ***\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_*** |
|  | ***1a*** ***https://www.clinicalnutritionjournal.com/action/showPdf?pii=S0261-5614%2821%2900079-0*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1127</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión, Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 78 e (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***78e. Underlines that the results of cancer treatment can be hampered by malnutrition thus optimal nutritional care is essential for cancer care; calls on the Commission and Member States to ensure nutritional support to cancer patients at all stages of the disease and to take all the necessary steps to include an oncology dietitian specialist into the multidisciplinary team (MDT);*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1128</NumAm>

<RepeatBlock-By><Members>Antoni Comín i Oliveres</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 78 f (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***78f. Urges the Commission, Member States, regions and all public administrations to widen and seek innovative approaches for cancer treatment and management by integrating the One Health and Health in All Policies principles as cross-sectoral principles; proposes the creation of an interoperable database as a network of hospitals and specialised oncological centres, as well as fostering the development of high-quality multidisciplinary approaches in the fight against cancer;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1129</NumAm>

<RepeatBlock-By><Members>Dolors Montserrat, Aldo Patriciello, Juan Ignacio Zoido Álvarez, Herbert Dorfmann, Rosa Estaràs Ferragut, Francisco José Millán Mon, José Manuel García-Margallo y Marfil, Gabriel Mato, Esteban González Pons, Lídia Pereira, Pilar del Castillo Vera, Cindy Franssen, Antonio López-Istúriz White, Adrián Vázquez Lázara, Pablo Arias Echeverría, Javier Zarzalejos, Ewa Kopacz, Isabel Benjumea Benjumea</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 78 g (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***78g. Highlights the importance of encouraging the use of complementary therapies based on scientific evidences, in support of conventional treatments, in the framework of an integrative oncology, given the value of this approach in improving the quality of life of patients;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1130</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin, Stefania Zambelli</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 78 h (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***78h. Encourages Member States to pay attention to the specific needs – in terms of pain relief or access to palliative care – of patients suffering from an advanced or metastatic cancer;*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>1131</NumAm>

<RepeatBlock-By><Members>Christian Sagartz</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 78 i (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***78i. Stresses the need for medical and psychological aftercare for cancer survivors; notes the general underestimation of aftercare compared to the equally important cancer prevention;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1132</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión, Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 78 j (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***78j. Encourages Member States to facilitate the removal of excessive red tape in the assessment process of a disability related to cancer or to a cancer treatment;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1133</NumAm>

<RepeatBlock-By><Members>Michèle Rivasi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 78 k (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***78k. Calls for Quality of Life (QoL) to be fully integrated in the development of cancer treatments and for the Patient Reported Outcome Measures (PROMS) to be mandatory for the registration trials leading to market authorisation; calls for enhanced use of therapy optimisation clinical trials, including de-escalation trials, with QoL as primary endpoints;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1134</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión, Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 78 l (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***78l. Calls on Member States to develop recommendations to add nutrition as a fundamental, integral and key part of an adequate treatment and care of cancer patients;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1135</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión, Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 78 m (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***78m. Acknowledges that for cancer patients, cancer survivors and for those for whom cure is no longer possible, poor nutritional status impairs quality of life and reduces survival time; calls on the Commission and Member States to protect a patient’s nutritional status across the continuum of cancer care and to provide access to appropriate nutrition support and dietetic services that meet the patient’s individual needs;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1136</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión, Pietro Fiocchi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 78 n (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***78n. Welcomes the planned inter-speciality training on nutrition support; calls on the Commission and Member States to develop minimum standards for continuous training on nutritional care for the multidisciplinary workforce, including nurses, oncologists, radiotherapists, general practitioners, pre- and postgraduates and resident doctors;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1137</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 78 o (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***78o. Stresses the importance for the patient's recovery of the company and presence of his family and loved ones as a fundamental support to find hope and peace during the difficult moments of the disease; urges that it should be a priority to ensure the necessary conditions so that these contacts can take place;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1138</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 78 p (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***78p. Calls on the Commission to encourage Member States to offer specific training in primary care for survivors and provide medical personnel with expertise in survivorship, as well as ensure that oncologists can liaise with the primary care physician on behalf of the survivors;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1139</NumAm>

<RepeatBlock-By><Members>Bartosz Arłukowicz</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 79</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 79. Encourages Member States to take into account the frequent exhaustion of the families and relatives of cancer patients and to provide them with psychological assistance and ***rest periods in the workplace***; | 79. Encourages Member States to take into account the frequent exhaustion of the families and relatives of cancer patients and to provide them with psychological assistance and ***increased flexibility in their working time, or to adapt their working time to the care needs of the patient***; |

Or. <Original>{PL}pl</Original>

</Amend>

<Amend>Amendment <NumAm>1140</NumAm>

<RepeatBlock-By><Members>João Pimenta Lopes, Giorgos Georgiou, Alexis Georgoulis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 79</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 79. Encourages Member States to take into account the frequent exhaustion of the families and relatives of cancer patients and to provide them with psychological assistance and rest periods in the workplace; | 79. Encourages Member States to take into account the frequent exhaustion of the families and relatives of cancer patients and to provide them with psychological assistance and ***stronger employee protection, considering, among other options,*** rest periods in the workplace***, increases in the number of days with justified and paid absences to support family members, leave and care allowances for direct relatives with 100% remuneration***; |

Or. <Original>{PT}pt</Original>

</Amend>

<Amend>Amendment <NumAm>1141</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 79</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 79. Encourages Member States to take into account the frequent exhaustion of the families and relatives of cancer patients and to provide them with psychological assistance and rest periods in the workplace; | 79. Encourages Member States to take into account the frequent exhaustion of the families and relatives of cancer patients and to provide them with psychological assistance and rest periods in the workplace***, as well as support during*** ***mourning***; ***encourages also the development of integrated support schemes for cancer patients and their families, taking into account health, community and social services;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1142</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin, Angelo Ciocca, Stefania Zambelli</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 79</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 79. Encourages Member States to take into account the frequent exhaustion of the families and relatives of cancer patients and to provide them with psychological assistance and rest periods in the workplace; | 79. Encourages Member States to take into account the frequent exhaustion of the families and relatives of cancer patients and to provide them with psychological assistance and rest periods in the workplace; ***calls for more carers to be trained and for day centre services to be made available for family carers;*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>1143</NumAm>

<RepeatBlock-By><Members>Dolors Montserrat, Aldo Patriciello, Juan Ignacio Zoido Álvarez, Herbert Dorfmann, Rosa Estaràs Ferragut, Francisco José Millán Mon, José Manuel García-Margallo y Marfil, Gabriel Mato, Esteban González Pons, Lídia Pereira, Pilar del Castillo Vera, Cindy Franssen, Antonio López-Istúriz White, Adrián Vázquez Lázara, Pablo Arias Echeverría, Javier Zarzalejos, Ewa Kopacz, Isabel Benjumea Benjumea</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 79</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 79. Encourages Member States to take into account the frequent exhaustion of the families and relatives of cancer patients and to provide them with psychological assistance and rest periods in the workplace; | 79. Encourages Member States to take into account the frequent exhaustion of the families and relatives of cancer patients and to provide them with psychological ***and socio-economic*** assistance***, especially for the most vulnerable ones,*** and rest periods in the workplace***, along all the illness, as well as bereavement support***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1144</NumAm>

<RepeatBlock-By><Members>Nicolae Ştefănuță, Alin Mituța, Ivars Ijabs, Vlad Gheorghe</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 79</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 79. Encourages Member States to take into account the frequent exhaustion of the families and relatives of cancer patients and to provide them with psychological assistance ***and*** rest periods in the workplace; | 79. Encourages Member States to take into account the frequent exhaustion of the families and relatives of cancer patients and to provide them with psychological assistance rest periods in the workplace ***and to put in place adequate and accessible support systems***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1145</NumAm>

<RepeatBlock-By><Members>Nicolás González Casares, Maria Arena, Romana Jerković, Sara Cerdas, Marc Angel, Estrella Durá Ferrandis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 79</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 79. Encourages Member States to take into account the frequent exhaustion of the families and relatives of cancer patients and to provide them with psychological assistance and rest periods in the workplace; | 79. Encourages Member States to take into account the frequent exhaustion of the families and relatives of cancer patients and to provide them with psychological assistance and rest periods in the workplace ***as well as support after death***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1146</NumAm>

<RepeatBlock-By><Members>Nathalie Colin-Oesterlé</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 79 a (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***79a. Calls on Member States and relevant authorities to recognise the pivotal role of informal carers, to integrate them within the health and care team and empower them with the possibility of making informed choice regarding available supportive measures;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1147</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 79 a (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***79a. Stresses the importance of financial and care support for families of patients who may be attending to their needs daily, even if they have to stop their professional life;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1148</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 79 b (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***79b. Calls on Member States to respect a patient's decision when he/she wishes to accept suffering and its consequences in the course of the disease;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1149</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 79 c (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***79c. Calls on Member States to ensure that all social agents and health professionals respect the defence of life itself in the face of illness in all of their practices;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1150</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 80</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 80. Recalls that patient ***empowerment*** is crucial for the European cancer strategy and that patient-centeredness and participatory decision-making must be at the heart of treatment and care development processes; encourages the therapeutic education of caregivers and patients and their ***empowerment*** in the care programmes; | 80. Recalls that patient ***proactivity*** is crucial for the European cancer strategy and that patient-centeredness and participatory decision-making must be at the heart of treatment and care development processes; encourages the therapeutic education ***and self-care training*** of caregivers and patients and their ***engagement*** in the care programmes ***for the promotion of active and expert patients, using tools such as peer-to-peer learning***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1151</NumAm>

<RepeatBlock-By><Members>Bartosz Arłukowicz</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 80</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 80. Recalls that patient empowerment is crucial for the European cancer strategy and that patient-centeredness and participatory decision-making must be at the heart of treatment and care development processes; encourages the therapeutic education of caregivers and patients and their empowerment in the care programmes; | 80. Recalls that patient empowerment is crucial for the European cancer strategy and that patient-centeredness and participatory decision-making must be at the heart of treatment and care development processes; encourages the therapeutic education of caregivers and patients and their empowerment in the care programmes; ***encourages the development of the role of treatment coordinator in each Member State, which could serve as a contact point to help patients make optimal use of the services provided by the health system;*** |

Or. <Original>{PL}pl</Original>

</Amend>

<Amend>Amendment <NumAm>1152</NumAm>

<RepeatBlock-By><Members>Michèle Rivasi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 80</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 80. Recalls that patient empowerment is crucial for the European cancer strategy and that patient-centeredness and participatory decision-making must be at the heart of treatment and care development processes; encourages the therapeutic education of caregivers and patients and their empowerment in the care programmes; | 80. Recalls that patient empowerment is crucial for the European cancer strategy and that patient-centeredness and participatory decision-making must be at the heart of treatment and care development processes; encourages the therapeutic education of caregivers and patients and their empowerment in the care programmes; ***calls for participatory decision-making with personalised and understandable evidence-based information provided to patients as an integral part of the National Cancer Control Programs (NCCPs), supported by the EBCP;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1153</NumAm>

<RepeatBlock-By><Members>Nicolás González Casares, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 80</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 80. Recalls that patient empowerment is crucial for the European cancer strategy and that patient-centeredness and participatory decision-making must be at the heart of treatment and care development processes; encourages the therapeutic education of caregivers and patients and their empowerment in the care programmes; | 80. Recalls that patient empowerment is crucial for the European cancer strategy and that patient-centeredness and participatory decision-making must be at the heart of treatment and care development processes; encourages the therapeutic education of caregivers and patients and their empowerment in the care programmes; ***considers that given the specific characteristics and needs of paediatric patients, a specifically tailored methodology should be used for the training and empowerment process of paediatric patients;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1154</NumAm>

<RepeatBlock-By><Members>Hilde Vautmans, Irena Joveva</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 80</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 80. Recalls that patient empowerment is crucial for the European cancer strategy and that patient-centeredness and participatory decision-making must be at the heart of treatment and care development processes; encourages the therapeutic education of caregivers and patients and their empowerment in the care programmes; | 80. Recalls that patient empowerment is crucial for the European cancer strategy and that patient-centeredness and participatory decision-making must be at the heart of treatment and care development processes; encourages the therapeutic education of caregivers and patients and their empowerment in the care programmes; ***considers that, given the paediatric specific developmental characteristics, a specifically tailored methodology should be applied to the training and empowerment process of paediatric patients;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1155</NumAm>

<RepeatBlock-By><Members>Alexis Georgoulis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 80</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 80. Recalls that patient empowerment is crucial for the European cancer strategy and that patient-centeredness and participatory decision-making must be at the heart of treatment and care development processes; encourages the therapeutic education of caregivers and patients and their empowerment in the care programmes; | 80. Recalls that patient empowerment is crucial for the European cancer strategy and that patient-centeredness and participatory decision-making must be at the heart of treatment and care development processes; encourages the therapeutic education of caregivers and patients and their empowerment in the care programmes; ***recommends the support of such initiatives and actions to empower cancer patients through EU funding such as the EU4Health programme;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1156</NumAm>

<RepeatBlock-By><Members>Tomislav Sokol, Sunčana Glavak, Cindy Franssen</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 80</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 80. Recalls that patient empowerment is crucial for the European cancer strategy and that patient-centeredness and participatory decision-making must be at the heart of treatment and care development processes; encourages the therapeutic education of caregivers and patients and their empowerment in the care programmes; | 80. Recalls that patient empowerment is crucial for the European cancer strategy and that patient-centeredness and participatory decision-making must be at the heart of treatment and care development processes; encourages the therapeutic education of caregivers and patients and their empowerment in the care programmes; ***recommends that EU4Health programme supports initiatives and actions to empower cancer patients.*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1157</NumAm>

<RepeatBlock-By><Members>Peter Liese</Members>

<AuNomDe>{EPP}on behalf of the EPP Group</AuNomDe>

<Members>Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Marian-Jean Marinescu, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 80 a (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***80a. Points to the high percentage of informal carers among the European population and to the disparities regarding the way they are supported and how their rights are recognized between Member States; calls on the Commission to consider the formalization of an informal caregiver status, ensuring the recognition of a certain minimum standard of rights, especially for those who are providing long-term care;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1158</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin, Stefania Zambelli</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 80 a (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***80a. Points out that more than 75% of patients diagnosed with cancer are over 60 years old and that a fully fledged geriatric approach is therefore required;*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>1159</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin, Stefania Zambelli</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 80 b (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***80b. Strongly calls, therefore, for caregivers of the elderly to be made aware of the need for a fresh approach to look out for the misleading symptomatology senior citizens experience;*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>1160</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin, Stefania Zambelli</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 80 c (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***80c. Urges states to work together to create a safe environment for elderly cancer patients, particularly those who are isolated;*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>1161</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin, Stefania Zambelli</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 80 d (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***80d. Therefore encourages the Member States to develop home-based care and hospitalisation systems;*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>1162</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 80 e (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***80e. Encourages research into non-profit clinical trials with a view to improving treatment strategies, particularly for the elderly;*** |

Or. <Original>{FR}fr</Original>

</Amend>

<Amend>Amendment <NumAm>1163</NumAm>

<RepeatBlock-By><Members>Tomislav Sokol, Sunčana Glavak, Cindy Franssen</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 81</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 81. Acknowledges the ***positive*** role of patients’ associations in relation to patient advocacy and accompaniment; calls on the Commission and the Member States to take into account their requests and recommendations when formulating cancer-related policies and legislation and to provide them with public support in order to guarantee their independence from private funding; | 81. Acknowledges the ***central*** role of patients***’ and carers***’ associations in relation to patient advocacy and accompaniment***, dissemination of health literacy, and awareness and ongoing support both at EU and national level***; calls on the Commission and the Member States to ***include them in upcoming financial programs and specific projects and to guarantee operational funding,*** take into account their requests and recommendations when formulating cancer-related policies and legislation and to provide them with public support in ***form of both operating grants and project related grants in*** order to guarantee their independence from private funding; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1164</NumAm>

<RepeatBlock-By><Members>Hilde Vautmans, Irena Joveva</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 81</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 81. Acknowledges the positive role of patients’ associations in relation to patient advocacy and accompaniment; calls on the Commission and the Member States to take into account their requests and recommendations when formulating cancer-related policies and legislation and to provide them with public support in order to guarantee their independence from private funding; | 81. Acknowledges the positive role of patients’ associations ***and Young Patients Advisory Groups (YPAGS)*** in relation to patient advocacy and accompaniment; calls on the Commission and the Member States to take into account their requests and recommendations when formulating cancer-related policies and legislation and to provide them with public support in order to guarantee their independence from private funding; ***considers that paediatric patients should play a role, both individually and collectively, in improving healthcare and research procedures for all patients by contributing with their specific experiences; takes the view, therefore, that adequate learning and educational tools should be developed to plan and ensure the involvement of children, which is properly financed;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1165</NumAm>

<RepeatBlock-By><Members>Nicolás González Casares, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 81</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 81. Acknowledges the positive role of patients’ associations in relation to patient advocacy and accompaniment; calls on the Commission and the Member States to take into account their requests and recommendations when formulating cancer-related policies and legislation and to provide them with public support in order to guarantee their independence from private funding; | 81. Acknowledges the positive role of patients’ associations ***and Young Patients Advisory Groups (YPAGS)*** in relation to patient advocacy and accompaniment; calls on the Commission and the Member States to take into account their requests and recommendations when formulating cancer-related policies and legislation and to provide them with public support in order to guarantee their independence from private funding; ***recalls the need for paediatric patients (individually and collectively) to play a role in improving healthcare and research procedures by contributing with their specific experiences; considers that adequate learning and educational tools should be developed to plan and carry out an appropriately resourced involvement of children;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1166</NumAm>

<RepeatBlock-By><Members>Michèle Rivasi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 81</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 81. Acknowledges the positive role of patients’ associations in relation to patient advocacy and accompaniment; calls on the Commission and the Member States to take into account their requests and recommendations when formulating cancer-related policies and legislation and to provide them with public support in order to guarantee their independence from private funding; | 81. Acknowledges the positive role of patients’ associations in relation to patient advocacy and accompaniment; calls on the Commission and the Member States to take into account their requests and recommendations when formulating cancer-related policies and legislation and to provide them with public support in order to guarantee their independence from private funding; ***calls for the Commission to set clear criteria according to which public financial support can be awarded;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1167</NumAm>

<RepeatBlock-By><Members>Ondřej Knotek, Irena Joveva</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 81</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 81. Acknowledges the positive role of patients’ associations in relation to patient advocacy ***and*** accompaniment; calls on the Commission and the Member States to take into account their requests and recommendations when formulating cancer-related policies and legislation and to provide them with public support in order to guarantee their independence from private funding; | 81. Acknowledges the positive role of patients’ associations in relation to patient advocacy***,*** accompaniment ***and services provided to cancer patients and caregivers***; calls on the Commission and the Member States to take into account their requests and recommendations when formulating cancer-related policies and legislation and to provide them with public support in order to guarantee their independence from private funding; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1168</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 81</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 81. Acknowledges the positive role of patients’ associations in relation to patient advocacy and accompaniment; calls on the Commission and the Member States to take into account their requests and recommendations when formulating cancer-related policies and legislation and to provide them with public support in order to guarantee their independence from private funding; | 81. Acknowledges the positive role of patients’ associations in relation to patient advocacy and accompaniment; calls on the Commission and the Member States to take into account ***their formal participation, as well as*** their requests and recommendations when formulating cancer-related policies and legislation and to provide them with public support in order to guarantee their independence from private funding; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1169</NumAm>

<RepeatBlock-By><Members>Nicolás González Casares, Alessandra Moretti, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Johan Danielsson, Estrella Durá Ferrandis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 81 a (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***81a. Stresses the importance to secure that proper compensation claim options exists for workers in cases of occupational cancer; calls on Member States to fully implement the Commission recommendation on occupational diseases1a*** ***and to ensure that proper compensation claim options exist for workers in cases of occupational cancer, securing every worker a chance to be properly compensated when having been exposed to harmful substances or affected by work-related cancer; calls on the Commission to create a European minimum list of occupational diseases with comparable recognition criteria across the EU;*** |
|  | ***\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_*** |
|  | ***1a*** ***Commission Recommendation of 19 September 2003 concerning the European schedule of occupational diseases, OJ L 238, 25.9.2003, p. 28*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1170</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 81 a (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***81a. Highlights the need to recognise the relevant and indispensable role of solidarity initiatives that, with great creativity, are achieving an important boost in raising awareness, obtaining resources for diagnosis, treatment and research of cancer, and generating a sense of hope, which is a relief for both patients and their families, and an invaluable contribution to society;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1171</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 81 b (new)</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
|  | ***81b. Highlights the importance of testimony by cancer patients and survivors, whose suffering represents, for society as a whole, a model of overcoming and accepting life's setbacks, generating hope and motivation to follow their example;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1172</NumAm>

<RepeatBlock-By><Members>Michèle Rivasi</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 82</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 82. Calls on the Member States to improve the reintegration of cancer survivors into the labour market and to facilitate the return to school of paediatric cancer survivors; advocates specific EU recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation; | 82. Calls on the Member States to improve the reintegration of cancer survivors into the labour market and to facilitate the return to school of paediatric cancer survivors***; recalls the recommendations and tools developed by the CHRODIS+ Joint Action to foster patients’ retention at work, return to work and reintegration into the labour market; encourages the Commission to support their implementation across the Member States***; advocates specific EU recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation; ***calls for information on recurrence of cancer to be an integral part of cancer registries;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1173</NumAm>

<RepeatBlock-By><Members>Alexis Georgoulis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 82</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 82. Calls on the Member States to improve the reintegration of cancer survivors into the labour market and to facilitate the return to school of paediatric cancer survivors; advocates specific EU recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation; | 82. Calls on the Member States to improve the reintegration of cancer survivors into the labour market and to facilitate the return to school of paediatric cancer survivors; ***recalls the recommendations and tools developed by the CHRODIS+ Joint Action to foster patients’ retention at work, return to work and reintegration into the labour market; and encourages the European Commission to support their implementation across Europe*** advocates specific EU recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation; ***recommends the improvement of cancer registry information across Europe on recurrence of cancer;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1174</NumAm>

<RepeatBlock-By><Members>Bartosz Arłukowicz</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 82</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 82. Calls on the Member States to improve the reintegration of cancer survivors into the labour market and to facilitate the return to school of paediatric cancer survivors; advocates specific EU recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation; | 82. Calls on the Member States to improve the reintegration of cancer survivors into the labour market and to facilitate the return to school of paediatric cancer survivors; advocates specific EU recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation; ***calls on the Member States to support the reintegration of people with cancer into the labour market and to facilitate the balancing of work with treatment and rehabilitation needs; calls for support for employers who employ people who have had or who currently have cancer;*** |

Or. <Original>{PL}pl</Original>

</Amend>

<Amend>Amendment <NumAm>1175</NumAm>

<RepeatBlock-By><Members>Peter Liese</Members>

<AuNomDe>{EPP}on behalf of the EPP Group</AuNomDe>

<Members>Tomislav Sokol, Nathalie Colin-Oesterlé, Liudas Mažylis, Maria Spyraki, Dolors Montserrat, Cindy Franssen, Adam Jarubas, Deirdre Clune, Sunčana Glavak, Bartosz Arłukowicz</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 82</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 82. Calls on the Member States to improve the reintegration of cancer survivors into the labour market and to facilitate the return to school of paediatric cancer survivors; advocates specific EU recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation; | 82. Calls on the Member States to improve the reintegration of cancer survivors into the labour market and to facilitate the return to school of paediatric cancer survivors; advocates specific EU recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation; ***calls on the Member States to support the re-entry of cancer patients to the labour market and to facilitate the sharing of work and rehabilitation process;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1176</NumAm>

<RepeatBlock-By><Members>Nicolás González Casares, Alessandra Moretti, Maria Arena, Romana Jerković, Cyrus Engerer, Sara Cerdas, Patrizia Toia, Marc Angel, Estrella Durá Ferrandis</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 82</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 82. Calls on the Member States to improve the reintegration of cancer survivors into the labour market and to facilitate the return to school of paediatric cancer survivors; advocates specific EU recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation; | 82. Calls on the Member States to improve the reintegration of cancer survivors into the ***social activities and the*** labour market***, also helping them in the transition to a new professional role in case of sequelae preventing their continuity in the same job,*** and to facilitate the return to school of paediatric cancer survivors; advocates specific EU recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1177</NumAm>

<RepeatBlock-By><Members>Giorgos Georgiou, Alexis Georgoulis, João Pimenta Lopes</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 82</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 82. Calls on the Member States to improve the reintegration of cancer survivors into the labour market and to facilitate the return to school of paediatric cancer survivors; advocates specific EU recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation; | 82. Calls on the Member States to improve the reintegration of cancer survivors into the labour market and to facilitate the return to school of paediatric cancer survivors; advocates specific EU recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation***, including specific provisions for long-term follow-up care for childhood cancer survivors as they transition into adulthood***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1178</NumAm>

<RepeatBlock-By><Members>Loucas Fourlas</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 82</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 82. Calls on the Member States to improve the reintegration of cancer survivors into the labour market and to facilitate the return to school of paediatric cancer survivors; advocates specific EU recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation; | 82. Calls on the Member States to improve the reintegration of cancer survivors into the labour market and to facilitate the return to school of paediatric cancer survivors; advocates specific EU recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation; ***including specific provisions for long-term follow-up care for childhood cancer survivors as they transition into adulthood;*** |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1179</NumAm>

<RepeatBlock-By><Members>Nicolae Ştefănuță, Alin Mituța, Ivars Ijabs, Vlad Gheorghe</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 82</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 82. Calls on the Member States to improve the reintegration of cancer survivors into the labour market and to facilitate the return to school of paediatric cancer survivors; advocates specific EU recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation; | 82. Calls on the Member States to improve the reintegration of cancer survivors into the labour market and to facilitate the return to school of paediatric cancer survivors; advocates specific EU recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation***, including specific provisions for long-term follow-up care for childhood cancer survivors as they transition into adulthood***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1180</NumAm>

<RepeatBlock-By><Members>Tomislav Sokol, Sunčana Glavak, Cindy Franssen</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 82</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 82. Calls on the Member States to improve the reintegration of cancer survivors into the labour market and to facilitate the return to school of paediatric cancer survivors; advocates specific EU recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation; | 82. Calls on the Member States to improve the reintegration of cancer survivors into the labour market and to facilitate the return to school ***or higher education*** of paediatric cancer survivors; advocates specific EU recommendations for measures for cancer survivors to prevent the recurrence of primary cancer and the development of new cancers and for their rehabilitation; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1181</NumAm>

<RepeatBlock-By><Members>Dolors Montserrat, Aldo Patriciello, Juan Ignacio Zoido Álvarez, Herbert Dorfmann, Rosa Estaràs Ferragut, Francisco José Millán Mon, José Manuel García-Margallo y Marfil, Gabriel Mato, Esteban González Pons, Lídia Pereira, Pilar del Castillo Vera, Cindy Franssen, Antonio López-Istúriz White, Adrián Vázquez Lázara, Pablo Arias Echeverría, Javier Zarzalejos, Ewa Kopacz, Isabel Benjumea Benjumea</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 83</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 83. Considers that the European Agency for Health and Safety at Work should be mandated to play a stronger role in promoting good practices in Member States with respect to the integration of cancer patients and survivors into the workplace and their protection from discrimination; looks forward to the new study, announced in Europe’s Beating Cancer Plan, on the return to work of cancer survivors, which will map national employment and social protection policies and identify obstacles and the remaining challenges; | 83. Considers that the European Agency for Health and Safety at Work should be mandated to play a stronger role in promoting good practices in Member States with respect to the integration of cancer patients and survivors into the workplace and their protection from discrimination; looks forward to the new study, announced in Europe’s Beating Cancer Plan, on the return to work of cancer survivors, which will map national employment and social protection policies and identify obstacles and the remaining challenges***, as well as the direct economic impact that cancer has on patients and their families, especially on those groups that are most vulnerable due to their socio-economic situation***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1182</NumAm>

<RepeatBlock-By><Members>Margarita de la Pisa Carrión</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 83</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 83. Considers that the European Agency for Health and Safety at Work should be mandated to play a stronger role in promoting good practices in Member States with respect to the integration of cancer patients and survivors into the workplace and their protection from discrimination; looks forward to the new study, announced in Europe’s Beating Cancer Plan, on the return to work of cancer survivors, which will map national employment and social protection policies and identify obstacles and the remaining challenges; | 83. Considers that the European Agency for Health and Safety at Work should be mandated to play a stronger role in promoting good practices in Member States with respect to the integration of cancer patients and survivors into the workplace and their protection from discrimination; looks forward to the new study, announced in Europe’s Beating Cancer Plan, on the return to work of cancer survivors, which will map national employment and social protection policies and identify obstacles and the remaining challenges***, as well as the direct economic impact which cancer causes on patients and their families, taking into account their specific social and economic situation***; |

Or. <Original>{EN}en</Original>

</Amend>

<Amend>Amendment <NumAm>1183</NumAm>

<RepeatBlock-By><Members>Joëlle Mélin</Members>

</RepeatBlock-By>

<DocAmend>Motion for a resolution</DocAmend>

<Article>Paragraph 83</Article>

|  |  |
| --- | --- |
|  | |
| Motion for a resolution | Amendment |
| 83. Considers that the European Agency for Health and Safety at Work should be mandated to play a stronger role in promoting good practices in Member States with respect to the integration of cancer patients and survivors into the workplace and their protection from discrimination; looks forward to the new study, announced in Europe’s Beating Cancer Plan, on the return to work of cancer survivors, which will map national employment and social protection policies and identify obstacles and the remaining challenges; | 83. Considers that the European Agency for Health and Safety at Work should be mandated to play a stronger role in promoting good practices in Member States with respect to the integration of cancer patients and survivors into the workplace and their protection from discrimination; looks forward to the new study, announced in Europe’s Beating Cancer Plan, on the return to work of cancer survivors, which will map national employment and social protection policies and identify obstacles and the remaining challenges; ***already calls on the Member States to raise awareness among employers;*** |

Or. <Original>{FR}fr</Original>

</Amend></RepeatBlock-Amend>